<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006763" GROUP_ID="RENAL" ID="496506070406392216" MERGED_FROM="" MODIFIED="2010-11-10 05:10:03 +0100" MODIFIED_BY="Narelle Willis" REVIEW_NO="156" REVMAN_SUB_VERSION="5.0.25" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2010-11-10 05:10:03 +0100" MODIFIED_BY="Narelle Willis">
<TITLE>Altered dietary salt intake for preventing and treating diabetic kidney disease</TITLE>
<CONTACT MODIFIED="2010-11-10 05:10:03 +0100" MODIFIED_BY="Narelle Willis"><PERSON ID="37CE85AC82E26AA20003EB8A7DE1EA03" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Rebecca</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Suckling</LAST_NAME><POSITION>Clinical Research Fellow</POSITION><EMAIL_1>rsuckling@sgul.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Blood Pressure Unit</DEPARTMENT><ORGANISATION>St. George's Hospital Medical School</ORGANISATION><ADDRESS_1>Crammer Terrace</ADDRESS_1><CITY>London</CITY><ZIP>SW17 0RE</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 020 87250673</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2010-11-10 05:10:03 +0100" MODIFIED_BY="Narelle Willis"><PERSON ID="37CE85AC82E26AA20003EB8A7DE1EA03" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Rebecca</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Suckling</LAST_NAME><POSITION>Clinical Research Fellow</POSITION><EMAIL_1>rsuckling@sgul.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Blood Pressure Unit</DEPARTMENT><ORGANISATION>St. George's Hospital Medical School</ORGANISATION><ADDRESS_1>Crammer Terrace</ADDRESS_1><CITY>London</CITY><ZIP>SW17 0RE</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 020 87250673</PHONE_1></ADDRESS></PERSON><PERSON ID="44A7539E82E26AA200991D5608C41514" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Feng</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>He</LAST_NAME><EMAIL_1>f.he@qmul.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine &amp; Dentistry</DEPARTMENT><ORGANISATION>Queen Mary University of London</ORGANISATION><ADDRESS_1>Charterhouse Square</ADDRESS_1><CITY>London</CITY><ZIP>EC1M 6BQ</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 44 (0)20 7882 6266</PHONE_1><FAX_1>+44 (0)20 7882 6270</FAX_1></ADDRESS></PERSON><PERSON ID="18275" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Graham</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>MacGregor</LAST_NAME><POSITION>Professor of Cardiovascular Medicine</POSITION><EMAIL_1>g.macgregor@qmul.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine &amp; Dentistry</DEPARTMENT><ORGANISATION>Queen Mary University of London</ORGANISATION><ADDRESS_1>Charterhouse Square</ADDRESS_1><CITY>London</CITY><ZIP>EC1M 6BQ</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 (0)20 7882 6217</PHONE_1><FAX_1>+44 (0)20 7882 6270</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2010-09-27 15:21:31 +1000" MODIFIED_BY="Narelle S Willis">
<UP_TO_DATE>
<DATE DAY="29" MONTH="1" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="29" MONTH="1" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="10" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2010-02-23 15:46:50 +1100" MODIFIED_BY="[Empty name]"/>
<HISTORY/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-11-10 11:29:57 +1100" MODIFIED_BY="Narelle S Willis">
<SUMMARY MODIFIED="2010-10-26 17:14:57 +1100" MODIFIED_BY="Narelle S Willis">
<TITLE MODIFIED="2010-10-26 17:14:57 +1100" MODIFIED_BY="Narelle S Willis">Does altering dietary salt intake aid in the prevention and treatment of diabetic kidney disease?</TITLE>
<SUMMARY_BODY MODIFIED="2010-09-27 15:55:40 +1000" MODIFIED_BY="Narelle S Willis">
<P>There is strong evidence that our current consumption of salt is a major factor in increasing blood pressure (BP), whether BP levels are normal or raised. Diabetes makes it more likely to develop high BP, which increases the risk of strokes, heart attacks and speeds up the progression of diabetic kidney disease. This review found 13 studies including 254 patients with type 1 and type 2 diabetes. Reducing salt intake by 8.5 g/day lowered BP by 7/3 mm Hg. Public health guidelines recommend reducing dietary salt intake to less than 5-6 g/day and people with diabetes would benefit from reducing salt in their diet to at least this level.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-11-10 11:22:44 +1100" MODIFIED_BY="Narelle S Willis">
<ABS_BACKGROUND MODIFIED="2010-09-19 19:07:40 +1000" MODIFIED_BY="Narelle S Willis">
<P>There is strong evidence that our current consumption of salt is a major factor for increased blood pressure (BP) and a modest reduction in salt intake lowers BP whether BP levels are normal or raised. Tight control of BP in diabetics lowers the risk of strokes, heart attacks and heart failure and slows the progression of diabetic kidney disease (DKD). Currently there is no consensus in restricting salt intake in diabetic patients.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-09-27 15:46:56 +1000" MODIFIED_BY="Narelle S Willis">
<P>To evaluate the effect of altered salt intake on BP and markers of cardiovascular disease and DKD.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-10-26 17:13:36 +1100" MODIFIED_BY="Narelle S Willis">
<P>In January 2010, we searched the Cochrane Renal Group's Specialised Register, CENTRAL (in <I>The Cochrane Library</I>), MEDLINE (from 1966) and EMBASE (from 1980) to identify appropriate articles.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-09-21 17:17:20 +1000" MODIFIED_BY="Narelle S Willis">
<P>We included all randomised controlled trials of salt reduction in individuals with type 1 and type 2 diabetes.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-09-20 16:56:02 +1000" MODIFIED_BY="Narelle S Willis">
<P>Two authors independently assessed studies and resolved differences by discussion with a third independent author. We calculated mean effect sizes using both the fixed-effect and random-effects models.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-09-27 16:24:50 +1000" MODIFIED_BY="Narelle S Willis">
<P>Thirteen studies (254 individuals) met our inclusion criteria. These included 75 individuals with type 1 diabetes and 158 individuals with type 2 diabetes. The median reduction in urinary sodium was 203 mmol/24 h (11.9 g/day) in type 1 diabetes and 125 mmol/24 h (7.3 g/day) in type 2 diabetes. The median duration of salt restriction was one week in both type 1 and type 2 diabetes. BP was reduced in both type 1 and type 2 diabetes. In type 1 diabetes (56 individuals), salt restriction reduced BP by -7.11/-3.13 mm Hg (systolic/diastolic); 95% CI: systolic BP (SBP) -9.13 to -5.10; diastolic BP (DBP) -4.28 to -1.98). In type 2 diabetes (56 individuals), salt restriction reduced BP by -6.90/-2.87 mm Hg (95% CI: SBP -9.84 to -3.95; DBP -4.39 to -1.35). There was a greater reduction in BP in normotensive patients, possibly due to a larger decrease in salt intake in this group.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-11-10 11:22:44 +1100" MODIFIED_BY="Narelle S Willis">
<P>Although the studies are not extensive, this meta-analysis shows a large fall in BP with salt restriction, similar to that of single drug therapy. All diabetics should consider reducing salt intake at least to less than 5-6 g/day in keeping with current recommendations for the general population and may consider lowering salt intake to lower levels, although further studies are needed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-11-10 11:29:57 +1100" MODIFIED_BY="Narelle S Willis">
<BACKGROUND MODIFIED="2010-09-27 16:44:04 +1000" MODIFIED_BY="Narelle S Willis">
<P>Approximately 75% of cardiovascular disease (CVD) in diabetes can be attributed to raised blood pressure (BP) and is the largest direct cause of death due to the strokes, heart attacks and heart failure in diabetic patients (<LINK REF="REF-Adler-2000" TYPE="REFERENCE">Adler 2000</LINK>; <LINK REF="REF-Sowers-2001" TYPE="REFERENCE">Sowers 2001</LINK>). Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease (CKD) and these patients form the largest group on dialysis programs, with a significant burden on healthcare resources (<LINK REF="REF-Harvey-2003" TYPE="REFERENCE">Harvey 2003</LINK>). Lowering BP reduces the progression of DKD and diabetic patients with BP less than 130/80 mm Hg have the same reduction in glomerular filtration rate (GFR) due to age as healthy individuals (<LINK REF="REF-Giunti-2006" TYPE="REFERENCE">Giunti 2006</LINK>; <LINK REF="REF-Schrier-2002" TYPE="REFERENCE">Schrier 2002</LINK>).</P>
<P>Diabetes increases sodium retention in the kidney. Activity of the sodium-glucose co-transporter increases proximal tubular reabsorption of sodium and this reduces distal sodium delivery (<LINK REF="REF-Woods-1987" TYPE="REFERENCE">Woods 1987</LINK>). Insulin directly increases distal tubular sodium reabsorption (<LINK REF="REF-DeFronzo-1981" TYPE="REFERENCE">DeFronzo 1981</LINK>). Furthermore, increased angiotensin II in tubular fluid also activates sodium channels in the collecting duct (<LINK REF="REF-Nishiyama-2002" TYPE="REFERENCE">Nishiyama 2002</LINK>). The renin-angiotensin-aldosterone system (RAAS) is critical in feedback to maintain salt and water balance. Diabetic patients have a lower incidence of low renin state and a higher plasma renin activity (PRA) on a high salt diet compared to volunteers. It has been suggested that this lack of suppression of the renin-angiotensin system (RAS) with a high salt diet may play a part in the development of high BP (<LINK REF="STD-De_x0027_oliveira-1997" TYPE="STUDY">De'oliveira 1997</LINK>; <LINK REF="REF-Price-1999" TYPE="REFERENCE">Price 1999</LINK>). Lowering salt intake reduces urinary protein excretion in several populations and not only is this an important marker of CVD, but also of DKD (<LINK REF="REF-Allen-1997" TYPE="REFERENCE">Allen 1997</LINK>; <LINK REF="STD-Cianciaruso-1998" TYPE="STUDY">Cianciaruso 1998</LINK>; <LINK REF="REF-He-2009a" TYPE="REFERENCE">He 2009a</LINK>; <LINK REF="STD-Swift-2005" TYPE="STUDY">Swift 2005</LINK>).</P>
<P>There is strong evidence that our current consumption of salt is a major factor in increasing BP (<LINK REF="REF-He-2009b" TYPE="REFERENCE">He 2009b</LINK>). Despite the high cardiovascular risk and theoretical reasons for increased salt sensitivity in diabetic patients, the current knowledge of the role of salt in regulating BP and its impact on DKD is limited to small studies. We therefore carried out a systematic review and a meta-analysis of all studies where salt intake was changed in diabetes. There are no standard criteria for high and low salt diets; however as with previous meta-analyses of salt reduction, we considered a change in salt intake of 2 g/day between high and low salt periods to be adequate for this meta-analysis (<LINK REF="REF-He-2002" TYPE="REFERENCE">He 2002</LINK>; <LINK REF="REF-He-2003" TYPE="REFERENCE">He 2003</LINK>; <LINK REF="REF-Law-1991a" TYPE="REFERENCE">Law 1991a</LINK>).</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-09-27 16:44:14 +1000" MODIFIED_BY="Narelle S Willis">
<P>We aimed to evaluate the effects of salt restriction on the prevention and progression of DKD by studying the effects of changing salt intake on BP and surrogate markers of CVD and DKD.</P>
</OBJECTIVES>
<METHODS MODIFIED="2010-11-10 11:29:57 +1100" MODIFIED_BY="Narelle S Willis">
<SELECTION_CRITERIA MODIFIED="2010-09-27 16:46:43 +1000" MODIFIED_BY="Narelle S Willis">
<CRIT_STUDIES MODIFIED="2010-09-27 16:46:43 +1000" MODIFIED_BY="Narelle S Willis">
<P>For inclusion, studies needed to satisfy the following inclusion criteria.<BR/>
</P>
<UL>
<LI>Random allocation to either a low or a high salt diet.</LI>
<LI>Sodium intake was estimated by 24 hour urinary sodium excretion (24h UNa) and studies achieved a minimum difference in 24h UNa of 34 mmol (i.e. 2 g salt/day). The reduction in 24h UNa was calculated as UNa (high) - UNa (low) in crossover studies and was calculated as (U Na (high) - UNa (low)) low salt group - (UNa (high) - UNa (low)) control group in parallel studies. For crossover studies, UNa (low) was the 24h UNa at the end of the reduced salt period and the UNa (high) was the 24h UNa at the end of the high salt period. For parallel studies, UNa (high) and UNa (low) was the 24h UNa at baseline and at the end of the intervention for each group.</LI>
<LI>Studies where concomitant interventions, such as antihypertensive medication or other dietary modifications, were used during the study period, providing that these interventions were constant throughout the low and high salt period.</LI>
</UL>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-07-14 14:06:32 +1000" MODIFIED_BY="Narelle S Willis">
<P>We included all RCTs of adults (18 years or older) with type 1 or type 2 diabetes mellitus, irrespective of ethnicity or gender. We excluded studies of children and pregnant women.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-07-14 14:06:32 +1000" MODIFIED_BY="Narelle S Willis">
<P>We included studies where low salt intake was compared to high salt intake.<BR/>
</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-09-20 16:51:43 +1000" MODIFIED_BY="Narelle S Willis">
<P>The main outcome measures extracted were net change in 24h UNa and BP. Where available we additionally extracted data on urinary albumin excretion (UAE), creatinine clearance (CrCl) or glomerular filtration rate (GFR), effective renal plasma flow (ERPF), body weight, body mass index (BMI) and glycated haemoglobin (HbA1c).</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-11-10 11:29:57 +1100" MODIFIED_BY="Narelle S Willis">
<P>We designed and carried out the search strategy in collaboration with the Trials Search Co-ordinator from the Cochrane Renal Group (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> - Electronic search strategies).</P>
<ELECTRONIC_SEARCHES MODIFIED="2010-11-10 11:29:57 +1100" MODIFIED_BY="Narelle S Willis">
<P>We searched the following databases:</P>
<OL>
<LI>The Cochrane Renal Group&#8217;s specialised register using keywords relevant to this review. The register is populated using the following strategies:</LI>
<OL>
<LI>Screening of weekly Ovid MEDLINE AutoAlerts using a search strategy covering the scope of the Group (see the Renal Group&#8217;s module under Specialised Register at <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/RENAL/frame.html">http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/RENAL/frame.html</A>) plus the optimally sensitive strategy developed for the Cochrane Collaboration for the identification of RCTs (<LINK REF="REF-Lefebvre-2008" TYPE="REFERENCE">Lefebvre 2008</LINK>).</LI>
<LI>Quarterly searches of NEW records in the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library using a search strategy covering the scope of the Group.</LI>
<LI>Records handsearched by the Renal Group. The Renal Group has undertaken extensive handsearching of renal-related journals and conference proceedings, therefore we did not specifically search conference proceedings. Please refer to The Cochrane Renal Review Group's module in <I>The Cochrane Library </I>for the most current list of conference proceedings (<LINK REF="REF-Renal-Group-2010" TYPE="REFERENCE">Renal Group 2010</LINK>).</LI>
</OL>
<LI>Cochrane Register of Controlled Trials (CENTRAL). The latest issue will be searched using a strategy developed for this review with input from the Trials Search Co-ordinator.</LI>
<LI>MEDLINE (OvidSP interface) from 1966. The optimally sensitive strategy developed for The Cochrane Collaboration to identify RCTs (<LINK REF="REF-Lefebvre-2008" TYPE="REFERENCE">Lefebvre 2008</LINK>) with a specific search strategy developed with input from the Trial Search Co-ordinator.</LI>
<LI>EMBASE (OvidSP interface) from 1980. A search was made for records added since the latest contribution to CENTRAL by the UK Cochrane Centre, using the strategy developed with input from the Trials Search Co-ordinator.</LI>
</OL>
<P>Date of last search: January 2010</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2010-09-20 16:54:24 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>Reference lists of nephrology textbooks, review articles and relevant studies.</LI>
<LI>Letters seeking information about unpublished or incomplete studies to investigators known to be involved in previous studies.</LI>
</OL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-09-27 16:49:40 +1000" MODIFIED_BY="Narelle S Willis">
<STUDY_SELECTION MODIFIED="2010-09-26 16:51:05 +1000" MODIFIED_BY="Narelle S Willis">
<P>Two review authors independently undertook assessment of citations. We retrieved full articles if the initial assessment suggested that studies or reviews might include relevant data. We independently assessed abstracts and, if necessary, the full text to identify suitable studies. We resolved disagreements in consultation with the third author.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-09-26 16:50:33 +1000" MODIFIED_BY="Narelle S Willis">
<P>We extracted data using standard data extraction forms. We recorded relevant data including characteristics of the study, design (parallel or crossover), type of study (open, single-blind, double-blind), method of blinding, study duration and pre- and post-intervention results. Where more than one publication of a study existed, we used the publication with the most complete data.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-09-26 16:51:58 +1000" MODIFIED_BY="Narelle S Willis">
<P>Criteria for the assessment of study quality were as follows.</P>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<UL>
<LI>Adequate (A): the randomisation method described would not allow participants and investigators to foresee assignment.</LI>
<LI>Unclear (B): randomisation method is stated but no information of the method used described.</LI>
<LI>Inadequate (C): method of randomisation allowed participants and investigators to foresee assignment, e.g. unsealed envelopes or alternate medical record numbers.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding</HEADING>
<UL>
<LI>Blinding of the investigator: yes/no/not stated.</LI>
<LI>Blinding of the participant: yes/no/not stated.</LI>
<LI>Blinding of the outcome assessor: yes/no/not stated.</LI>
<LI>Blinding of the data analysis: yes/no/not stated.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Intention to treat analysis</HEADING>
<UL>
<LI>Yes: specifically reported by authors that intention to treat analysis was undertaken and confirmed on study assessment.</LI>
<LI>Yes: not specifically reported but confirmed on study assessment.</LI>
<LI>No: not reported and lack of intention to treat analysis confirmed on study assessment.</LI>
<LI>No: stated but not confirmed upon study assessment.</LI>
<LI>Not stated.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Completeness of follow-up</HEADING>
<P>The percentage of participants excluded or lost to follow-up was recorded.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2010-09-27 16:49:40 +1000" MODIFIED_BY="Narelle S Willis">
<P>We calculated treatment effect for each study. We calculated mean difference (MD) for outcome measurements. In crossover studies, we calculated the MD in outcomes as the difference between the end of the low salt period and the end of the high salt period. For parallel studies we calculated the treatment effect as the difference between the two treatment groups in the change in outcomes from baseline.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2010-09-26 16:50:47 +1000" MODIFIED_BY="Narelle S Willis">
<P>We contacted the original authors when relevant data were not reported in the publication.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2010-09-26 16:49:23 +1000" MODIFIED_BY="Narelle S Willis">
<P>We examined heterogeneity using the I² and Q statistics. I² describes the percent variation across studies that results from heterogeneity rather than chance (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). We performed subgroup analysis to explore sources of heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2010-09-26 16:49:13 +1000" MODIFIED_BY="Narelle S Willis">
<P>We pooled data using both fixed-effect and random-effects models, to ensure robustness of the model chosen and susceptibility to outliers.</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-10-26 17:16:04 +1100" MODIFIED_BY="Narelle S Willis">
<STUDY_DESCRIPTION MODIFIED="2010-09-27 16:55:30 +1000" MODIFIED_BY="Narelle S Willis">
<SEARCH_RESULTS MODIFIED="2010-09-26 16:43:28 +1000" MODIFIED_BY="Narelle S Willis">
<P>The search strategy identified 884 citations, of which we excluded 818 on the basis of abstract and title. We conducted full text analysis in 66 articles, of which 13, with 254 subjects, met our inclusion criteria (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2010-09-27 16:55:30 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>One article presented two separate studies (one with crossover design and the other with parallel design); we entered the data for these as separate studies in this meta-analysis (<LINK REF="STD-Dodson_x005f_P-1989" TYPE="STUDY">Dodson_P 1989</LINK>; <LINK REF="STD-Dodson_x005f_X-1989" TYPE="STUDY">Dodson_X 1989</LINK>).</LI>
<LI>Six articles enrolled patients with normal levels of albuminuria (<LINK REF="STD-Miller-1995" TYPE="STUDY">Miller 1995</LINK>; <LINK REF="STD-Miller-1997" TYPE="STUDY">Miller 1997</LINK>; <LINK REF="STD-Lopes-De-Faria-1997" TYPE="STUDY">Lopes De Faria 1997</LINK>; <LINK REF="STD-Petrie-1998" TYPE="STUDY">Petrie 1998</LINK>; <LINK REF="STD-Dodson_x005f_X-1989" TYPE="STUDY">Dodson_X 1989</LINK>; <LINK REF="STD-Luik-2002" TYPE="STUDY">Luik 2002</LINK>); two articles included patients with microalbuminuria (<LINK REF="STD-Mulhauser-1996" TYPE="STUDY">Mulhauser 1996</LINK>; <LINK REF="STD-Houlihan_x005f_Losartan-2002" TYPE="STUDY">Houlihan_Losartan 2002</LINK>); and four articles presented data for different categories of albuminuria (<LINK REF="STD-Trevisan_x005f_Micro-1998" TYPE="STUDY">Trevisan_Micro 1998</LINK>; <LINK REF="STD-Yoshioka_x005f_Normo-1998" TYPE="STUDY">Yoshioka_Normo 1998</LINK>; <LINK REF="STD-Imanishi_x005f_Normo-2001" TYPE="STUDY">Imanishi_Normo 2001</LINK>; <LINK REF="STD-Vedovato_x005f_Micro-2004" TYPE="STUDY">Vedovato_Micro 2004</LINK>). We entered the data for each category of UAE into the meta-analysis as separate studies.</LI>
<LI>One study compared salt reduction in two groups of patients with type 2 diabetes, on losartan or placebo, and presented data for both categories separately. We included these as two separate study entries (<LINK REF="STD-Houlihan_x005f_Losartan-2002" TYPE="STUDY">Houlihan_Losartan 2002</LINK>; <LINK REF="STD-Houlihan_x005f_Placebo-2002" TYPE="STUDY">Houlihan_Placebo 2002</LINK>). To avoid confusion, we used the term "study" for each entry throughout this meta-analysis. There were 20 separate study entries from 13 reports.</LI>
<LI>Three studies used parallel design (<LINK REF="STD-Mulhauser-1996" TYPE="STUDY">Mulhauser 1996</LINK>; <LINK REF="STD-De_x0027_oliveira-1997" TYPE="STUDY">De'oliveira 1997</LINK>; <LINK REF="STD-Dodson_x005f_P-1989" TYPE="STUDY">Dodson_P 1989</LINK>) and 17 studies used a crossover design.</LI>
<LI>Five studies were of longer duration (i.e. more than two weeks) and there were no studies longer than three months' duration (<LINK REF="STD-Dodson_x005f_P-1989" TYPE="STUDY">Dodson_P 1989</LINK>; <LINK REF="STD-Dodson_x005f_X-1989" TYPE="STUDY">Dodson_X 1989</LINK>; <LINK REF="STD-Mulhauser-1996" TYPE="STUDY">Mulhauser 1996</LINK>; <LINK REF="STD-Houlihan_x005f_Losartan-2002" TYPE="STUDY">Houlihan_Losartan 2002</LINK>; <LINK REF="STD-Houlihan_x005f_Placebo-2002" TYPE="STUDY">Houlihan_Placebo 2002</LINK>). The remaining studies were shorter (i.e. less than two weeks).</LI>
<LI>Six studies included 72 patients with high BP (&gt; 140/90 mm Hg) (<LINK REF="STD-De_x0027_oliveira-1997" TYPE="STUDY">De'oliveira 1997</LINK>; <LINK REF="STD-Dodson_x005f_P-1989" TYPE="STUDY">Dodson_P 1989</LINK>; <LINK REF="STD-Dodson_x005f_X-1989" TYPE="STUDY">Dodson_X 1989</LINK>; <LINK REF="STD-Petrie-1998" TYPE="STUDY">Petrie 1998</LINK>; <LINK REF="STD-Houlihan_x005f_Losartan-2002" TYPE="STUDY">Houlihan_Losartan 2002</LINK>; <LINK REF="STD-Houlihan_x005f_Placebo-2002" TYPE="STUDY">Houlihan_Placebo 2002</LINK>) and 14 studies in 182 patients with normal BP (&lt; 140/90 mm Hg).</LI>
<LI>UNa excretion was available graphically in two studies (<LINK REF="STD-Vedovato_x005f_Micro-2004" TYPE="STUDY">Vedovato_Micro 2004</LINK>; <LINK REF="STD-Vedovato_x005f_Normo-2004" TYPE="STUDY">Vedovato_Normo 2004</LINK>).</LI>
<LI>The median age was 57 years, ranging from 23 to 63 years.</LI>
<LI>The median duration of salt restriction was one week, ranging from five days to 12 weeks.</LI>
</UL>
<P>We have summarised the characteristics of studies included in the meta-analyses in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2010-09-26 16:43:04 +1000" MODIFIED_BY="Narelle S Willis">
<P>Reasons for exclusion were: study population not diabetic (33); non-randomised design (10); multiple randomised interventions (3); review article (3); duplicate publication (2) and appropriate data unavailable (2). </P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-09-27 16:26:05 +1000" MODIFIED_BY="Narelle S Willis">
<P>All included studies were small and of variable methodology. </P>
<ALLOCATION MODIFIED="2010-09-21 17:25:58 +1000" MODIFIED_BY="Narelle S Willis">
<P>All the 20 identified studies were randomised. The method of randomisation was reported as random number allocation in one study (<LINK REF="STD-Luik-2002" TYPE="STUDY">Luik 2002</LINK>). All other studies provided no details of the method of randomisation.</P>
</ALLOCATION>
<BLINDING MODIFIED="2010-09-26 16:44:37 +1000" MODIFIED_BY="Narelle S Willis">
<P>Four of the 20 studies were double-blinded (<LINK REF="STD-Dodson_x005f_X-1989" TYPE="STUDY">Dodson_X 1989</LINK>; <LINK REF="STD-Miller-1995" TYPE="STUDY">Miller 1995</LINK>; <LINK REF="STD-Mulhauser-1996" TYPE="STUDY">Mulhauser 1996</LINK>; <LINK REF="STD-Petrie-1998" TYPE="STUDY">Petrie 1998</LINK>); 5/20 were investigator blinded (<LINK REF="STD-Dodson_x005f_P-1989" TYPE="STUDY">Dodson_P 1989</LINK>; <LINK REF="STD-Trevisan_x005f_Micro-1998" TYPE="STUDY">Trevisan_Micro 1998</LINK>; <LINK REF="STD-Trevisan_x005f_Normo-1998" TYPE="STUDY">Trevisan_Normo 1998</LINK>; <LINK REF="STD-Imanishi_x005f_Micro-2001" TYPE="STUDY">Imanishi_Micro 2001</LINK>; <LINK REF="STD-Imanishi_x005f_Normo-2001" TYPE="STUDY">Imanishi_Normo 2001</LINK>) and blinding was unclear in 11 studies.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2010-09-27 16:26:05 +1000" MODIFIED_BY="Narelle S Willis">
<P>None of the 20 studies reported intention-to-treat analysis. Data were complete in all studies with the exception of one study where 1/9 patients was lost to follow-up (<LINK REF="STD-Petrie-1998" TYPE="STUDY">Petrie 1998</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Outcome reporting</HEADING>
<P>All studies reported BP measurements and 24h UNa excretion. There was more variability in reporting of measurements of kidney function and urinary albumin. Studies used different isotopes to measure GFR and other haemodynamic measurements (<LINK REF="STD-De_x0027_oliveira-1997" TYPE="STUDY">De'oliveira 1997</LINK>; <LINK REF="STD-Lopes-De-Faria-1997" TYPE="STUDY">Lopes De Faria 1997</LINK>; <LINK REF="STD-Miller-1997" TYPE="STUDY">Miller 1997</LINK>; <LINK REF="STD-Trevisan_x005f_Micro-1998" TYPE="STUDY">Trevisan_Micro 1998</LINK>; <LINK REF="STD-Trevisan_x005f_Normo-1998" TYPE="STUDY">Trevisan_Normo 1998</LINK>; <LINK REF="STD-Yoshioka_x005f_Adva_x005f_alb-1998" TYPE="STUDY">Yoshioka_Adva_alb 1998</LINK>; <LINK REF="STD-Yoshioka_x005f_Micro-1998" TYPE="STUDY">Yoshioka_Micro 1998</LINK>; <LINK REF="STD-Yoshioka_x005f_Normo-1998" TYPE="STUDY">Yoshioka_Normo 1998</LINK>; <LINK REF="STD-Imanishi_x005f_Micro-2001" TYPE="STUDY">Imanishi_Micro 2001</LINK>; <LINK REF="STD-Imanishi_x005f_Normo-2001" TYPE="STUDY">Imanishi_Normo 2001</LINK>; <LINK REF="STD-Houlihan_x005f_Losartan-2002" TYPE="STUDY">Houlihan_Losartan 2002</LINK>; <LINK REF="STD-Houlihan_x005f_Placebo-2002" TYPE="STUDY">Houlihan_Placebo 2002</LINK>; <LINK REF="STD-Luik-2002" TYPE="STUDY">Luik 2002</LINK>). UAE was reported in ways that could not be entered into pooled analysis, with two studies reporting data as geometric mean and percentage change (<LINK REF="STD-Houlihan_x005f_Losartan-2002" TYPE="STUDY">Houlihan_Losartan 2002</LINK>; <LINK REF="STD-Houlihan_x005f_Placebo-2002" TYPE="STUDY">Houlihan_Placebo 2002</LINK>) and two studies presenting data as median and interquartile range (<LINK REF="STD-Vedovato_x005f_Micro-2004" TYPE="STUDY">Vedovato_Micro 2004</LINK>; <LINK REF="STD-Vedovato_x005f_Normo-2004" TYPE="STUDY">Vedovato_Normo 2004</LINK>). We have summarised the outcomes in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>.</P>
</SUBSECTION>
</EXCLUSIONS>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-10-26 17:16:04 +1100" MODIFIED_BY="Narelle S Willis">
<P>As studies were not of sufficient duration to test the efficacy of salt reduction on outcome measurements such as heart attacks, end-stage kidney disease (ESKD) or death, changes in salt intake on BP and surrogate markers of DKD were considered in evaluating the evidence for this review.</P>
<SUBSECTION>
<HEADING LEVEL="3">Urinary sodium (UNa)</HEADING>
<P>Median 24h UNa on the high salt intake was 200 mmol (11.7 g salt/day), ranging from 167 to 324 mmol/24h (9.8 to 18.9 g salt/day) and was 67 mmol (3.9 g salt/day) ranging from 10 to 136.8 mmol (0.6 to 8.0 g salt/day) on low salt intake. The median net change in 24h UNa was 145 mmol/24h (8.5 g salt/day), ranging from 61.9 to 298 mmol (3.6 to 17.4 g salt/day).</P>
<P>In longer studies, median 24h UNa on the high salt diet was 198.8 mmol (11.6 g salt/day), ranging from 167 to 230 mmol (9.7 to 13.4 g salt/day) and was 92 mmol (5.4 g salt/day), ranging from 80 to 136.8 mmol (4.7 to 8 g salt/day) on the low salt diet. The median net change in 24h UNa was 76.2 mmol (4.5 g salt/day), ranging from 61.90 to 145 mmol (3.6 to 8.5 g salt/day).</P>
<P>In short studies, median 24h UNa on the usual/high salt diet was 220 mmol (12.9 g salt/day), ranging from 171 to 324 mmol (10 to 18.9 g salt/day) and was 44 mmol (2.6 g salt/day), ranging from 10 to 97 mmol (0.6 to 5.7 g salt/day) on the low salt diet. The median net change in 24hr UNa was 188.5 mmol (11 g salt/day), ranging from 104 to 298 mmol (6.1 to 17.4 g salt/day).</P>
<P>The median net change in 24h UNa in type 1 diabetes was 196 mmol (11 g salt/day) and 125 mmol (7.3 g salt/day) in type 2 diabetes.</P>
<P>In patients with hypertension, the median net change in 24h UNa was 130 mmol (7.6 g salt/day), ranging from 61.9 to 180 mmol and in those with normal BP it was 198 mmol (11.6 g salt/day) ranging from 104 to 337 mmol.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blood pressure</HEADING>
<P>All studies included in the meta-analysis reported measurements of BP as systolic BP (SBP) and diastolic BP (DBP) or as mean arterial pressure (MAP), defined as DBP + (SBP-DBP)/3.</P>
<SUBSECTION>
<HEADING LEVEL="4">Systolic and diastolic blood pressure</HEADING>
<P>Data from 11 studies including 135 individuals were available for analysis of SBP and DBP and are presented in <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> and <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>. Reducing salt intake significantly reduced SBP by -7.04 mm Hg (95% CI -8.71 to -5.38) and DBP by -3.03 mm Hg (95% CI -3.95 to -2.11).</P>
<SUBSECTION>
<HEADING LEVEL="5">Type of diabetes</HEADING>
<P>Salt restriction lowered BP in both type 1 and type 2 diabetes (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
<P>In type 1 diabetes (56 individuals), salt restriction reduced SBP by -7.11 mm Hg (95% CI -9.13 to -5.10) and DBP by -3.13 mm Hg (95% CI -4.28 to -1.98).</P>
<P>In type 2 diabetes (56 individuals), salt restriction reduced SBP by -6.90 mm Hg (95% CI -9.84 to -3.95) and DBP by -2.87 mm Hg (95% CI -4.39 to -1.35). There was significant heterogeneity among studies in type 1 diabetes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Level of initial blood pressure</HEADING>
<P>Salt restriction lowered BP in both hypertensive patients (N = 88) and normotensive patients (N = 56). Salt restriction reduced SBP by -4.86 mm Hg (95% CI -8.31 to -1.41) in hypertensive patients and by -7.70 mm Hg (95% CI -9.60 to -5.81) in normotensive patients. DBP was reduced with salt restriction by -2.96 mm Hg (95% CI -4.81 to -1.11) in hypertensive patients and by -3.06 mm Hg (95% CI 4.11 to -2.00) in normotensive patients (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Length of study</HEADING>
<P>In five studies (70 individuals) of longer duration, salt restriction reduced SBP by -6.20 mm Hg (95% CI -9.98 to -2.43) and DBP by -3.78 mm Hg (95% CI -5.73. to -1.84). In six studies (65 individuals) of shorter duration, salt restriction reduced SBP by -7.25 mm Hg (95% CI -9.10 to -5.40) and DBP by -2.82 mm Hg (95% CI -3.86 to -1.78) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Concomitant intervention</HEADING>
<P>Salt restriction has been demonstrated to be more effective when the RAAS is blocked (<LINK REF="REF-MacGregor-1987" TYPE="REFERENCE">MacGregor 1987</LINK>). Therefore we calculated pooled data excluding data from one study where participants were treated with losartan (<LINK REF="STD-Houlihan_x005f_Losartan-2002" TYPE="STUDY">Houlihan_Losartan 2002</LINK>). Pooled estimates of change showed a reduction in both SBP (-6.91 mm Hg, 95% CI -8.61 to -5.20) and DBP (-2.76 mm Hg, 95% CI -3.73 to -1.79) with salt restriction (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mean arterial blood pressure (MAP)</HEADING>
<P>Pooled estimates of change were available for 11 studies (130 individuals). Salt restriction reduced MAP by -2.19 mm Hg (95% CI -3.32 to -1.06). The effect was greater in longer studies where MAP was reduced by -4.98 mm Hg (95% CI -8.27 to -1.69) compared to -1.82 mm Hg (95% CI -3.02 to -0.62) in shorter studies (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Random-effects model</HEADING>
<P>To ensure robustness, we performed analysis using both fixed-effect and random-effects models. Overall, reductions in SBP, DBP and MAP were similar using both types of analysis. With subgroup analysis net change in DBP in longer studies (-3.15 mm Hg, 95% CI -6.49 to 0.18) and hypertensive patients (-1.87 mm Hg, 95% CI -5.57 to 1.83) did not reach significance and the reduction of MAP was significant in type 1 diabetes, but not in other subgroups.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">The effects of altering salt intake on measurements of kidney function</HEADING>
<P>Two studies (40 individuals) reported changes in SCr. Pooled analysis showed that SCr was not changed with salt restriction in these studies (-0.52 µmol/L, 95% CI -4.74 to 3.71) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
<P>Five studies (59 individuals) reported change in CrCl. Pooled analysis showed that salt restriction reduced CrCl by -6.33 mL/min (95% CI -10.47 to -2.19) (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>). However, pooled analysis of 10 studies (114 individuals) reporting changes in GFR did not significantly change GFR in these studies (-1.92 mL/min, 95% CI -4.49 to 0.64) (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). </P>
<P>Eight studies (114 patients) reported change in ERPF. Salt restriction did not alter ERPF overall in longer studies (MD -0.73, 95% CI -2.83 to 1.37). Salt restriction reduced ERPF by -31.58 (95% CI -49.14 to -14.02) in short studies. There was significant heterogeneity among shorter studies (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">The effect of altering salt intake on urinary albumin and protein</HEADING>
<P>Six studies (85 individuals) presented changes in urinary albumin and protein. Most of these studies reported the data in a way which was not suitable for meta-analysis, therefore we did not perform pooled analysis although we have presented available data in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>. Salt restriction reduced UAE in patients with microalbuminuria in one study of type 2 diabetes (<LINK REF="STD-Vedovato_x005f_Normo-2004" TYPE="STUDY">Vedovato_Normo 2004</LINK>; <LINK REF="STD-Vedovato_x005f_Micro-2004" TYPE="STUDY">Vedovato_Micro 2004</LINK>). Salt restriction also reduced UAE in hypertensive type 2 diabetics on losartan but had no effect on those on placebo (<LINK REF="STD-Houlihan_x005f_Losartan-2002" TYPE="STUDY">Houlihan_Losartan 2002</LINK>; <LINK REF="STD-Houlihan_x005f_Placebo-2002" TYPE="STUDY">Houlihan_Placebo 2002</LINK>). Salt restriction did not changed UAE in a short study including normotensive type 1 diabetics (<LINK REF="STD-Luik-2002" TYPE="STUDY">Luik 2002</LINK>). One study reported 24 hour protein excretion in hypertensive type 1 diabetes (<LINK REF="STD-Mulhauser-1996" TYPE="STUDY">Mulhauser 1996</LINK>) and showed no significant change (-0.41 g/24 h; 95% CI -1.03 to 0.21) (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">The effect of altering salt intake on HbA1c</HEADING>
<P>Six studies (104 individuals) reported change in HbA1c. Pooled analysis did not show a significant change in HbA1c. There was a small reduction in HbA1c limited to shorter studies (-0.19%, 95% CI -0.38 to 0.00) using a fixed-effect model with significant heterogeneity among studies (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>). This was not significant when analysis was performed with a random-effects model.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">The effect of altering salt intake on body weight and BMI</HEADING>
<P>Eleven studies (161 individuals) reported data on body weight. Salt restriction lowered body weight by -1.01 kg (95% CI -1.20 to -0.82) (<LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>). This effect was primarily due to changes in short-term studies, with no significant weight change with salt restriction in longer studies, indicating that these changes are likely to be due to reduction in extracellular volume. Random-effects model showed similar results, with salt restriction reducing weight in all studies by -1.13 kg (95% CI -0.62 to -0.64), shorter studies by -1.21 kg (95% CI -1.74 to -0.69) and with no significant effect in longer studies.</P>
<P>BMI was reported in four studies (56 patients). Salt restriction reduced BMI by 0.40 (95% CI -0.53 to -0.28) with significant heterogeneity among studies (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Investigation of sources of heterogeneity</HEADING>
<P>We used subgroup analysis to explore sources of heterogeneity. The results showed that heterogeneity was greater in shorter studies than longer studies. We did not perform a funnel plot to look for publication bias because the number of studies was too small.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-09-27 17:30:10 +1000" MODIFIED_BY="Narelle S Willis">
<SUBSECTION>
<HEADING LEVEL="2">Summary of main results</HEADING>
<P>In this meta-analysis of RCTs of salt reduction, the first in diabetic subjects, we have shown that reducing salt intake by 8.5 g/day lowers BP by 7/3 mm Hg in type 1 and type 2 diabetes. This fall is similar to that of single drug therapy. Although the aetiology of type 1 and 2 diabetes differs, reducing salt intake was equally effective in type 1 and type 2 diabetes. There was a small reduction in CrCl of 6 mL/min with reduced salt intake although there was no change in GFR or ERPF. There were limited data for the effect of reducing salt intake on UAE and proteinuria, and these were not reported in a way that could be entered into the meta-analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Quality of the evidence</HEADING>
<P>There are important limitations to this review. The number of well-controlled studies on the effects of salt reduction in diabetics was limited, and the majority of available studies were of short duration. The included studies show considerable heterogeneity and the small number of studies limit the ability to explore potential sources of this. It is likely that differing methodology and degrees and duration of salt restriction do have an impact on heterogeneity. Studies varied from five days to 12 weeks and longer studies had more modest changes in salt intake. Several short studies restricted levels of salt intake to as low as 0.6 g/day followed by loading of up to 20 g/day salt. Acute, large changes in dietary salt intake such as this will stimulate the RAAS and increase sympathetic activity. This will have an impact on the effects on BP and renal haemodynamics. This is demonstrated by the lack of any difference in BP between shorter and longer studies, despite a change in median salt intake of almost double that seen in the shorter studies.</P>
<P>Owing to the small number of studies, it is difficult to assess any publication bias. The lack of published negative non-significant findings is the most likely source of bias. Despite using a search strategy to include both published and unpublished studies, we were unable to include any unpublished studies. Outcome measurements were mostly restricted to measurements of BP and surrogate markers of kidney function. We did not find any available data on outcome measurements such as time to ESKD and death. This is not surprising, as studies of this kind are difficult to implement on a practical basis. Although 24 h UNa is a surrogate method of estimating salt intake, approximately 90% of the salt we eat is excreted through the kidneys. Compared with all other methods, e.g. dietary record or recall, measuring 24 h UNa excretion is the most accurate and accepted method for assessing dietary salt intake.</P>
</SUBSECTION>
<APPLICABILITY_OF_FINDINGS MODIFIED="2010-09-27 17:30:10 +1000" MODIFIED_BY="Narelle S Willis">
<P>The available data from this meta-analysis of RCTs of salt reduction indicate that lowering salt intake has clear benefits by reducing BP in both type 1 and type 2 diabetes with and without high BP. It is often difficult in clinical practice to control BP to the levels now recommended by guidelines, and judicious BP control with pharmacological interventions reduces the rate of progression of DKD to ESRF. Commonly, inhibitors of the RAS are used to reduce BP and UAE. High salt intake reduces the efficacy of these agents on BP (<LINK REF="REF-MacGregor-1987" TYPE="REFERENCE">MacGregor 1987</LINK>). In longer studies included in this analysis, reducing salt intake by 6 g/day to the current recommended level of 5 g/day lowered BP by 6/4 mm Hg. This is in keeping with the modest, sustained reductions recommended in UK and WHO public health guidelines of a long-term modest salt reduction to less than 5-6 g/day for populations (<LINK REF="REF-WHO-2002" TYPE="REFERENCE">WHO 2002</LINK>; <LINK REF="REF-SACN-2003" TYPE="REFERENCE">SACN 2003</LINK>). However it is well recognised that this intervention is poorly utilised. Our meta-analysis demonstrates that this intervention lowers BP in diabetes and such reductions in salt intake are achievable and practical. Diabetic patients stand as much to gain as would the general population with modest sustained reduction in salt intake.</P>
<P>There were limited data available to assess the effect of salt reduction on kidney function. UAE is important in monitoring the progression of DKD and is an independent predictor of CVD (<LINK REF="REF-Hillege-2002" TYPE="REFERENCE">Hillege 2002</LINK>). We found only six studies in this meta-analysis where urinary albumin or protein excretion was reported and it was not possible to perform pooled analysis due to the diversity of the data reported (<LINK REF="STD-Mulhauser-1996" TYPE="STUDY">Mulhauser 1996</LINK>; <LINK REF="STD-Luik-2002" TYPE="STUDY">Luik 2002</LINK>; <LINK REF="STD-Houlihan_x005f_Losartan-2002" TYPE="STUDY">Houlihan_Losartan 2002</LINK>; <LINK REF="STD-Vedovato_x005f_Micro-2004" TYPE="STUDY">Vedovato_Micro 2004</LINK>). An acute reduction in salt intake in type 2 diabetics with microalbuminuria reduced UAE in one study, and a more modest salt reduction in type 2 diabetics on losartan also reduced UAE, with no effect in those on placebo (<LINK REF="STD-Houlihan_x005f_Losartan-2002" TYPE="STUDY">Houlihan_Losartan 2002</LINK>; <LINK REF="STD-Vedovato_x005f_Micro-2004" TYPE="STUDY">Vedovato_Micro 2004</LINK>). This is in keeping with studies in other populations, where modest salt reduction reduced UAE and albumin/creatinine ratios in mild hypertension, in White, Black and Asian hypertensive patients and a lower 24 h UNa is associated with reduced albuminuria in individuals with CKD (<LINK REF="REF-Cianciaruso-1998" TYPE="REFERENCE">Cianciaruso 1998</LINK>; <LINK REF="REF-Swift-2005" TYPE="REFERENCE">Swift 2005</LINK>; <LINK REF="REF-He-2009a" TYPE="REFERENCE">He 2009a</LINK>). A recent review of dietary salt intake in CKD concluded that it is likely that salt reduction does reduce UAE (<LINK REF="REF-Jones_x002d_Burton-2006" TYPE="REFERENCE">Jones-Burton 2006</LINK>). From our study, on balance, this seems likely in diabetics with microalbuminuria, but better controlled large studies are needed before definitive conclusions can be drawn in this population. It is impossible to say whether this reduction is BP dependent or independent. However, epidemiological studies and animal experiments have shown that salt has a direct effect on albuminuria independent of BP (<LINK REF="REF-Allen-1997" TYPE="REFERENCE">Allen 1997</LINK>; <LINK REF="REF-Verhave-2004" TYPE="REFERENCE">Verhave 2004</LINK>; <LINK REF="REF-Daviglus-2005" TYPE="REFERENCE">Daviglus 2005</LINK>). While there was an isolated small reduction in CrCl, there was no significant change in SCr, GFR or ERPF. CrCl tends to overestimate GFR and, with differing methods of measuring GFR, different duration of study and magnitude of salt reduction and significant heterogeneity, it is difficult to draw any conclusions on the effect of salt on GFR.</P>
</APPLICABILITY_OF_FINDINGS>
<AGREEMENT MODIFIED="2010-09-27 16:12:29 +1000" MODIFIED_BY="Narelle S Willis">
<P>Previous published meta-analyses of salt reduction studies have shown that reducing salt intake lowers BP in normotensive and hypertensive subjects (<LINK REF="REF-Midgley-1996" TYPE="REFERENCE">Midgley 1996</LINK>; <LINK REF="REF-Law-1991a" TYPE="REFERENCE">Law 1991a</LINK>; <LINK REF="REF-Hooper-2002" TYPE="REFERENCE">Hooper 2002</LINK>; <LINK REF="REF-He-2003" TYPE="REFERENCE">He 2003</LINK>). The degree of reduction in BP is affected by the degree and duration of salt intake (<LINK REF="REF-Law-1991a" TYPE="REFERENCE">Law 1991a</LINK>; <LINK REF="REF-He-2003" TYPE="REFERENCE">He 2003</LINK>). In this meta-analysis, BP response was not changed by study duration. This is likely to be due to the difference in the degree of salt restriction between shorter and longer term studies. Shorter studies had larger changes in salt intake, including restriction to levels as low as 0.6 g salt/day. Some studies were of salt loading. Studies of longer duration were of limited number, with only one study of more than four weeks. It is unlikely that the maximum effect on BP of reduced salt intake will have exerted its full effect within this time frame (<LINK REF="REF-Law-1991b" TYPE="REFERENCE">Law 1991b</LINK>). Despite this, BP was lowered by 6/4 mm Hg with a reduction of salt intake of 6 g/day in studies of longer duration. This is in keeping with a previous meta-analysis where reducing salt intake by 6 g lowers BP by 7/4 mm Hg in hypertensive and 4/2 mm Hg in normotensive subjects (<LINK REF="REF-He-2003" TYPE="REFERENCE">He 2003</LINK>). Whilst previous analysis has suggests a dose response between salt reduction and fall in BP, there were insufficient studies to perform to examine the dose response relationship in this study (<LINK REF="REF-He-2003" TYPE="REFERENCE">He 2003</LINK>).</P>
<P>The initial BP can determine the effect of salt reduction, with a higher initial BP leading to a greater responses to salt reduction (<LINK REF="REF-Law-1991b" TYPE="REFERENCE">Law 1991b</LINK>; <LINK REF="REF-He-2003" TYPE="REFERENCE">He 2003</LINK>). In this meta-analysis, we found that normotensive diabetics had a greater fall in BP with a salt reduction compared to hypertensive diabetics. This is likely to be due to the fact that normotensive patients achieved a greater reduction in salt intake, i.e. 11.6 g/day in normotensive patients compared to 7.6 g/day in those with hypertension.</P>
<P>The effect of salt on insulin resistance has been debated. Studies have, in the majority, examined the effects of large changes in dietary salt on glucose tolerance in healthy or hypertensive populations. Studies using alternative, more sensitive methods, such as euglycaemic clamps, have shown variable results (<LINK REF="REF-Da-Costa-1997" TYPE="REFERENCE">Da Costa 1997</LINK>; <LINK REF="STD-Petrie-1998" TYPE="STUDY">Petrie 1998</LINK>; <LINK REF="STD-Meland-1997" TYPE="STUDY">Meland 1997</LINK>; <LINK REF="STD-Ames-2001" TYPE="STUDY">Ames 2001</LINK>). The small reduction in HbA1c observed in our analysis, which is not as sensitive a measurement of insulin sensitivity, is of debatable significance. </P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-09-27 17:32:19 +1000" MODIFIED_BY="Narelle S Willis">
<IMPLICATIONS_PRACTICE MODIFIED="2010-09-27 17:31:53 +1000" MODIFIED_BY="Narelle S Willis">
<P>This meta-analysis demonstrates that salt reduction reduces BP in individuals with both type 1 and type 2 diabetes. It is often difficult in clinical practice to control BP to the levels now recommended by guidelines, and judicious BP control with pharmacological interventions reduces the rate of progression of DKD to ESRF. These findings, in conjunction with other evidence relating salt intake to BP and albuminuria in hypertensive and normotensive people, make a strong case to reduce salt intake in diabetes, as is recommended for the general population in public health guidelines, to less than 5-6 g/day.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-09-27 17:32:19 +1000" MODIFIED_BY="Narelle S Willis">
<P>The majority of studies in this review are of shorter duration and involve large changes in dietary salt intake. Future studies should focus on a more modest, sustained salt reduction, particularly in those with "normal" BP and early on in the development of DKD. Although outcome evidence on ESKD and cardiovascular death from long-term RCTs is ideal to have, such studies are extremely difficult to implement on a practical basis. Studies of the effects of modest salt reduction on surrogate markers of kidney function, including urinary albumin and on the cardiovascular system, including left ventricular function and pulse wave velocity, would be valuable.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-11-10 11:24:27 +1100" MODIFIED_BY="Narelle S Willis">
<P>We would like to thank;</P>
<UL>
<LI>the referees for their editorial advice during the preparation of this review,</LI>
<LI>the Cochrane Renal Group for their help with the search.</LI>
</UL>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.<B>
<BR/>
</B>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-09-25 18:25:07 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Writing of protocol and review - RS, FH</LI>
<LI>Screening of titles and abstracts - RS, FH</LI>
<LI>Assessment for inclusion - RS, FH</LI>
<LI>Quality assessment - RS, FH</LI>
<LI>Data extraction - RS, FH</LI>
<LI>Data entry into RevMan - RS, FH</LI>
<LI>Data analysis - RS, FH</LI>
<LI>Disagreement resolution - GM</LI>
</UL>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2010-07-14 14:06:32 +1000" MODIFIED_BY="Narelle S Willis">
<P>Data on weight were included for analysis in addition to BMI.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-09-27 16:19:53 +1000" MODIFIED_BY="Narelle S Willis">
<STUDIES MODIFIED="2010-09-27 16:19:53 +1000" MODIFIED_BY="Narelle S Willis">
<INCLUDED_STUDIES MODIFIED="2010-09-14 15:06:18 +1000" MODIFIED_BY="Narelle S Willis">
<STUDY DATA_SOURCE="SOUGHT" ID="STD-De_x0027_oliveira-1997" MODIFIED="2010-09-14 14:15:35 +1000" MODIFIED_BY="Narelle S Willis" NAME="De'oliveira 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-09-14 14:15:35 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De'oliveira JM, Price DA, Fisher NDL, Allan DR, McKnight JA, Williams GH, et al</AU>
<TI>Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition</TI>
<SO>Kidney International</SO>
<YR>1997</YR>
<VL>52</VL>
<NO>3</NO>
<PG>771-7</PG>
<IDENTIFIERS MODIFIED="2010-09-14 14:15:35 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-09-14 14:15:35 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9291199"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Dodson_x005f_P-1989" MODIFIED="2010-09-14 14:22:46 +1000" MODIFIED_BY="Narelle S Willis" NAME="Dodson_P 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-09-14 14:22:46 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dodson PM, Beevers M, Hallworth R, Webberley MJ, Fletcher RF, Taylor KG, et al</AU>
<TI>Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation</TI>
<SO>BMJ</SO>
<YR>1989</YR>
<VL>298</VL>
<NO>6668</NO>
<PG>227-30</PG>
<IDENTIFIERS MODIFIED="2010-09-14 14:22:46 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-09-14 14:22:46 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="2493869"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Dodson_x005f_X-1989" MODIFIED="2010-09-14 15:06:18 +1000" MODIFIED_BY="Narelle S Willis" NAME="Dodson_X 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-09-14 15:06:18 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dodson PM, Beevers M, Hallworth R, Webberley MJ, Fletcher RF, Taylor KG, et al</AU>
<TI>Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation</TI>
<SO>BMJ</SO>
<YR>1989</YR>
<VL>298</VL>
<NO>6668</NO>
<PG>227-30</PG>
<IDENTIFIERS MODIFIED="2010-09-14 15:06:18 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-09-14 15:06:18 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="2493869"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Houlihan_x005f_Losartan-2002" MODIFIED="2010-08-23 17:15:38 +1000" MODIFIED_BY="Narelle S Willis" NAME="Houlihan_Losartan 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-08-23 17:14:11 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Houlihan C, Allen T, Hovey A, Jenkins M, Cooper M, Jerums G</AU>
<TI>A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract]</TI>
<SO>Nephrology</SO>
<YR>2000</YR>
<VL>5</VL>
<PG>32</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:14:11 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:14:11 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00509238"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-08-02 17:07:09 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Houlihan CA, Akdeniz A, Tsalamandris C, Cooper ME, Jerums G, Gilbert RE</AU>
<TI>Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction</TI>
<SO>Diabetes Care</SO>
<YR>2002</YR>
<VL>25</VL>
<NO>6</NO>
<PG>1072-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12032117"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-08-23 17:15:16 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Houlihan CA, Allen T, Hovey A, Jenkins M, Cooper M, Jerums G</AU>
<TI>Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2000</YR>
<VL>11</VL>
<NO>Sept</NO>
<PG>116A</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:15:16 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:15:16 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00615874"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-08-23 17:15:38 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Houlihan CA, Allen TJ, Baxter AL, Panangiotopoulos S, Casley DJ, Cooper ME, et al</AU>
<TI>A low-sodium diet potentiates the effects of losartan in type 2 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2002</YR>
<VL>25</VL>
<NO>4</NO>
<PG>663-71</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:15:38 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:15:38 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11919122"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Houlihan_x005f_Placebo-2002" MODIFIED="2010-08-23 17:15:49 +1000" MODIFIED_BY="Narelle S Willis" NAME="Houlihan_Placebo 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-08-23 17:14:32 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Houlihan C, Allen T, Hovey A, Jenkins M, Cooper M, Jerums G</AU>
<TI>A low salt diet in patients with type II diabetes significantly amplifies the effects of angiotensin II receptor blockade with losartan [abstract]</TI>
<SO>Nephrology</SO>
<YR>2000</YR>
<VL>5</VL>
<PG>32</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:14:32 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:14:32 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00509238"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-08-02 17:07:15 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Houlihan CA, Akdeniz A, Tsalamandris C, Cooper ME, Jerums G, Gilbert RE</AU>
<TI>Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction</TI>
<SO>Diabetes Care</SO>
<YR>2002</YR>
<VL>25</VL>
<NO>6</NO>
<PG>1072-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12032117"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-08-23 17:15:26 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Houlihan CA, Allen T, Hovey A, Jenkins M, Cooper M, Jerums G</AU>
<TI>Comparison of regular versus low sodium diet on the effects of losartan in hypertensive subjects with type II diabetes [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2000</YR>
<VL>11</VL>
<NO>Sept</NO>
<PG>116A</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:15:26 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:15:26 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00615874"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-08-23 17:15:49 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Houlihan CA, Allen TJ, Baxter AL, Panangiotopoulos S, Casley DJ, Cooper ME, et al</AU>
<TI>A low-sodium diet potentiates the effects of losartan in type 2 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2002</YR>
<VL>25</VL>
<NO>4</NO>
<PG>663-71</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:15:49 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:15:49 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11919122"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Imanishi_x005f_Micro-2001" MODIFIED="2010-09-14 14:26:30 +1000" MODIFIED_BY="Narelle S Willis" NAME="Imanishi_Micro 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-09-14 14:26:30 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Imanishi M, Yoshioka K, Okumura M, Konishi Y, Okada N, Morikawa T, et al</AU>
<TI>Sodium sensitivity related to albuminuria appearing before hypertension in type 2 diabetic patients</TI>
<SO>Diabetes Care</SO>
<YR>2001</YR>
<VL>24</VL>
<NO>1</NO>
<PG>111-6</PG>
<IDENTIFIERS MODIFIED="2010-09-14 14:26:30 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-09-14 14:26:30 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11194215"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Imanishi_x005f_Normo-2001" MODIFIED="2010-08-18 13:55:20 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Imanishi_Normo 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-08-18 13:55:20 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Imanishi M, Yoshioka K, Okumura M, Konishi Y, Okada N, Morikawa T, et al</AU>
<TI>Sodium sensitivity related to albuminuria appearing before hypertension in type 2 diabetic patients</TI>
<SO>Diabetes Care</SO>
<YR>2001</YR>
<VL>24</VL>
<NO>1</NO>
<PG>111-6</PG>
<IDENTIFIERS MODIFIED="2010-08-18 13:55:20 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2010-08-18 13:55:20 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="11194215"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lopes-De-Faria-1997" MODIFIED="2010-09-14 14:30:58 +1000" MODIFIED_BY="Narelle S Willis" NAME="Lopes De Faria 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-09-14 14:30:58 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lopes de Faria JB, Friedman R, de Cosmo S, Dodds RA, Mortton JJ, Viberti GC, et al</AU>
<TI>Renal functional response to protein loading in type 1 (insulin-dependent) diabetic patients on normal or high salt intake</TI>
<SO>Nephron</SO>
<YR>1997</YR>
<VL>76</VL>
<NO>4</NO>
<PG>411-7</PG>
<IDENTIFIERS MODIFIED="2010-09-14 14:30:58 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-09-14 14:30:58 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9274838"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luik-2002" MODIFIED="2010-08-02 17:59:19 +1000" MODIFIED_BY="Narelle S Willis" NAME="Luik 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-08-02 17:59:19 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luik PT, Hoogenberg K, Van Der Kleij FG, Beusekamp BJ, Kerstens MN, De Jong PE, et al</AU>
<TI>Short-term moderate sodium restriction induces relative hyperfiltration in normotensive normoalbuminuric Type I diabetes mellitus</TI>
<SO>Diabetologia</SO>
<YR>2002</YR>
<VL>45</VL>
<NO>4</NO>
<PG>535-41</PG>
<IDENTIFIERS MODIFIED="2010-08-02 17:59:19 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-02 17:59:19 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="12032630"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-1995" MODIFIED="2010-09-14 14:32:36 +1000" MODIFIED_BY="Narelle S Willis" NAME="Miller 1995" YEAR="1995, August 1, 1995">
<REFERENCE MODIFIED="2010-09-14 14:32:36 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller JA</AU>
<TI>Sympathetic vasoconstrictive responses to high- and low-sodium diets in diabetic and normal subjects</TI>
<SO>American Journal of Physiology</SO>
<YR>1995</YR>
<VL>269</VL>
<PG>R380-8</PG>
<IDENTIFIERS MODIFIED="2010-09-14 14:32:36 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-09-14 14:32:36 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="7653660"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-1997" MODIFIED="2010-09-14 14:33:21 +1000" MODIFIED_BY="Narelle S Willis" NAME="Miller 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-09-14 14:33:21 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller JA</AU>
<TI>Renal responses to sodium restriction in patients with early diabetes mellitus</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1997</YR>
<VL>8</VL>
<NO>5</NO>
<PG>749-55</PG>
<IDENTIFIERS MODIFIED="2010-09-14 14:33:21 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-09-14 14:33:21 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9176844"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mulhauser-1996" MODIFIED="2010-09-14 14:50:09 +1000" MODIFIED_BY="Narelle S Willis" NAME="Mulhauser 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-09-14 14:50:09 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mulhauser I, Prange K, Sawicki PT, Bender R, Dworschak A, Schaden W, et al</AU>
<TI>Effects of dietary sodium on blood pressure in IDDM patients with nephropathy</TI>
<SO>Diabetologia</SO>
<YR>1996</YR>
<VL>39</VL>
<NO>2</NO>
<PG>212-9</PG>
<IDENTIFIERS MODIFIED="2010-09-14 14:50:09 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-09-14 14:50:09 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8635674"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petrie-1998" MODIFIED="2010-09-14 14:56:39 +1000" MODIFIED_BY="Narelle S Willis" NAME="Petrie 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-09-14 14:56:39 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petrie JR, Morris AD, Minamisawa K, Hilditch TE, Elliott HL, Small M, et al</AU>
<TI>Dietary sodium restriction impairs insulin sensitivity in noninsulin-dependent diabetes mellitus</TI>
<SO>Journal of Clinical Endocrinology &amp; Metabolism</SO>
<YR>1998</YR>
<VL>83</VL>
<NO>5</NO>
<PG>1552-7</PG>
<IDENTIFIERS MODIFIED="2010-09-14 14:56:39 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-09-14 14:56:39 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9589654"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trevisan_x005f_Micro-1998" MODIFIED="2010-09-14 14:59:28 +1000" MODIFIED_BY="Narelle S Willis" NAME="Trevisan_Micro 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-09-14 14:59:28 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trevisan R, Bruttomesso D, Vedovato M, Brocco S, Pianta A, Mazzon C, et al</AU>
<TI>Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria</TI>
<SO>Diabetes</SO>
<YR>1998</YR>
<VL>47</VL>
<NO>8</NO>
<PG>1347-53</PG>
<IDENTIFIERS MODIFIED="2010-09-14 14:59:28 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-09-14 14:59:28 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9703338"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trevisan_x005f_Normo-1998" MODIFIED="2010-08-23 17:16:43 +1000" MODIFIED_BY="Narelle S Willis" NAME="Trevisan_Normo 1998" YEAR="">
<REFERENCE MODIFIED="2010-08-23 17:16:43 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trevisan R, Bruttomesso D, Vedovato M, Brocco S, Pianta A, Mazzon C, et al</AU>
<TI>Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria</TI>
<SO>Diabetes</SO>
<YR>1998</YR>
<VL>47</VL>
<NO>8</NO>
<PG>1347-53</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:16:43 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:16:43 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9703338"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vedovato_x005f_Micro-2004" MODIFIED="2010-09-14 15:01:16 +1000" MODIFIED_BY="Narelle S Willis" NAME="Vedovato_Micro 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-09-14 15:01:16 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vedovato M, Lepore G, Coracina A, Dodesini AR, Jori E, Tiengo A, et al</AU>
<TI>Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance</TI>
<SO>Diabetologia</SO>
<YR>2004</YR>
<VL>47</VL>
<NO>2</NO>
<PG>300-3</PG>
<IDENTIFIERS MODIFIED="2010-09-14 15:01:16 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-09-14 15:01:16 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="14704836"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vedovato_x005f_Normo-2004" MODIFIED="2010-08-18 14:09:55 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Vedovato_Normo 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-08-18 14:09:55 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vedovato M, Lepore G, Coracina A, Dodesini AR, Jori E, Tiengo A, et al</AU>
<TI>Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance</TI>
<SO>Diabetologia</SO>
<YR>2004</YR>
<VL>47</VL>
<NO>2</NO>
<PG>300-3</PG>
<IDENTIFIERS MODIFIED="2010-08-18 14:09:55 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2010-08-18 14:09:55 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="14704836"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yoshioka_x005f_Adva_x005f_alb-1998" MODIFIED="2010-09-14 15:04:40 +1000" MODIFIED_BY="Narelle S Willis" NAME="Yoshioka_Adva_alb 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-09-14 15:04:40 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yoshioka K, Imanishi M, Konishi Y, Sato T, Tanaka S, Kimura G, et al</AU>
<TI>Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients</TI>
<SO>Diabetes Care</SO>
<YR>1998</YR>
<VL>21</VL>
<NO>4</NO>
<PG>482-6</PG>
<IDENTIFIERS MODIFIED="2010-09-14 15:04:40 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-09-14 15:04:40 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9571328"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yoshioka_x005f_Micro-1998" MODIFIED="2010-08-18 14:11:07 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Yoshioka_Micro 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-08-18 14:11:07 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yoshioka K, Imanishi M, Konishi Y, Sato T, Tanaka S, Kimura G, et al</AU>
<TI>Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients</TI>
<SO>Diabetes Care</SO>
<YR>1998</YR>
<VL>21</VL>
<NO>4</NO>
<PG>482-6</PG>
<IDENTIFIERS MODIFIED="2010-08-18 14:11:07 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2010-08-18 14:11:07 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="9571328"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yoshioka_x005f_Normo-1998" MODIFIED="2010-08-18 14:11:23 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Yoshioka_Normo 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-08-18 14:11:23 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yoshioka K, Imanishi M, Konishi Y, Sato T, Tanaka S, Kimura G, et al</AU>
<TI>Glomerular charge and size selectivity assessed by changes in salt intake in type 2 diabetic patients</TI>
<SO>Diabetes Care</SO>
<YR>1998</YR>
<VL>21</VL>
<NO>4</NO>
<PG>482-6</PG>
<IDENTIFIERS MODIFIED="2010-08-18 14:11:23 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2010-08-18 14:11:23 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="9571328"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-09-27 16:19:53 +1000" MODIFIED_BY="Narelle S Willis">
<STUDY DATA_SOURCE="PUB" ID="STD-Ames-2001" MODIFIED="2010-08-23 17:16:56 +1000" MODIFIED_BY="Narelle S Willis" NAME="Ames 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-08-23 17:16:56 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ames RP</AU>
<TI>The effect of sodium supplementation on glucose tolerance and insulin concentrations in patients with hypertension and diabetes mellitus</TI>
<SO>American Journal of Hypertension</SO>
<YR>2001</YR>
<VL>14</VL>
<NO>7 Pt 1</NO>
<PG>653-9</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:16:56 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:16:56 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11465650"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bakris-1996" MODIFIED="2010-08-18 14:58:49 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Bakris 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-08-18 14:58:49 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bakris GL, Smith A</AU>
<TI>Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1996</YR>
<VL>125</VL>
<NO>3</NO>
<PG>201-4</PG>
<IDENTIFIERS MODIFIED="2010-08-18 14:58:49 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2010-08-18 14:58:49 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="8686978"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barsotti-1993" MODIFIED="2010-08-23 17:17:38 +1000" MODIFIED_BY="Narelle S Willis" NAME="Barsotti 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-08-23 17:17:38 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Barsotti G, Cupisti A, Morelli E, Meola M, Meriggioli M, Giovannetti S</AU>
<TI>Implications of dietary treatment in diabetic nephropathy [abstract]</TI>
<SO>12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel</SO>
<YR>1993</YR>
<PG>440</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:17:38 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:17:38 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00740508"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bellini-1996" MODIFIED="2010-08-23 17:17:43 +1000" MODIFIED_BY="Narelle S Willis" NAME="Bellini 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-08-23 17:17:43 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bellini C, Ferri C, Carlomagno A, Necozione S, Lepore AR, Desideri G, et al</AU>
<TI>Impaired inactive to active kallikrein conversion in human salt-sensitive hypertension</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1996</YR>
<VL>7</VL>
<NO>12</NO>
<PG>2565-77</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:17:43 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:17:43 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8989735"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boero-1998" MODIFIED="2010-08-23 17:20:15 +1000" MODIFIED_BY="Narelle S Willis" NAME="Boero 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-08-23 17:18:34 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boero R, Pignataro A, Iadarola GM, Guarena C, Alfieri V, Quarello F</AU>
<TI>Effects of salt on intrarenal hemodynamics in essential hypertensive patients [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>Program &amp; Abstracts</NO>
<PG>321A</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:18:32 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:18:32 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00444466"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-08-23 17:19:17 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Boero R, Pignataro A, Iadarola GM, Quarello F</AU>
<TI>Effects of high salt intake on 24 hour blood pressure and systemic hemodynamics in essential hypertensive patients [abstract]</TI>
<SO>35th Congress. European Renal Association. European Dialysis and Transplantation Association; 1998 Jun 6-9; Rimini, Italy</SO>
<YR>1998</YR>
<PG>87</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:19:17 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:19:17 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00483277"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-08-23 17:20:15 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Boero R, Pignataro A, Iadarola GM, Quarello F</AU>
<TI>Renal effects of high salt intake in patients with essential hypertension [abstract]</TI>
<SO>35th Congress. European Renal Association. European Dialysis and Transplantation Association; 1998 Jun 6-9; Rimini, Italy</SO>
<YR>1998</YR>
<PG>89</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:20:15 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:20:15 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00483278"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buter-1998" MODIFIED="2010-08-18 15:00:38 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Buter 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-08-18 15:00:38 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buter H, Hemmelder M, Navis G, de Jong P, de Zeeuw D</AU>
<TI>The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1998</YR>
<VL>13</VL>
<NO>7</NO>
<PG>1682-5</PG>
<IDENTIFIERS MODIFIED="2010-08-18 15:00:38 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2010-08-18 15:00:38 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="9681711"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cianciaruso-1998" MODIFIED="2010-07-14 14:51:01 +1000" MODIFIED_BY="Narelle S Willis" NAME="Cianciaruso 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-07-14 14:51:01 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cianciaruso B, Bellizzi V, Minutolo R, Tavera A, Capuano A, Conte G, et al</AU>
<TI>Salt intake and renal outcome in patients with progressive renal disease</TI>
<SO>Mineral &amp; Electrolyte Metabolism</SO>
<YR>1998</YR>
<VL>24</VL>
<PG>296-301</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9554571"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cuzzola-2001" MODIFIED="2010-08-23 17:20:23 +1000" MODIFIED_BY="Narelle S Willis" NAME="Cuzzola 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-08-23 17:20:23 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cuzzola F, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Cataliotti A, et al</AU>
<TI>Urinary adrenomedullin is related to ET-1 and salt intake in patients with mild essential hypertension. Salt Sensitivity Group of Italian Society of Hypertension</TI>
<SO>American Journal of Hypertension</SO>
<YR>2001</YR>
<VL>14</VL>
<NO>3</NO>
<PG>224-30</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:20:23 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:20:23 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11281233"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Del-Rio-1993" MODIFIED="2010-08-23 17:20:28 +1000" MODIFIED_BY="Narelle S Willis" NAME="Del Rio 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-08-23 17:20:28 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Del Rio A, Rodriguez-Villamil JL</AU>
<TI>Metabolic effects of strict salt restriction in essential hypertensive patients</TI>
<SO>Journal of Internal Medicine</SO>
<YR>1993</YR>
<VL>233</VL>
<NO>5</NO>
<PG>409-14</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:20:28 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:20:28 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8487006"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dengel-1998" MODIFIED="2010-08-23 17:20:38 +1000" MODIFIED_BY="Narelle S Willis" NAME="Dengel 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-08-23 17:20:38 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dengel DR, Hogikyan RV, Brown MD, Glickman SG, Supiano MA</AU>
<TI>Insulin sensitivity is associated with blood pressure response to sodium in older hypertensives</TI>
<SO>American Journal of Physiology</SO>
<YR>1998</YR>
<VL>274</VL>
<NO>3</NO>
<PG>E403-9</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:20:38 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:20:38 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9530121"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dodson-1984" MODIFIED="2010-08-23 17:20:42 +1000" MODIFIED_BY="Narelle S Willis" NAME="Dodson 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-08-23 17:20:42 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dodson PM, Pacy PJ, Bal P, Kubicki AJ, Fletcher RF, Taylor KG</AU>
<TI>A controlled trial of a high fibre, low fat and low sodium diet for mild hypertension in Type 2 (non-insulin-dependent) diabetic patients</TI>
<SO>Diabetologia</SO>
<YR>1984</YR>
<VL>27</VL>
<NO>5</NO>
<PG>522-6</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:20:42 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:20:42 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="6096193"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Donovan-1993" MODIFIED="2010-08-23 17:20:48 +1000" MODIFIED_BY="Narelle S Willis" NAME="Donovan 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-08-23 17:20:48 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Donovan DS, Solomon CG, Seely EW, Williams GH, Simonson DC</AU>
<TI>Effect of sodium intake on insulin sensitivity</TI>
<SO>American Journal of Physiology</SO>
<YR>1993</YR>
<VL>264</VL>
<NO>5 27-5</NO>
<PG>E730-4</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:20:48 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:20:48 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8498495"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DUAAL-Study" MODIFIED="2010-08-23 17:21:12 +1000" MODIFIED_BY="Narelle S Willis" NAME="DUAAL Study" YEAR="2006">
<REFERENCE MODIFIED="2010-08-23 17:21:12 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>ISRCTN50137410</AU>
<TI>Dual renin-angiotensin system-blockade by angiotension-converting enzyme-inhibition and angiotension receptor type 1 receptor blockade, role of the angiotension-converting enzyme inhibitor or D genotype and low sodium diet in non-diabetic proteinuric patients</TI>
<SO>controlled-trials.com/ISRCTN50137410</SO>
<YR>(accessed 16 August 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-08-18 15:08:03 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2010-08-18 15:08:03 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="ISRCTN" VALUE="50137410"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Egan-1993" MODIFIED="2010-08-23 17:21:00 +1000" MODIFIED_BY="Narelle S Willis" NAME="Egan 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-08-23 17:21:00 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Egan BM, Stepniakowski K</AU>
<TI>Effects of enalapril on the hyperinsulinemic response to severe salt restriction in obese young men with mild systemic hypertension</TI>
<SO>American Journal of Cardiology</SO>
<YR>1993</YR>
<VL>72</VL>
<NO>1</NO>
<PG>53-7</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:21:00 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:21:00 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8517428"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evrenkaya-1999" MODIFIED="2010-09-27 16:19:53 +1000" MODIFIED_BY="Narelle S Willis" NAME="Evrenkaya 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-09-27 16:19:53 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evrenkaya R, Kurtoglu S, Atasoyu EN, Onde E, Ersoz HO, Tulbek MY</AU>
<TI>Assessment of the relation between sodium sensitivity and insulin resistance in norm and hypertensive non-diabetic individuals [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>9</NO>
<PG>A64</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:21:53 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:21:53 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00483894"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feldman-1996" MODIFIED="2010-08-23 17:21:58 +1000" MODIFIED_BY="Narelle S Willis" NAME="Feldman 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-08-23 17:21:58 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feldman RD, Logan AG, Schmidt ND</AU>
<TI>Dietary salt restriction increases vascular insulin resistance</TI>
<SO>Clinical Pharmacology &amp; Therapeutics</SO>
<YR>1996</YR>
<VL>60</VL>
<NO>4</NO>
<PG>444-51</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:21:58 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:21:58 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8873692"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feldman-1999" MODIFIED="2010-08-23 17:22:04 +1000" MODIFIED_BY="Narelle S Willis" NAME="Feldman 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-08-23 17:22:04 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feldman RD, Schmidt ND</AU>
<TI>Moderate dietary salt restriction increases vascular and systemic insulin resistance</TI>
<SO>American Journal of Hypertension</SO>
<YR>1999</YR>
<VL>12</VL>
<NO>6</NO>
<PG>643-7</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:22:04 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:22:04 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="10371376"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feldt_x002d_Rasmussen-1987" MODIFIED="2010-08-23 17:22:13 +1000" MODIFIED_BY="Narelle S Willis" NAME="Feldt-Rasmussen 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-08-23 17:22:13 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feldt-Rasmussen B, Mathiesen ER, Deckert T, Giese J, Christensen NJ, Bent-Hansen L, et al</AU>
<TI>Central role for sodium in the pathogenesis of blood pressure changes independent of angiotensin, aldosterone and catecholamines in Type 1 (insulin-dependent) diabetes mellitus</TI>
<SO>Diabetologia</SO>
<YR>1987</YR>
<VL>30</VL>
<NO>8</NO>
<PG>610-7</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:22:13 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:22:13 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="3653559"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fliser-1995" MODIFIED="2010-08-23 17:22:21 +1000" MODIFIED_BY="Narelle S Willis" NAME="Fliser 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-08-23 17:22:21 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fliser D, Fode P, Arnold U, Nowicki M, Kohl B, Ritz E</AU>
<TI>The effect of dietary salt on insulin sensitivity</TI>
<SO>European Journal of Clinical Investigation</SO>
<YR>1995</YR>
<VL>25</VL>
<NO>1</NO>
<PG>39-43</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:22:21 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:22:21 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE=" 7705385"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerdts-1996" MODIFIED="2010-08-23 17:22:26 +1000" MODIFIED_BY="Narelle S Willis" NAME="Gerdts 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-08-23 17:22:26 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerdts E, Svarstad E, Myking OL, Lund-Johansen P, Omvik P, Gerdts E, et al</AU>
<TI>Salt sensitivity in hypertensive type-1 diabetes mellitus</TI>
<SO>Blood Pressure</SO>
<YR>1996</YR>
<VL>5</VL>
<NO>2</NO>
<PG>78-85</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:22:26 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:22:26 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9162448"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gilleran-1996" MODIFIED="2010-08-23 17:22:31 +1000" MODIFIED_BY="Narelle S Willis" NAME="Gilleran 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-08-23 17:22:31 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gilleran G, O'Leary M, Bartlett WA, Vinall H, Jones AF, Dodson PM</AU>
<TI>Effects of dietary sodium substitution with potassium and magnesium in hypertensive type II diabetics: a randomised blind controlled parallel study</TI>
<SO>Journal of Human Hypertension</SO>
<YR>1996</YR>
<VL>10</VL>
<NO>8</NO>
<PG>517-21</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:22:31 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:22:31 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8895035"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gomi-1998" MODIFIED="2010-08-23 17:22:45 +1000" MODIFIED_BY="Narelle S Willis" NAME="Gomi 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-08-23 17:22:45 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gomi T, Shibuya Y, Sakurai J, Hirawa N, Hasegawa K, Ikeda T</AU>
<TI>Strict dietary sodium reduction worsens insulin sensitivity by increasing sympathetic nervous activity in patients with primary hypertension</TI>
<SO>American Journal of Hypertension</SO>
<YR>1998</YR>
<VL>11</VL>
<NO>9</NO>
<PG>1048-55</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:22:45 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:22:45 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9752889"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grey-1996" MODIFIED="2010-08-23 17:22:50 +1000" MODIFIED_BY="Narelle S Willis" NAME="Grey 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-08-23 17:22:50 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grey A, Braatvedt G, Holdaway I</AU>
<TI>Moderate dietary salt restriction does not alter insulin resistance or serum lipids in normal men</TI>
<SO>American Journal of Hypertension</SO>
<YR>1996</YR>
<VL>9</VL>
<NO>4 Pt 1</NO>
<PG>317-22</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:22:50 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:22:50 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8722434"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gruska-1997" MODIFIED="2010-08-23 17:22:54 +1000" MODIFIED_BY="Narelle S Willis" NAME="Gruska 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-08-23 17:22:54 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gruska S, Wolf E, Jendral I, Wedler B, Kraatz G</AU>
<TI>Salt sensitivity and insulin resistance in normotensives</TI>
<SO>Experimental &amp; Clinical Endocrinology &amp; Diabetes</SO>
<YR>1997</YR>
<VL>105 Suppl 2</VL>
<PG>22-6</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:22:54 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:22:54 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9288538"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heeg-1989" MODIFIED="2010-08-23 17:22:59 +1000" MODIFIED_BY="Narelle S Willis" NAME="Heeg 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-08-23 17:22:59 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heeg Jan E, De Jong Paul E, Van der Hem Gjalt K, De Zeeuw D</AU>
<TI>Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril</TI>
<SO>Kidney International</SO>
<YR>1989</YR>
<VL>36</VL>
<NO>2</NO>
<PG>272-9</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:22:59 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:22:59 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="2550696"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iwaoka-1994" MODIFIED="2010-08-23 17:23:04 +1000" MODIFIED_BY="Narelle S Willis" NAME="Iwaoka 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-08-23 17:23:04 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iwaoka T, Umeda T, Inoue J, Naomi S, Sasaki M, Fujimoto Y, et al</AU>
<TI>Dietary NaCl restriction deteriorates oral glucose tolerance in hypertensive patients with impairment of glucose tolerance</TI>
<SO>American Journal of Hypertension</SO>
<YR>1994</YR>
<VL>7</VL>
<PG>460-3</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:23:04 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:23:04 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8060581"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jafar-2006" MODIFIED="2010-08-23 17:23:10 +1000" MODIFIED_BY="Narelle S Willis" NAME="Jafar 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-08-23 17:23:10 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jafar TH</AU>
<TI>Blood pressure, diabetes, and increased dietary salt associated with stroke - results from a community-based study in Pakistan [1]</TI>
<SO>Journal of Human Hypertension</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>1</NO>
<PG>83-5</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:23:10 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:23:10 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="16151442"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones_x002d_Burton-2006" MODIFIED="2010-08-23 17:23:20 +1000" MODIFIED_BY="Narelle S Willis" NAME="Jones-Burton 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-08-23 17:23:20 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jones-Burton C, Mishra SI, Fink JC, Brown J, Gossa W, Bakris GL, et al</AU>
<TI>An in-depth review of the evidence linking dietary salt intake and progression of chronic kidney disease</TI>
<SO>American Journal of Nephrology</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>3</NO>
<PG>268-75</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:23:20 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:23:20 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="16763384"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Juncos-1976" MODIFIED="2010-08-23 17:24:04 +1000" MODIFIED_BY="Narelle S Willis" NAME="Juncos 1976" YEAR="1976">
<REFERENCE MODIFIED="2010-08-23 17:24:04 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Juncos L, Cade R, Fuller T, Mahoney J, Grubb W</AU>
<TI>Comparison of the effects of hydrochlorothiazide (H) and triamterene (T) in combination with low salt diet on both supine and standing systolic (SBP) and diastolic blood pressure (DBP), serum potassium (K+), weight (W) and peripheral plasma renin activity (PRA) and prostaglandin E2 concentration (PGE2). [abstract]</TI>
<SO>Kidney International</SO>
<YR>1976</YR>
<VL>10</VL>
<PG>531</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:24:04 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:24:04 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00583692"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keven-2006" MODIFIED="2010-05-13 03:46:36 +1000" MODIFIED_BY="[Empty name]" NAME="Keven 2006" YEAR="2006 Jun">
<REFERENCE MODIFIED="2010-05-13 03:46:36 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keven K, Yalcin S, Canbakan B, Kutlay S, Sengul S, Erturk S, et al</AU>
<TI>The impact of daily sodium intake on posttransplant hypertension in kidney allograft recipients</TI>
<SO>Transplantation Proceedings</SO>
<YR>2006</YR>
<VL>38</VL>
<NO>5</NO>
<PG>1323-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16797292"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kirby-2006" MODIFIED="2010-08-23 17:24:10 +1000" MODIFIED_BY="Narelle S Willis" NAME="Kirby 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-08-23 17:24:10 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kirby R</AU>
<TI>Salt sensitivity of blood pressure and diabetic nephropathy</TI>
<SO>Nature Clinical Practice Nephrology</SO>
<YR>2006</YR>
<VL>2</VL>
<NO>1</NO>
<PG>6</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:24:10 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:24:10 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="2006115437"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuroda-1999" MODIFIED="2010-08-23 17:24:16 +1000" MODIFIED_BY="Narelle S Willis" NAME="Kuroda 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-08-23 17:24:16 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuroda S, Uzu T, Fujii T, Nishimura M, Nakamura S, Inenaga T, et al</AU>
<TI>Role of insulin resistance in the genesis of sodium sensitivity in essential hypertension</TI>
<SO>Journal of Human Hypertension</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>4</NO>
<PG>257-62</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:24:16 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:24:16 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="10333344"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mallamaci-1999" MODIFIED="2010-08-23 17:25:11 +1000" MODIFIED_BY="Narelle S Willis" NAME="Mallamaci 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-08-23 17:25:11 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mallamaci F, Cuzzola F, Tripepi G, Parlongo S, Malatino L, Bellanuova I, et al</AU>
<TI>Renal excretion of adrenomedullin is strongly influenced by salt intake and it is tightly linked to endothelin-1 excretion in patients with essential hypertension (EH) [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>9</NO>
<PG>A67</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:25:11 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:25:11 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00583530"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mazouz-1999" MODIFIED="2010-08-23 17:25:15 +1000" MODIFIED_BY="Narelle S Willis" NAME="Mazouz 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-08-23 17:25:15 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mazouz H, Kacso I, Ghazali A, El Esper N, Moriniere P, Makdassi R, et al</AU>
<TI>Risk factors of renal failure progression two years prior to dialysis</TI>
<SO>Clinical Nephrology</SO>
<YR>1999</YR>
<VL>51</VL>
<NO>6</NO>
<PG>355-66</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:25:15 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:25:15 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="10404696"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meland-1997" MODIFIED="2010-08-23 17:26:12 +1000" MODIFIED_BY="Narelle S Willis" NAME="Meland 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-08-23 17:26:12 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meland E, Laerum E, Aakvaag A, Ulvik RJ, Hstmark AT</AU>
<TI>Salt restriction: effects on lipids and insulin production in hypertensive patients</TI>
<SO>Scandinavian Journal of Clinical and Laboratory Investigation</SO>
<YR>1997</YR>
<VL>57</VL>
<NO>6</NO>
<PG>501-5</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:26:12 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:26:12 +1000" MODIFIED_BY="Narelle S Willis" TYPE="PUBMED" VALUE="9350069"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Melander-2000" MODIFIED="2010-08-23 17:26:18 +1000" MODIFIED_BY="Narelle S Willis" NAME="Melander 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-08-23 17:26:18 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Melander O, Groop L, Hulthen UL</AU>
<TI>Effect of salt on insulin sensitivity differs according to gender and degree of salt sensitivity</TI>
<SO>Hypertension</SO>
<YR>2000</YR>
<VL>35</VL>
<NO>3</NO>
<PG>827-31</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:26:18 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:26:18 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="10720602"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Metcalf-1993" MODIFIED="2010-08-23 17:26:23 +1000" MODIFIED_BY="Narelle S Willis" NAME="Metcalf 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-08-23 17:26:23 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Metcalf PA, Baker JR, Scragg RK, Dryson E, Scott AJ, Wild CJ</AU>
<TI>Dietary nutrient intakes and slight albuminuria in people at least 40 years old</TI>
<SO>Clinical Chemistry</SO>
<YR>1993</YR>
<VL>39</VL>
<NO>10</NO>
<PG>2191-8</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:26:23 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:26:23 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8403406"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pacy-1984" MODIFIED="2010-08-23 17:26:32 +1000" MODIFIED_BY="Narelle S Willis" NAME="Pacy 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-08-23 17:26:32 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pacy PJ, Dodson PM, Kubicki AJ, Fletcher RF, Taylor KG</AU>
<TI>Comparison of the hypotensive and metabolic effects of metoprolol therapy with a high fibre, low sodium, low fat diet in hypertensive type 2 diabetic subjects</TI>
<SO>Diabetes Research</SO>
<YR>1984</YR>
<VL>1</VL>
<NO>4</NO>
<PG>201-7</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:26:32 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:26:32 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="6099231"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perry-2003" MODIFIED="2010-08-23 17:26:40 +1000" MODIFIED_BY="Narelle S Willis" NAME="Perry 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-08-23 17:26:40 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perry CG, Palmer T, Cleland SJ, Morton IJ, Salt IP, Petrie JR, et al</AU>
<TI>Decreased insulin sensitivity during dietary sodium restriction is not mediated by effects of angiotensin II on insulin action</TI>
<SO>Clinical Science</SO>
<YR>2003</YR>
<VL>105</VL>
<NO>2</NO>
<PG>187-94</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:26:40 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:26:40 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="12691602"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Price-1999" MODIFIED="2010-08-23 17:26:45 +1000" MODIFIED_BY="Narelle S Willis" NAME="Price 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-08-23 17:26:45 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Price DA, De'Oliveira JM, Fisher ND, Williams GH, Hollenberg NK, Price DA, et al</AU>
<TI>The state and responsiveness of the renin-angiotensin-aldosterone system in patients with type II diabetes mellitus</TI>
<SO>American Journal of Hypertension</SO>
<YR>1999</YR>
<VL>12</VL>
<NO>4 Pt 1</NO>
<PG>348-55</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:26:45 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:26:45 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="10232494"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raji-2001" MODIFIED="2010-08-23 17:26:50 +1000" MODIFIED_BY="Narelle S Willis" NAME="Raji 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-08-23 17:26:50 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raji A, Williams GH, Jeunemaitre X, Hopkins PN, Hunt SC, Hollenberg NK, et al</AU>
<TI>Insulin resistance in hypertensives: effect of salt sensitivity, renin status and sodium intake</TI>
<SO>Journal of Hypertension</SO>
<YR>2001</YR>
<VL>19</VL>
<NO>1</NO>
<PG>99-105</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:26:50 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:26:50 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11204310"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rudberg-1997" MODIFIED="2010-08-23 17:26:57 +1000" MODIFIED_BY="Narelle S Willis" NAME="Rudberg 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-08-23 17:26:57 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rudberg S, Lemne C, Persson B, Krekula A, De Faire U, Aperia A, et al</AU>
<TI>The dopaminuric response to high salt diet in insulin-dependent diabetes mellitus and in family history of hypertension</TI>
<SO>Pediatric Nephrology</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>2</NO>
<PG>169-73</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:26:57 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:26:57 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9090656"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharma-1991" MODIFIED="2010-08-23 17:59:50 +1000" MODIFIED_BY="Narelle S Willis" NAME="Sharma 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-08-23 17:59:50 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharma AM, Ruland K, Spies KP, Distler A</AU>
<TI>Salt sensitivity in young normotensive subjects is associated with a hyperinsulinemic response to oral glucose</TI>
<SO>Journal of Hypertension</SO>
<YR>1991</YR>
<VL>9</VL>
<NO>4</NO>
<PG>329-35</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:27:03 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:27:03 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="1646259"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharma-1993" MODIFIED="2010-08-18 15:32:09 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Sharma 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-08-18 15:32:09 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharma AM, Schorr U, Distler A</AU>
<TI>Insulin resistance in young salt-sensitive normotensive subjects</TI>
<SO>Hypertension</SO>
<YR>1993</YR>
<VL>21</VL>
<NO>3</NO>
<PG>273-9</PG>
<IDENTIFIERS MODIFIED="2010-08-18 15:32:09 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2010-08-18 15:32:09 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="8478036"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Suzuki-2000" MODIFIED="2010-08-23 17:27:08 +1000" MODIFIED_BY="Narelle S Willis" NAME="Suzuki 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-08-23 17:27:08 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Suzuki M, Kimura Y, Tsushima M, Harano Y</AU>
<TI>Association of insulin resistance with salt sensitivity and nocturnal fall of blood pressure</TI>
<SO>Hypertension</SO>
<YR>2000</YR>
<VL>35</VL>
<NO>4</NO>
<PG>864-8</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:27:08 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:27:08 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="10775552"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Swift-2005" MODIFIED="2010-08-23 17:28:00 +1000" MODIFIED_BY="Narelle S Willis" NAME="Swift 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-08-18 15:34:16 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swift PA, Markandu ND, Sagnella GA, He FJ, MacGregor GA</AU>
<TI>Modest salt reduction reduces blood pressure and urine protein excretion in black hypertensives: a randomized control trial</TI>
<SO>Hypertension</SO>
<YR>2005</YR>
<VL>46</VL>
<NO>2</NO>
<PG>308-12</PG>
<IDENTIFIERS MODIFIED="2010-08-18 15:34:13 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="15983240"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-08-23 17:28:00 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swift PA, Markandu ND, Sagnella GA, MacGregor GA</AU>
<TI>A double blind randomised control trial of modest salt reduction in black people with normal blood pressure [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>Abstracts</NO>
<PG>657A</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:28:00 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:28:00 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00716093"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Townsend-2007" MODIFIED="2010-08-23 17:28:05 +1000" MODIFIED_BY="Narelle S Willis" NAME="Townsend 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-08-23 17:28:05 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Townsend RR, Kapoor S, McFadden CB, Townsend RR, Kapoor S, McFadden CB</AU>
<TI>Salt intake and insulin sensitivity in healthy human volunteers</TI>
<SO>Clinical Science</SO>
<YR>2007</YR>
<VL>113</VL>
<NO>3</NO>
<PG>141-8</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:28:05 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:28:05 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="17425514"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trujillo-1989" MODIFIED="2010-08-23 17:28:09 +1000" MODIFIED_BY="Narelle S Willis" NAME="Trujillo 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-08-23 17:28:09 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trujillo A, Eggena P, Barrett J, Tuck M</AU>
<TI>Renin regulation in type II diabetes mellitus: influence of dietary sodium</TI>
<SO>Hypertension</SO>
<YR>1989</YR>
<VL>13</VL>
<NO>3</NO>
<PG>200-5</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:28:09 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:28:09 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="2646216"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tuck-1990" MODIFIED="2010-08-23 17:28:13 +1000" MODIFIED_BY="Narelle S Willis" NAME="Tuck 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-08-23 17:28:13 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tuck M, Corry D, Trujillo A</AU>
<TI>Salt-sensitive blood pressure and exaggerated vascular reactivity in the hypertension of diabetes mellitus</TI>
<SO>American Journal of Medicine</SO>
<YR>1990</YR>
<VL>88</VL>
<NO>3</NO>
<PG>210-6</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:28:13 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:28:13 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="2309737"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weir-1995" MODIFIED="2010-08-23 17:28:19 +1000" MODIFIED_BY="Narelle S Willis" NAME="Weir 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-08-23 17:28:19 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weir MR, Dengel DR, Behrens MT, Goldberg AP</AU>
<TI>Salt-induced increases in systolic blood pressure affect renal hemodynamics and proteinuria</TI>
<SO>Hypertension</SO>
<YR>1995</YR>
<VL>25</VL>
<NO>6</NO>
<PG>1339-44</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:28:19 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:28:19 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="7768584"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weir-1998" MODIFIED="2010-08-23 17:28:31 +1000" MODIFIED_BY="Narelle S Willis" NAME="Weir 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-08-23 17:28:31 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weir MR, Dworkin LD</AU>
<TI>Antihypertensive drugs, dietary salt, and renal protection: how low should you go and with which therapy?</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1998</YR>
<VL>32</VL>
<NO>1</NO>
<PG>1-22</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:28:31 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:28:31 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9669419"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zanchi-2004" MODIFIED="2010-08-23 17:28:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Zanchi 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-08-23 17:28:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zanchi A, Chiolero A, Maillard M, Nussberger J, Brunner HR, Burnier M</AU>
<TI>Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men</TI>
<SO>Journal of Clinical Endocrinology &amp; Metabolism</SO>
<YR>2004</YR>
<VL>89</VL>
<NO>3</NO>
<PG>1140-5</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:28:37 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:28:37 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="15001599"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zarraga-2006" MODIFIED="2010-08-23 17:28:43 +1000" MODIFIED_BY="Narelle S Willis" NAME="Zarraga 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-08-23 17:28:43 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zarraga IGE, Schwarz ER</AU>
<TI>Impact of dietary patterns and interventions on cardiovascular health</TI>
<SO>Circulation</SO>
<YR>2006</YR>
<VL>114</VL>
<NO>9</NO>
<PG>961-73</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:28:43 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:28:43 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="16940205"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2010-05-13 03:48:43 +1000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-09-27 15:41:27 +1000" MODIFIED_BY="Narelle S Willis">
<ADDITIONAL_REFERENCES MODIFIED="2010-09-27 15:41:27 +1000" MODIFIED_BY="Narelle S Willis">
<REFERENCE ID="REF-Adler-2000" MODIFIED="2010-08-23 17:35:26 +1000" MODIFIED_BY="Narelle S Willis" NAME="Adler 2000" TYPE="JOURNAL_ARTICLE">
<AU>Adler A, Stratton I, Neil H, Yudkin J, Matthews D, Cull C, et al</AU>
<TI>Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study</TI>
<SO>BMJ</SO>
<YR>2000</YR>
<VL>321</VL>
<NO>7258</NO>
<PG>412-9</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:35:26 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:35:26 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="10938049"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Allen-1997" MODIFIED="2008-09-25 18:25:11 +1000" MODIFIED_BY="Narelle S Willis" NAME="Allen 1997" TYPE="JOURNAL_ARTICLE">
<AU>Allen TJ, Waldron MJ, Casley D, Jerums G, Cooper ME</AU>
<TI>Salt restriction reduces hyperfiltration, renal enlargement, and albuminuria in experimental diabetes</TI>
<SO>Diabetes</SO>
<YR>1997</YR>
<VL>46</VL>
<NO>1</NO>
<PG>19-24</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8971091"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cianciaruso-1998" MODIFIED="2010-08-23 18:00:20 +1000" MODIFIED_BY="Narelle S Willis" NAME="Cianciaruso 1998" TYPE="JOURNAL_ARTICLE">
<AU>Cianciaruso B, Bellizzi V, Minutolo R, Tavera A, Capuano A, Conte G, et al</AU>
<TI>Salt intake and renal outcome in patients with progressive renal disease</TI>
<SO>Mineral &amp; Electrolyte Metabolism</SO>
<YR>1998</YR>
<VL>24</VL>
<NO>4</NO>
<PG>296-301</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9554571"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Da-Costa-1997" MODIFIED="2010-07-14 15:03:20 +1000" MODIFIED_BY="Narelle S Willis" NAME="Da Costa 1997" TYPE="JOURNAL_ARTICLE">
<AU>Da Costa Lima NK, Lima FB, Dos Santos EA, Okamoto MM, Matsushita DH, Hell NS, et al</AU>
<TI>Chronic salt overload increases blood pressure and improves glucose metabolism without changing insulin sensitivity</TI>
<SO>American Journal of Hypertension</SO>
<YR>1997</YR>
<VL>10</VL>
<NO>7 Pt 1</NO>
<PG>720-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9234825"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Daviglus-2005" MODIFIED="2010-08-23 17:39:31 +1000" MODIFIED_BY="Narelle S Willis" NAME="Daviglus 2005" TYPE="JOURNAL_ARTICLE">
<AU>Daviglus M, Greenland P, Stamler J, Elliott P, Appel L, Carnethon M, et al</AU>
<TI>Relation of nutrient intake to microalbuminuria in nondiabetic middle-aged men and women: International Population Study on Macronutrients and Blood Pressure (INTERMAP)</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2005</YR>
<VL>45</VL>
<PG>256-66</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:39:31 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:39:31 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="15685502"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-DeFronzo-1981" MODIFIED="2010-08-23 17:40:35 +1000" MODIFIED_BY="Narelle S Willis" NAME="DeFronzo 1981" TYPE="JOURNAL_ARTICLE">
<AU>DeFronzo RA</AU>
<TI>The effect of insulin on renal sodium metabolism. A review with clinical implications</TI>
<SO>Diabetologia</SO>
<YR>1981</YR>
<VL>21</VL>
<NO>3</NO>
<PG>165-71</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:40:35 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:40:35 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="7028550"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Giunti-2006" MODIFIED="2008-09-25 18:25:31 +1000" MODIFIED_BY="Narelle S Willis" NAME="Giunti 2006" TYPE="JOURNAL_ARTICLE">
<AU>Giunti S, Barit D, Cooper M</AU>
<TI>Mechanisms of diabetic nephropathy: role of hypertension</TI>
<SO>Hypertension</SO>
<YR>2006</YR>
<VL>48</VL>
<NO>4</NO>
<PG>519-26</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16952978"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Harvey-2003" MODIFIED="2010-08-23 17:41:20 +1000" MODIFIED_BY="Narelle S Willis" NAME="Harvey 2003" TYPE="JOURNAL_ARTICLE">
<AU>Harvey JN</AU>
<TI>Trends in the prevalence of diabetic nephropathy in type 1 and type 2 diabetes</TI>
<SO>Current Opinions in Nephrology &amp; Hypertension</SO>
<YR>2003</YR>
<VL>12</VL>
<PG>317-22</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:41:20 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:41:20 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="12698072"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-He-2002" MODIFIED="2008-09-25 18:25:33 +1000" MODIFIED_BY="Narelle S Willis" NAME="He 2002" TYPE="JOURNAL_ARTICLE">
<AU>He FJ, MacGregor GA</AU>
<TI>Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health</TI>
<SO>Journal of Human Hypertension</SO>
<YR>2002</YR>
<VL>16</VL>
<NO>11</NO>
<PG>761-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12444537"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-He-2003" MODIFIED="2010-08-23 17:41:57 +1000" MODIFIED_BY="Narelle S Willis" NAME="He 2003" TYPE="JOURNAL_ARTICLE">
<AU>He FJ, MacGregor GA</AU>
<TI>How far should salt intake be reduced?</TI>
<SO>Hypertension</SO>
<YR>2003</YR>
<VL>42</VL>
<NO>6</NO>
<PG>1093-9</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:41:57 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:41:57 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="14610100"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-He-2009a" MODIFIED="2010-08-23 17:43:24 +1000" MODIFIED_BY="Narelle S Willis" NAME="He 2009a" TYPE="JOURNAL_ARTICLE">
<AU>He FJ, Marciniak M, Visagie E, Markandu ND, Anand V, Dalton RN, et al</AU>
<TI>Effect of modest salt reduction on blood pressure, urinary albumin, and pulse wave velocity in white, black, and Asian mild hypertensives</TI>
<SO>Hypertension</SO>
<YR>2009</YR>
<VL>54</VL>
<NO>3</NO>
<PG>482-8</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:43:24 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:43:24 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19620514"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-He-2009b" MODIFIED="2010-08-23 17:44:14 +1000" MODIFIED_BY="Narelle S Willis" NAME="He 2009b" TYPE="JOURNAL_ARTICLE">
<AU>He F, MacGregor GA</AU>
<TI>A comprehensive review on salt and health and current experience of worldwide salt reduction programmes</TI>
<SO>Journal of Human Hypertension</SO>
<YR>2009</YR>
<VL>23</VL>
<NO>6</NO>
<PG>363-84</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:44:12 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:44:12 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19110538"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2008-09-25 18:25:36 +1000" MODIFIED_BY="Narelle S Willis" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12958120"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hillege-2002" MODIFIED="2010-07-14 15:05:56 +1000" MODIFIED_BY="Narelle S Willis" NAME="Hillege 2002" TYPE="JOURNAL_ARTICLE">
<AU>Hillege HL, Fidler V, Diercks GFH, Van Gilst WH, De Zeeuw D, Van Veldhuisen DJ, et al</AU>
<TI>Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population</TI>
<SO>Circulation</SO>
<YR>2002</YR>
<VL>106</VL>
<NO>14</NO>
<PG>1777-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12356629"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hooper-2002" MODIFIED="2010-08-23 17:45:16 +1000" MODIFIED_BY="Narelle S Willis" NAME="Hooper 2002" TYPE="JOURNAL_ARTICLE">
<AU>Hooper L, Bartlett C, Davey Smith G, Ebrahim S</AU>
<TI>Systematic review of long term effects of advice to reduce dietary salt in adults</TI>
<SO>BMJ</SO>
<YR>2002</YR>
<VL>325</VL>
<NO>7365</NO>
<PG>628-34</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:45:14 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:45:14 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="12242173"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jones_x002d_Burton-2006" MODIFIED="2010-08-23 17:46:09 +1000" MODIFIED_BY="Narelle S Willis" NAME="Jones-Burton 2006" TYPE="JOURNAL_ARTICLE">
<AU>Jones-Burton C, Mishra SI, Fink JC, Brown J, Gossa W, Bakris GL, et al</AU>
<TI>An in-depth review of the evidence linking dietary salt intake and progression of chronic kidney disease</TI>
<SO>American Journal of Nephrology</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>3</NO>
<PG>268-75</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:46:09 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:46:09 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="16763384"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Law-1991a" MODIFIED="2010-08-23 17:47:29 +1000" MODIFIED_BY="Narelle S Willis" NAME="Law 1991a" TYPE="JOURNAL_ARTICLE">
<AU>Law MR, Frost CD, Wald NJ</AU>
<TI>By how much does dietary salt reduction lower blood pressure? III - Analysis of data from trials of salt reduction</TI>
<SO>BMJ</SO>
<YR>1991</YR>
<VL>302</VL>
<NO>6780</NO>
<PG>819-24</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:47:29 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:47:29 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="1827353"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Law-1991b" MODIFIED="2010-08-23 17:48:24 +1000" MODIFIED_BY="Narelle S Willis" NAME="Law 1991b" TYPE="JOURNAL_ARTICLE">
<AU>Law MR, Frost CD, Wald NJ</AU>
<TI>By how much does dietary salt reduction lower blood pressure? I - Analysis of observational data among populations</TI>
<SO>BMJ</SO>
<YR>1991</YR>
<VL>302</VL>
<NO>6780</NO>
<PG>811-5</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:48:24 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:48:24 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="2025703"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2008" MODIFIED="2010-09-27 15:39:27 +1000" MODIFIED_BY="Narelle S Willis" NAME="Lefebvre 2008" TYPE="OTHER">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies. In Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration. Available from www.cochrane-handbook.org</TI>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MacGregor-1987" MODIFIED="2008-09-25 18:25:49 +1000" MODIFIED_BY="Narelle S Willis" NAME="MacGregor 1987" TYPE="JOURNAL_ARTICLE">
<AU>MacGregor G, Markandu ND, Singer DR, Cappuccio FP, Shore AC, Sagnella GA</AU>
<TI>Moderate sodium restriction with angiotensin converting enzyme inhibitor in essential hypertension: a double blind study</TI>
<SO>British Medical Journal Clinical Research Ed</SO>
<YR>1987</YR>
<VL>294</VL>
<NO>6571</NO>
<PG>531-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3103761"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Midgley-1996" MODIFIED="2010-08-23 17:49:22 +1000" MODIFIED_BY="Narelle S Willis" NAME="Midgley 1996" TYPE="JOURNAL_ARTICLE">
<AU>Midgley JP, Matthew AG, Greenwood CM, Logan AG</AU>
<TI>Effect of reduced dietary sodium on blood pressure: a meta-analysis of randomized controlled trials</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>275</VL>
<NO>20</NO>
<PG>1590-7</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:49:22 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:49:22 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8622251"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nishiyama-2002" MODIFIED="2010-08-23 17:50:03 +1000" MODIFIED_BY="Narelle S Willis" NAME="Nishiyama 2002" TYPE="JOURNAL_ARTICLE">
<AU>Nishiyama A, Seth D, Navar L</AU>
<TI>Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats</TI>
<SO>Hypertension</SO>
<YR>2002</YR>
<VL>39</VL>
<NO>1</NO>
<PG>129-34</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:50:03 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:50:03 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11799091"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Price-1999" MODIFIED="2010-09-19 19:21:22 +1000" MODIFIED_BY="Narelle S Willis" NAME="Price 1999" TYPE="JOURNAL_ARTICLE">
<AU>Price DA, De'Oliveira JM, Fisher ND, Williams GH, Hollenberg NK</AU>
<TI>The state and responsiveness of the renin-angiotensin-aldosterone system in patients with type II diabetes mellitus</TI>
<SO>American Journal of Hypertension</SO>
<YR>1999</YR>
<VL>12</VL>
<NO>4 Pt 1</NO>
<PG>348-55</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10232494"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Renal-Group-2010" MODIFIED="2010-09-27 15:39:57 +1000" MODIFIED_BY="Narelle S Willis" NAME="Renal Group 2010" TYPE="OTHER">
<AU>Willis NS, Mitchell R, Higgins GY, Webster AC, Craig JC</AU>
<TI>Cochrane Renal Group</TI>
<SO>About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2010, Issue 9. Art. No.: RENAL</SO>
<YR>(accessed October 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-SACN-2003" MODIFIED="2010-08-23 17:52:47 +1000" MODIFIED_BY="Narelle S Willis" NAME="SACN 2003" TYPE="OTHER">
<AU>Scientific Advisory Committee on Nutrition</AU>
<TI>Salt and Health</TI>
<SO>http://www.sacn.gov.uk/pdfs/sacn_salt_final.pdf</SO>
<YR>2003 (accessed August 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schrier-2002" MODIFIED="2008-09-25 18:25:53 +1000" MODIFIED_BY="Narelle S Willis" NAME="Schrier 2002" TYPE="JOURNAL_ARTICLE">
<AU>Schrier RW, Estacio RO, Esler A, Mehler P</AU>
<TI>Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes</TI>
<SO>Kidney International</SO>
<YR>2002</YR>
<VL>61</VL>
<NO>3</NO>
<PG>1086-97</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11849464"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sowers-2001" MODIFIED="2010-08-23 17:54:30 +1000" MODIFIED_BY="Narelle S Willis" NAME="Sowers 2001" TYPE="JOURNAL_ARTICLE">
<AU>Sowers JR, Epstein M, Frohlich ED</AU>
<TI>Diabetes, hypertension, and cardiovascular disease: an update</TI>
<SO>Hypertension</SO>
<YR>2001</YR>
<VL>37</VL>
<NO>4</NO>
<PG>1053-9</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:54:26 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:54:26 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11304502"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Swift-2005" MODIFIED="2008-09-25 18:25:57 +1000" MODIFIED_BY="Narelle S Willis" NAME="Swift 2005" TYPE="JOURNAL_ARTICLE">
<AU>Swift PA, Markandu ND, Sagnella GA, He FJ, MacGregor GA</AU>
<TI>Modest salt reduction reduces blood pressure and urine protein excretion in black hypertensives: a randomized control trial</TI>
<SO>Hypertension</SO>
<YR>2005</YR>
<VL>46</VL>
<NO>2</NO>
<PG>308-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15983240"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Verhave-2004" MODIFIED="2010-08-23 17:55:32 +1000" MODIFIED_BY="Narelle S Willis" NAME="Verhave 2004" TYPE="JOURNAL_ARTICLE">
<AU>Verhave JC, Hillege HL, Burgerhof JG, Janssen WM, Ganesvoort RT, Navis GJ, et al</AU>
<TI>Sodium intake affects urinary albumin excretion especially in overweight subjects</TI>
<SO>Journal of Internal Medicine</SO>
<YR>2004</YR>
<VL>256</VL>
<NO>4</NO>
<PG>324-30</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:55:32 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:55:32 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="15367175"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-WHO-2002" MODIFIED="2010-08-23 17:57:40 +1000" MODIFIED_BY="Narelle S Willis" NAME="WHO 2002" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>The World Health Report 2002 - Reducing Risks, Promoting Healthy Life</TI>
<SO>http://www.who.int/whr/2002/en/index.html</SO>
<YR>(accessed August 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Woods-1987" MODIFIED="2010-08-23 17:59:07 +1000" MODIFIED_BY="Narelle S Willis" NAME="Woods 1987" TYPE="JOURNAL_ARTICLE">
<AU>Woods LL, Mizelle HL, Hall JE</AU>
<TI>Control of renal hemodynamics in hyperglycemia: possible role of tubuloglomerular feedback</TI>
<SO>American Journal of Physiology</SO>
<YR>1987</YR>
<VL>252</VL>
<NO>1 Pt 2</NO>
<PG>F65-73</PG>
<IDENTIFIERS MODIFIED="2010-08-23 17:59:07 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-08-23 17:59:07 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="3812702"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-10-22 09:17:49 +1100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-10-22 09:17:49 +1100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-09-18 23:07:04 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-De_x0027_oliveira-1997">
<CHAR_METHODS MODIFIED="2010-08-23 21:23:41 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: Parallel RCT</LI>
<LI>Time frame: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-23 22:13:14 +1000" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Setting: Hospital</LI>
<LI>Country: USA</LI>
<LI>DM: Type 2</LI>
<LI>Hypertensive SBP &gt; 140 mm Hg and DBP &gt; 90 mm Hg on at least 3 outpatient visits</LI>
<LI>Mean BMI: 30 ± 1</LI>
<LI>Number (treatment/control): 9/10</LI>
<LI>Mean age ± SD: 55 ± 2 years</LI>
<UL>
<LI>Treatment/control: 56 ± 3 years/55 ± 2 years</LI>
</UL>
<LI>Sex (M/F): 16/3</LI>
<UL>
<LI>Treatment: 7/2</LI>
<LI>Control: 9/1</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Age &lt; 30 years</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-14 14:17:00 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Low salt diet: 50 mmol/d</LI>
<LI>Duration: 5-7 days</LI>
</UL>
<P> Control group</P>
<UL>
<LI>High salt diet: 200 mmol/d</LI>
<LI>Duration: 5-7 days</LI>
</UL>
<P> Co-interventions: No</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-23 21:43:04 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>MAP</LI>
<LI>RPF</LI>
<LI>GFR</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-23 21:48:21 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre-intervention: None</LI>
<LI>Stop or end point/s: Not stated</LI>
<LI>Additional data requested from authors: Yes but no response to request</LI>
<LI>Completeness of follow-up</LI>
</UL>
<UL>
<UL>
<LI>Analysed 100%</LI>
<LI>Per cent followed 100%</LI>
</UL>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-14 15:41:40 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Dodson_x005f_P-1989">
<CHAR_METHODS MODIFIED="2010-08-23 22:05:43 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: Parallel RCT followed by crossover study</LI>
<LI>Time frame: not stated</LI>
<LI>Follow-up period: 3 months</LI>
<LI>Loss to follow-up: 0</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-23 21:59:52 +1000" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Setting: Hospital</LI>
<LI>Country: UK</LI>
<LI>Hypertension SBP &gt; 160 mm Hg or DBP &gt; 95 mm Hg</LI>
<LI>DM: type 2</LI>
<LI>No past or current history of treatment with insulin</LI>
<LI>Number (treatment/control): 17/17</LI>
<LI>Mean age (SD)</LI>
<UL>
<LI>Treatment: 61.9 (7.5) years</LI>
<LI>Control: 61.1 (6.3) years</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>Treatment: 12/5</LI>
<LI>Control: 11/6</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>DKD or hypertensive kidney disease (proteinuria or raised serum creatinine concentration), cardiac failure, pregnancy</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-14 15:41:40 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group (parallel study)</P>
<UL>
<LI>Moderate sodium restriction: Dietary advice</LI>
<LI>Duration: 3 months</LI>
</UL>
<P>Control group (parallel study)</P>
<UL>
<LI>Usual diabetic diet: No advice</LI>
<LI>Duration: 3 months</LI>
</UL>
<P>Co-interventions: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-23 22:01:55 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SBP</LI>
<LI>DBP</LI>
<LI>Weight</LI>
<LI>HbA1c</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-23 22:02:31 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Stop or end point/s: Not stated</LI>
<LI>Per cent followed: 100%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-14 15:41:53 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Dodson_x005f_X-1989">
<CHAR_METHODS MODIFIED="2010-08-23 22:05:32 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: Parallel RCT followed by crossover study</LI>
<LI>Time frame: not stated</LI>
<LI>Follow-up period: 3 months</LI>
<LI>Loss to follow-up: 4</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-14 13:33:39 +1000" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Setting: Hospital</LI>
<LI>Country: UK</LI>
<LI>Hypertension SBP &gt; 160 mm Hg or DBP &gt; 95 mm Hg</LI>
<LI>DM: type 2</LI>
<LI>No past or current history of treatment with insulin</LI>
<LI>Number: 9</LI>
<LI>Mean age (SD): 62 (6.5) years</LI>
<LI>Sex (M/F): 6/3</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>DKD or hypertensive kidney disease (proteinuria or raised serum creatinine concentration), cardiac failure, pregnancy</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-14 15:41:53 +1000" MODIFIED_BY="Narelle S Willis">
<P>Crossover study</P>
<UL>
<LI>Sodium restriction diet + slow release sodium supplement (80 mmol/d) for 1 month</LI>
<LI>Sodium restriction diet + placebo for 1 month</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-23 22:08:43 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SBP</LI>
<LI>DBP</LI>
<LI>Weight</LI>
<LI>HbA1c</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-23 22:08:43 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Stop or end point/s: Not stated</LI>
<LI>Per cent followed: 100%</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-19 19:05:15 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Houlihan_x005f_Losartan-2002">
<CHAR_METHODS MODIFIED="2010-09-18 22:00:57 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: Parallel for losartan versus placebo, crossover for salt intervention</LI>
<LI>Time frame: not stated</LI>
<LI>Follow-up period: 12 weeks</LI>
<LI>Loss to follow-up: 0</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-19 19:05:15 +1000" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Setting: Hospital</LI>
<LI>Country: Australia</LI>
<LI>SBP &gt; 130 mm Hg and/or DBP &gt; 85 mm Hg</LI>
<LI>DM: type 2</LI>
<LI>AER 10-200 µg/min</LI>
<LI>HbA1c &lt; 11.0%</LI>
<LI>Number (placebo/losartan): 10/10</LI>
<LI>Mean age (SD)</LI>
<UL>
<LI>Placebo: 63.1 (3.9) years</LI>
<LI>Losartan: 60.6 (3.7) years</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>Placebo: 9/1</LI>
<LI>Losartan: 10/0</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Serious systemic illness; substance abuse; 24 hour urinary sodium &gt; 100 mmol/24 h; SBP &gt; 165 mm Hg, DBP &gt; 100 mm Hg; plasma Cr &gt; 200 µmol/L, long-term use of NSAID; UTIs; BMI &gt; 35 kg/m²; intolerance of ACEi.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-14 14:13:04 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment</P>
<UL>
<LI>Low sodium phase: 50-70 mmol/d</LI>
</UL>
<P>Control</P>
<UL>
<LI>Regular sodium phase: &gt; 100 mmol/d</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Losartan versus placebo with parallel study</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-14 13:45:15 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SBP</LI>
<LI>DBP</LI>
<LI>MAP</LI>
<LI>GFR</LI>
<LI>ERPF</LI>
<LI>HbA1c</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-14 13:47:47 +1000" MODIFIED_BY="Narelle S Willis">
<P>Additional data requested from authors: UAE, no response from authors</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-19 19:05:17 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Houlihan_x005f_Placebo-2002">
<CHAR_METHODS MODIFIED="2010-09-18 22:00:52 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: Parallel for losartan versus placebo, crossover for salt intervention</LI>
<LI>Time frame: not stated</LI>
<LI>Follow-up period: 12 weeks</LI>
<LI>Loss to follow-up: 0</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-19 19:05:17 +1000" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Setting: Hospital</LI>
<LI>Country: Australia</LI>
<LI>SBP &gt; 130 mm Hg and/or DBP &gt; 85 mm Hg</LI>
<LI>DM: type 2</LI>
<LI>AER 10-200 µg/min</LI>
<LI>HbA1c &lt; 11.0%</LI>
<LI>Number (placebo/losartan): 10/10</LI>
<LI>Mean age (SD)</LI>
<UL>
<LI>Placebo: 63.1 (3.9) years</LI>
<LI>Losartan: 60.6 (3.7) years</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>Placebo: 9/1</LI>
<LI>Losartan: 10/0</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Serious systemic illness; substance abuse; 24 hour urinary sodium &gt; 100 mmol/24 h; SBP &gt; 165 mm Hg, DBP &gt; 100 mm Hg; plasma Cr &gt; 200 µmol/L, long-term use of NSAID; UTIs; BMI &gt; 35 kg/m²; intolerance of ACEi.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-18 21:19:57 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment</P>
<UL>
<LI>Low sodium phase: 50-70 mmol/d</LI>
</UL>
<P>Control</P>
<UL>
<LI>Regular sodium phase: &gt; 100 mmol/d</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Losartan versus placebo with parallel study</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-18 21:19:57 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SBP</LI>
<LI>DBP</LI>
<LI>MAP</LI>
<LI>GFR</LI>
<LI>ERPF</LI>
<LI>HbA1c</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-18 21:19:57 +1000" MODIFIED_BY="Narelle S Willis">
<P>Additional data requested from authors: UAE, no response from authors</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-18 23:07:34 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Imanishi_x005f_Micro-2001">
<CHAR_METHODS MODIFIED="2010-09-18 23:07:34 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: crossover RCT</LI>
<LI>Time frame: not stated</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-14 13:55:38 +1000" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Japan</LI>
<LI>Setting: Hospital</LI>
<LI>DM: type 2 with simple retinopathy divided into microalbuminuria and normoalbuminuria</LI>
<LI>Number (normoalbuminuria/microalbuminuria): 8/8</LI>
<LI>Mean age ± SD</LI>
<UL>
<LI>Normoalbuminuria: 59 ± 11 years</LI>
<LI>Microalbuminuria: 61 ± 10 years</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>Normoalbuminuria: 5/3</LI>
<LI>Microalbuminuria: 4/4</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Non-diabetic kidney disease; heart disease; UTI; SCr &gt; 97.4 µmol/L</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-18 21:30:30 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment</P>
<UL>
<LI>Low salt diet: 80 mmol/d</LI>
</UL>
<P>Control</P>
<UL>
<LI>Ordinary salt diet: 200 mmol/d</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-18 21:21:07 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SBP</LI>
<LI>DBP</LI>
<LI>CrCl</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-18 21:20:34 +1000" MODIFIED_BY="Narelle S Willis"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-18 23:07:39 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Imanishi_x005f_Normo-2001">
<CHAR_METHODS MODIFIED="2010-09-18 23:07:39 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: crossover RCT</LI>
<LI>Time frame: not stated</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-18 21:23:21 +1000" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Japan</LI>
<LI>Setting: Hospital</LI>
<LI>DM: type 2 with simple retinopathy divided into microalbuminuria and normoalbuminuria</LI>
<LI>Number (normoalbuminuria/microalbuminuria): 8/8</LI>
<LI>Mean age ± SD</LI>
<UL>
<LI>Normoalbuminuria: 59 ± 11 years</LI>
<LI>Microalbuminuria: 61 ± 10 years</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>Normoalbuminuria: 5/3</LI>
<LI>Microalbuminuria: 4/4</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Non-diabetic kidney disease; heart disease; UTI; SCr &gt; 97.4 µmol/L</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-18 21:30:53 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment</P>
<UL>
<LI>Low salt diet: 80 mmol/d</LI>
</UL>
<P>Control</P>
<UL>
<LI>Ordinary salt diet: 200 mmol/d</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-18 21:23:21 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SBP</LI>
<LI>DBP</LI>
<LI>CrCl</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-18 21:23:21 +1000" MODIFIED_BY="Narelle S Willis"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-18 23:09:05 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Lopes-De-Faria-1997">
<CHAR_METHODS MODIFIED="2010-09-18 23:07:47 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: crossover RCT</LI>
<LI>Time frame: NS</LI>
<LI>Loss to follow-up:0</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-18 21:37:06 +1000" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: UK</LI>
<LI>Setting: Hospital</LI>
<LI>Normoalbuminuria, normotensive, aged 18-55 years, body weight within 20% of ideal</LI>
<LI>DM: IDDM</LI>
<LI>Number: 10</LI>
<LI>Age: 30 ± 3 years</LI>
<LI>Sex (M/F): 7/3</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Patients on drugs other than insulin</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-18 23:09:05 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Regular salt diet: ~ 100 mmol/d</LI>
<LI>Duration: 7 days</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Sodium supplemented diet: regular salt diet + salt capsules (0.5g), 32 taken per day to elevate salt intake to ~ 300 mmol/d</LI>
<LI>Duration: 7 days</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-18 21:37:47 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Weight</LI>
<LI>MAP</LI>
<LI>HbA1c</LI>
<LI>GFR</LI>
<LI>RPF</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-24 11:47:24 +1100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-18 23:07:54 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Luik-2002">
<CHAR_METHODS MODIFIED="2010-09-18 23:07:54 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: crossover RCT</LI>
<LI>Time frame: NS</LI>
<LI>Loss to follow-up: 0</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-18 21:48:48 +1000" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: The Netherlands</LI>
<LI>DM: Type 1</LI>
<LI>BP &lt; 140/85 mm Hg</LI>
<LI>Number: 24</LI>
<LI>Age: 28.8 ± 6 years</LI>
<LI>Sex (M/F): 15/9</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-14 14:11:47 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment</P>
<UL>
<LI>Low salt diet: 50 mmol/d</LI>
</UL>
<P>Control</P>
<UL>
<LI>Liberal salt diet: 200 mmol/d</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-18 21:53:11 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SBP</LI>
<LI>DBP</LI>
<LI>SCr</LI>
<LI>CrCl</LI>
<LI>GFR</LI>
<LI>ERPF</LI>
<LI>Urinary albumin/Cr ratio</LI>
<LI>Albuminuria</LI>
<LI>Weight</LI>
<LI>BMI</LI>
<LI>HbA1c</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-24 11:47:24 +1100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-18 23:08:01 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Miller-1995">
<CHAR_METHODS MODIFIED="2010-09-18 23:08:01 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: crossover RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: NS</LI>
<LI>Loss to follow-up: 0</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-18 21:56:59 +1000" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Canada</LI>
<LI>Setting: Hospital</LI>
<LI>IDDM &lt; 5 years</LI>
<LI>Number: 9</LI>
<LI>Age: 25.6 ± 1.5 years (range 21-31)</LI>
<LI>Sex (M/F): 9/0</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-18 21:17:04 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Sodium restriction: 20 mmol/d</LI>
<LI>Duration: 7 days</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Sodium diet: 250 mmol/d</LI>
<LI>Duration: 7 days</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-18 21:57:40 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>MAP</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-24 11:47:24 +1100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-18 23:09:28 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Miller-1997">
<CHAR_METHODS MODIFIED="2010-09-18 23:08:09 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: crossover RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: NS</LI>
<LI>Loss to follow-up: 0</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-18 23:09:28 +1000" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Canada</LI>
<LI>Setting: Hospital</LI>
<LI>Early IDDM (duration. 2.8 ± 0.4 years)</LI>
<LI>Number: 12</LI>
<LI>Age: 23 ± 2 years</LI>
<LI>Se (M/F): 12/0</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-14 14:34:23 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Low salt diet: 20 mmol/d</LI>
<LI>Duration: 7 days</LI>
</UL>
<P>Control group</P>
<UL>
<LI>High salt diet: 200 mmol/d</LI>
<LI>Duration: 7 days </LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-18 22:07:06 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>MAP</LI>
<LI>Weight</LI>
<LI>GFR</LI>
<LI>ERPF</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-24 11:47:24 +1100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-18 23:09:43 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Mulhauser-1996">
<CHAR_METHODS MODIFIED="2010-09-18 23:09:43 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: 4 years</LI>
<LI>Follow-up period: not stated</LI>
<LI>Loss to follow-up: not stated</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-18 22:25:29 +1000" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Setting: Hospital</LI>
<LI>Country: Germany</LI>
<LI>IDDM &gt; 5 years</LI>
<LI>Number (treatment/control): 8/8</LI>
<LI>Mean age ± SD</LI>
<UL>
<LI>Treatment: 35 ± 11 years</LI>
<LI>Control: 27 ± 9 years</LI>
</UL>
<LI>Sex (M/F)</LI>
<UL>
<LI>Treatment: 5/3</LI>
<LI>Control: 7/1</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>UTI; drugs (including oral contraceptives); pregnancy</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-14 15:28:13 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Low sodium diet: 90 mmol/d</LI>
<LI>Placebo supplement</LI>
<LI>Duration: 4 weeks</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Low sodium diet: 90 mmol/d</LI>
<LI>Sodium supplement: 100 mmol/d</LI>
<LI>Duration: 4 weeks</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-18 22:08:58 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SBP</LI>
<LI>DBP</LI>
<LI>SCr</LI>
<LI>CrCl</LI>
<LI>GFR</LI>
<LI>ERPF</LI>
<LI>Weight</LI>
<LI>BMI</LI>
<LI>HbA1c%</LI>
<LI>Albuminuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-24 11:47:24 +1100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-18 22:29:39 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Petrie-1998">
<CHAR_METHODS MODIFIED="2010-09-18 22:29:39 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: crossover RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 12 days</LI>
<LI>Loss to follow-up: 0</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-14 16:46:14 +1000" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: UK</LI>
<LI>Setting: Hospital</LI>
<LI>BMI 28.6 ± 3.9 kg/m², fasting plasma glucose 9.0 ± 2.2 mmol/L (range 5.7&#8211;12.4 mmol/L), HbA1c 5.7 ± 0.8% (normal range 3.4&#8211;4.9%), total cholesterol 5.76 ± 1.25 mmol/L</LI>
<LI>DM: median duration 12 months (range 4-92)</LI>
<LI>Number: 9</LI>
<LI>Mean age ± SD: 57 ± 9.7 years</LI>
<LI>Sex (M/F): 8/1</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-14 16:52:25 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Low sodium diet: 40 mmol/d for 4 days then addition of placebo for 4 days</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Low sodium diet: 40 mmol/d for 4 days then addition of sodium tablets (120 mmol/d) for 4 days</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-14 16:54:39 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SBP</LI>
<LI>DBP</LI>
<LI>Weight</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-24 11:57:29 +1100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-21 17:11:59 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Trevisan_x005f_Micro-1998">
<CHAR_METHODS MODIFIED="2010-09-18 22:33:24 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: crossover RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 2 weeks</LI>
<LI>Loss to follow-up: 0</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-21 17:11:59 +1000" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Setting: Hospital</LI>
<LI>Country: Italy</LI>
<LI>IDDM, duration (mean ± SE) 24 ± 4 years</LI>
<LI>Number: 7</LI>
<LI>Age (mean ± SE): 38 ± 5 years</LI>
<LI>Sex (M/F): 6/1</LI>
</UL>
<P>Exclusion criteria:</P>
<UL>
<LI>No drugs other than insulin, non-DKD, endocrine disease, liver disease</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-18 22:38:56 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Low sodium diet: 20 mEq</LI>
</UL>
<P>Control group</P>
<UL>
<LI>High sodium diet: 250 mEq</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-18 22:39:24 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SBP</LI>
<LI>DBP</LI>
<LI>MAP</LI>
<LI>GFR</LI>
<LI>ERPF</LI>
<LI>Weight</LI>
<LI>BMI</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-24 11:47:24 +1100" MODIFIED_BY="[Empty name]">
<P> </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-18 22:42:49 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Trevisan_x005f_Normo-1998">
<CHAR_METHODS MODIFIED="2010-09-18 22:40:30 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: crossover RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 2 weeks</LI>
<LI>Loss to follow-up: 0</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-18 22:42:49 +1000" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Setting: Hospital</LI>
<LI>Country: Italy</LI>
<LI>IDDM, duration (mean ± SE) 22 ± 4 years</LI>
<LI>Number: 9</LI>
<LI>Age (mean ± SE): 42 ± 4 years</LI>
<LI>Sex (M/F): 6/3</LI>
</UL>
<P>Exclusion criteria:</P>
<UL>
<LI>No drugs other than insulin, non-diabetic kidney disease, endocrine disease, liver disease</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-18 22:40:30 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Low sodium diet: 20 mEq</LI>
</UL>
<P>Control group</P>
<UL>
<LI>High sodium diet: 250 mEq</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-18 22:40:30 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>SBP</LI>
<LI>DBP</LI>
<LI>MAP</LI>
<LI>GFR</LI>
<LI>ERPF</LI>
<LI>Weight</LI>
<LI>BMI</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-07-14 14:02:44 +1000" MODIFIED_BY="Narelle S Willis">
<P> </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-18 23:10:12 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Vedovato_x005f_Micro-2004">
<CHAR_METHODS MODIFIED="2010-09-18 22:53:10 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: crossover RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 2 weeks</LI>
<LI>Loss to follow-up: 0</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-18 23:10:08 +1000" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Italy</LI>
<LI>Setting: hospital</LI>
<LI>DM: type 2</LI>
<LI>BP &lt; 140/90 mm Hg; divided into two groups: with and without microalbuminuria</LI>
<LI>Number: 20</LI>
<LI>Age: 57 ± 1 years</LI>
<LI>Sex (M/F): 15/5</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>On antihypertensives</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-18 23:10:12 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Low salt diet: 20 mmol/d</LI>
<LI>Duration: 7 days</LI>
</UL>
<P>Control group</P>
<UL>
<LI>High sodium diet: 250 mmol/d</LI>
<LI>Duration: 7 days</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-18 22:53:49 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>MAP</LI>
<LI>Albuminuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-24 11:47:24 +1100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-18 23:10:13 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Vedovato_x005f_Normo-2004">
<CHAR_METHODS MODIFIED="2010-09-18 22:53:23 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: crossover RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 2 weeks</LI>
<LI>Loss to follow-up: 0</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-18 22:53:28 +1000" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Italy</LI>
<LI>Setting: hospital</LI>
<LI>DM: type 2BP &lt; 140/90 mm Hg; divided into two groups: with and without microalbuminuria</LI>
<LI>Number: 21</LI>
<LI>Age: 60 ± 2 years</LI>
<LI>Sex (M/F): 16/5</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>On antihypertensives</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-18 23:10:13 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Low salt diet: 20 mmol/d</LI>
<LI>Duration: 7 days</LI>
</UL>
<P>Control group</P>
<UL>
<LI>High sodium diet: 250 mmol/d</LI>
<LI>Duration: 7 days</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-18 22:54:13 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>MAP</LI>
<LI>Albuminuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-24 11:47:24 +1100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-18 23:04:52 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Yoshioka_x005f_Adva_x005f_alb-1998">
<CHAR_METHODS MODIFIED="2010-09-18 23:04:52 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: Crossover RCT</LI>
<LI>Time frame: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-18 22:59:21 +1000" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Japan</LI>
<LI>Setting: Hospital</LI>
<LI>DM: type 2 </LI>
<LI>Number: 19</LI>
<UL>
<LI>Divided into 3 groups: normoalbuminuria (8), microalbuminuria (7), advanced albuminuria (4)</LI>
</UL>
<LI>Age: 60 ± 2 years</LI>
<LI>Sex (M/F): 11/8</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Heart disease; non-diabetic kidney disease; UTI, SCr &gt; 1.0 mg/dL; BP &gt; 160/95 mm Hg; on antihypertensives.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-18 23:04:10 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment</P>
<UL>
<LI>Low salt diet: 85 mEq sodium</LI>
</UL>
<P>Control</P>
<UL>
<LI>High salt diet: 255 mEq sodium</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-18 23:04:29 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>MAP</LI>
<LI>CrCl</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-24 11:47:24 +1100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-18 23:05:20 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Yoshioka_x005f_Micro-1998">
<CHAR_METHODS MODIFIED="2010-09-18 23:05:20 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: Crossover RCT</LI>
<LI>Time frame: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-18 23:05:20 +1000" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Japan</LI>
<LI>Setting: Hospital</LI>
<LI>DM: type 2 </LI>
<LI>Number: 19</LI>
<UL>
<LI>Divided into 3 groups: normoalbuminuria (8), microalbuminuria (7), advanced albuminuria (4)</LI>
</UL>
<LI>Age: 60 ± 2 years</LI>
<LI>Sex (M/F): 11/8</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Heart disease; non-diabetic kidney disease; UTI, SCr &gt; 1.0 mg/dL; BP &gt; 160/95 mm Hg; on antihypertensives.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-18 23:05:20 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment</P>
<UL>
<LI>Low salt diet: 85 mEq sodium</LI>
</UL>
<P>Control</P>
<UL>
<LI>High salt diet: 255 mEq sodium</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-18 23:05:20 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>MAP</LI>
<LI>CrCl</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-18 23:05:20 +1000" MODIFIED_BY="Narelle S Willis"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-18 23:05:26 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Yoshioka_x005f_Normo-1998">
<CHAR_METHODS MODIFIED="2010-09-18 23:05:26 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: Crossover RCT</LI>
<LI>Time frame: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-18 23:05:26 +1000" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Country: Japan</LI>
<LI>Setting: Hospital</LI>
<LI>DM: type 2 </LI>
<LI>Number: 19</LI>
<UL>
<LI>Divided into 3 groups: normoalbuminuria (8), microalbuminuria (7), advanced albuminuria (4)</LI>
</UL>
<LI>Age: 60 ± 2 years</LI>
<LI>Sex (M/F): 11/8</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Heart disease; non-diabetic kidney disease; UTI, SCr &gt; 1.0 mg/dL; BP &gt; 160/95 mm Hg; on antihypertensives.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-18 23:05:26 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment</P>
<UL>
<LI>Low salt diet: 85 mEq sodium</LI>
</UL>
<P>Control</P>
<UL>
<LI>High salt diet: 255 mEq sodium</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-18 23:05:26 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>MAP</LI>
<LI>CrCl</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-18 23:05:26 +1000" MODIFIED_BY="Narelle S Willis"/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ACEi - angiotensin converting enzyme inhibitors; AER - albumin excretion ratio; BMI - body mass index; BP - blood pressure; Cr - creatinine; CrCl - creatinine clearance; DBP - diastolic blood pressure; DKD - diabetic kidney disease; ERPF - effective renal plasma flow; GFR - glomerular filtration rate; HbA1c - glycated haemoglobin; IDDM - idiopathic diabetes mellitus; MAP - mean arterial pressure; NSAID - nonsteroidal anti-inflammatory drugs; RPF - renal plasma flow; SBP - systolic blood pressure; SCr - serum creatinine; UTI - urinary tract infection<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-05-13 03:47:45 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ames-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Appropriate data in diabetic patients within the study cohort unavailable</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bakris-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-13 03:47:14 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barsotti-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-13 03:47:14 +1000" MODIFIED_BY="[Empty name]">
<P>Study not salt reduction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bellini-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Study not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boero-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Study not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Buter-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Study not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cianciaruso-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cuzzola-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Studies not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Del-Rio-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Study not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dengel-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Study not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dodson-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Multiple randomised interventions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Donovan-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Study not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DUAAL-Study">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Study not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Egan-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Studies not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Evrenkaya-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Study not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Feldman-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Study not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Feldman-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Study not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Feldt_x002d_Rasmussen-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fliser-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Study not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gerdts-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gilleran-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Multiple randomised interventions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gomi-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Study not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grey-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Study not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gruska-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Study not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Heeg-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Study not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Iwaoka-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Study not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jafar-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Study not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jones_x002d_Burton-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-11 08:41:40 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Juncos-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-11 08:41:40 +1000" MODIFIED_BY="[Empty name]">
<P>Study not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-13 03:47:32 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Keven-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-13 03:47:32 +1000" MODIFIED_BY="[Empty name]">
<P>Study not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kirby-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Appropriate data unavailable</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuroda-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Study not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mallamaci-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Study not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mazouz-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meland-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Study not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-11 08:40:00 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Melander-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-11 08:40:00 +1000" MODIFIED_BY="[Empty name]">
<P>Study not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Metcalf-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pacy-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Multiple randomised interventions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Perry-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Study not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Price-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Raji-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Study not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rudberg-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sharma-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Study not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sharma-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Study not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Suzuki-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Study not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Swift-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Study not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Townsend-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Study not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Trujillo-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tuck-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weir-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Study not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weir-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zanchi-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Study not in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zarraga-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 12:02:41 +1100" MODIFIED_BY="[Empty name]">
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-05-13 03:46:36 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2008-11-24 11:41:53 +1100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-10-19 09:14:19 +1100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-08-23 22:14:15 +1000" MODIFIED_BY="Narelle S Willis" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-09-18 23:06:42 +1000" MODIFIED_BY="Narelle S Willis" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-23 21:13:24 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-De_x0027_oliveira-1997">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-23 21:49:28 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Dodson_x005f_P-1989">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-23 22:03:22 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Dodson_x005f_X-1989">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-14 13:32:00 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Houlihan_x005f_Losartan-2002">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-14 13:48:38 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Houlihan_x005f_Placebo-2002">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-14 13:50:31 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Imanishi_x005f_Micro-2001">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 21:31:13 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Imanishi_x005f_Normo-2001">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 21:33:01 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Lopes-De-Faria-1997">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 21:41:45 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Luik-2002">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 21:54:43 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Miller-1995">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 22:06:10 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Miller-1997">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 22:09:29 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Mulhauser-1996">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-24 11:59:52 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Petrie-1998">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 22:30:06 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Trevisan_x005f_Micro-1998">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 22:43:12 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Trevisan_x005f_Normo-1998">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 22:46:46 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Vedovato_x005f_Micro-2004">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 22:51:32 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Vedovato_x005f_Normo-2004">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 23:06:22 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Yoshioka_x005f_Adva_x005f_alb-1998">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-24 11:58:45 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yoshioka_x005f_Micro-1998">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 23:06:42 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Yoshioka_x005f_Normo-1998">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-09-18 23:06:49 +1000" MODIFIED_BY="Narelle S Willis" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.04" NO="4">
<NAME>Data analysers</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Investigators</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Participants</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.03" NO="3">
<NAME>Outcome assessors</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-23 21:13:35 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-De_x0027_oliveira-1997">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-08-23 21:16:13 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-De_x0027_oliveira-1997">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-08-23 21:16:16 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-De_x0027_oliveira-1997">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-08-23 21:16:18 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-De_x0027_oliveira-1997">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-23 21:50:05 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Dodson_x005f_P-1989">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-08-23 21:50:07 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Dodson_x005f_P-1989">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-08-23 21:50:08 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Dodson_x005f_P-1989">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-08-23 21:50:03 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Dodson_x005f_P-1989">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-23 22:03:42 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Dodson_x005f_X-1989">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-08-23 22:03:44 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Dodson_x005f_X-1989">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-08-23 22:03:45 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Dodson_x005f_X-1989">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-08-23 22:03:23 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Dodson_x005f_X-1989">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-14 13:30:46 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Houlihan_x005f_Losartan-2002">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-09-14 13:30:55 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Houlihan_x005f_Losartan-2002">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-09-14 13:30:59 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Houlihan_x005f_Losartan-2002">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-09-14 13:31:03 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Houlihan_x005f_Losartan-2002">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-14 13:48:40 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Houlihan_x005f_Placebo-2002">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-09-14 13:48:38 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Houlihan_x005f_Placebo-2002">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-09-14 13:48:38 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Houlihan_x005f_Placebo-2002">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-09-14 13:48:38 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Houlihan_x005f_Placebo-2002">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-14 13:50:38 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Imanishi_x005f_Micro-2001">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-09-14 13:50:44 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Imanishi_x005f_Micro-2001">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-09-14 13:50:45 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Imanishi_x005f_Micro-2001">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-09-14 13:50:47 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Imanishi_x005f_Micro-2001">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-18 21:31:13 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Imanishi_x005f_Normo-2001">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-09-18 21:31:13 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Imanishi_x005f_Normo-2001">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-09-18 21:31:13 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Imanishi_x005f_Normo-2001">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-09-18 21:31:13 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Imanishi_x005f_Normo-2001">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-18 21:33:07 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Lopes-De-Faria-1997">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-09-18 21:33:12 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Lopes-De-Faria-1997">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-09-18 21:33:17 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Lopes-De-Faria-1997">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-09-18 21:33:20 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Lopes-De-Faria-1997">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-18 21:41:53 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Luik-2002">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-09-18 21:41:56 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Luik-2002">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-09-18 21:41:59 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Luik-2002">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-09-18 21:42:02 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Luik-2002">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-18 21:54:46 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Miller-1995">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-09-18 21:54:48 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Miller-1995">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-09-18 21:54:50 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Miller-1995">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-09-18 21:54:54 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Miller-1995">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-18 22:06:28 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Miller-1997">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-09-18 22:06:30 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Miller-1997">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-09-18 22:06:31 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Miller-1997">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-09-18 22:06:32 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Miller-1997">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-18 22:09:46 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Mulhauser-1996">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-09-18 22:09:48 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Mulhauser-1996">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-09-18 22:09:49 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Mulhauser-1996">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-09-18 22:09:50 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Mulhauser-1996">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-14 16:52:58 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Petrie-1998">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-09-14 16:53:03 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Petrie-1998">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-09-14 16:53:12 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Petrie-1998">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-09-14 16:53:18 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Petrie-1998">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-18 22:30:31 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Trevisan_x005f_Micro-1998">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-09-18 22:30:33 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Trevisan_x005f_Micro-1998">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-09-18 22:30:26 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Trevisan_x005f_Micro-1998">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-09-18 22:30:28 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Trevisan_x005f_Micro-1998">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-18 22:43:12 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Trevisan_x005f_Normo-1998">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-09-18 22:43:12 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Trevisan_x005f_Normo-1998">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-09-18 22:43:12 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Trevisan_x005f_Normo-1998">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-09-18 22:43:12 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Trevisan_x005f_Normo-1998">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-18 22:47:04 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Vedovato_x005f_Micro-2004">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-09-18 22:47:06 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Vedovato_x005f_Micro-2004">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-09-18 22:47:08 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Vedovato_x005f_Micro-2004">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-09-18 22:47:10 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Vedovato_x005f_Micro-2004">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-18 22:51:36 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Vedovato_x005f_Normo-2004">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-09-18 22:51:38 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Vedovato_x005f_Normo-2004">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-09-18 22:51:39 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Vedovato_x005f_Normo-2004">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-09-18 22:51:41 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Vedovato_x005f_Normo-2004">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-18 22:58:49 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Yoshioka_x005f_Adva_x005f_alb-1998">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-09-18 22:58:53 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Yoshioka_x005f_Adva_x005f_alb-1998">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-09-18 22:58:55 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Yoshioka_x005f_Adva_x005f_alb-1998">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-09-18 22:58:58 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Yoshioka_x005f_Adva_x005f_alb-1998">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-18 23:06:33 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Yoshioka_x005f_Micro-1998">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-09-18 23:06:34 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Yoshioka_x005f_Micro-1998">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-09-18 23:06:36 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Yoshioka_x005f_Micro-1998">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-09-18 23:06:37 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Yoshioka_x005f_Micro-1998">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-18 23:06:44 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Yoshioka_x005f_Normo-1998">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-09-18 23:06:46 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Yoshioka_x005f_Normo-1998">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-09-18 23:06:47 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Yoshioka_x005f_Normo-1998">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-09-18 23:06:49 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Yoshioka_x005f_Normo-1998">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-08-23 21:15:52 +1000" MODIFIED_BY="Narelle S Willis" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2010-09-18 23:06:41 +1000" MODIFIED_BY="Narelle S Willis" NO="7">
<NAME>Intention-to-treat analysis</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-23 21:13:54 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-De_x0027_oliveira-1997">
<DESCRIPTION>
<P>ITT analysis not performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-23 21:50:19 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Dodson_x005f_P-1989">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-23 22:03:48 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Dodson_x005f_X-1989">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-14 13:31:15 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Houlihan_x005f_Losartan-2002">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-14 13:48:38 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Houlihan_x005f_Placebo-2002">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-14 13:51:13 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Imanishi_x005f_Micro-2001">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 21:31:13 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Imanishi_x005f_Normo-2001">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 21:32:55 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Lopes-De-Faria-1997">
<DESCRIPTION>
<P>No ITT</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 21:42:05 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Luik-2002">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 21:54:56 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Miller-1995">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 22:06:25 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Miller-1997">
<DESCRIPTION>
<P>No ITT</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 22:09:44 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Mulhauser-1996">
<DESCRIPTION>
<P>No ITT</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-14 16:53:29 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Petrie-1998">
<DESCRIPTION>
<P>No ITT</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 22:30:54 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Trevisan_x005f_Micro-1998">
<DESCRIPTION>
<P>ITT performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 22:43:12 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Trevisan_x005f_Normo-1998">
<DESCRIPTION>
<P>ITT performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 22:47:18 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Vedovato_x005f_Micro-2004">
<DESCRIPTION>
<P>ITT performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 22:51:42 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Vedovato_x005f_Normo-2004">
<DESCRIPTION>
<P>ITT performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 22:59:08 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Yoshioka_x005f_Adva_x005f_alb-1998">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 23:06:30 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Yoshioka_x005f_Micro-1998">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 23:06:41 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Yoshioka_x005f_Normo-1998">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="STUDY" MODIFIED="2010-10-19 09:14:19 +1100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Funding source</NAME>
<DESCRIPTION>
<P>Was the study free of funding source bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-19 09:14:19 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-De_x0027_oliveira-1997">
<DESCRIPTION>
<P>NIH, Canadian Medical Research Fellowship Award, Northern Ireland Council for Postgraduate Education Award </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-23 21:50:44 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Dodson_x005f_P-1989">
<DESCRIPTION>
<P>Ciba provided slow sodium and placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-23 22:03:50 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Dodson_x005f_X-1989">
<DESCRIPTION>
<P>Ciba provided slow sodium and placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 22:27:42 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Houlihan_x005f_Losartan-2002">
<DESCRIPTION>
<P>Merck and Apex Diabetes Australia Research Grant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 22:27:35 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Houlihan_x005f_Placebo-2002">
<DESCRIPTION>
<P>Merck and Apex Diabetes Australia Research Grant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-14 13:50:58 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Imanishi_x005f_Micro-2001">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 21:31:13 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Imanishi_x005f_Normo-2001">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 21:34:33 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Lopes-De-Faria-1997">
<DESCRIPTION>
<P>None stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 22:27:20 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Luik-2002">
<DESCRIPTION>
<P>Work supported by grants from the Dutch Kidney Foundation and Diabetes Fonds Nederland (Diabetes Research fund)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 22:27:14 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Miller-1995">
<DESCRIPTION>
<P>This work was supported by Grant 92-27 from the physicians of Ontario through the Physicians Services Inc. Foundation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 23:09:38 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Miller-1997">
<DESCRIPTION>
<P>This work was supported by Grant 92-27 from the Physicians of Ontario through the Physicians&#8217; Services Inc. Foundation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 22:28:25 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Mulhauser-1996">
<DESCRIPTION>
<P>The study has been supported by Cassella Riedel, Frankfurt, Germany, and by the E Klockner Stiftung, Duisburg, Germany.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-14 16:54:14 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Petrie-1998">
<DESCRIPTION>
<P>This work was supported by the British Diabetic Association.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 22:39:48 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Trevisan_x005f_Micro-1998">
<DESCRIPTION>
<P>This work was supported by Consiglio Nazionale delle Ricerche Grants 9603475CT04 and 9504361CT04.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 22:43:12 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Trevisan_x005f_Normo-1998">
<DESCRIPTION>
<P>This work was supported by Consiglio Nazionale delle Ricerche Grants 9603475CT04 and 9504361CT04.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 22:51:18 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Vedovato_x005f_Micro-2004">
<DESCRIPTION>
<P>This study was supported by a research grant from the University of Padua, Italy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 22:51:44 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Vedovato_x005f_Normo-2004">
<DESCRIPTION>
<P>This study was supported by a research grant from the University of Padua, Italy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 23:06:03 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Yoshioka_x005f_Adva_x005f_alb-1998">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 23:06:30 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Yoshioka_x005f_Micro-1998">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 23:06:41 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Yoshioka_x005f_Normo-1998">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2010-10-26 17:26:41 +1100" MODIFIED_BY="Narelle S Willis">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2010-10-26 17:26:41 +1100" MODIFIED_BY="Narelle S Willis" NO="1">
<TITLE MODIFIED="2010-09-19 19:22:26 +1000" MODIFIED_BY="Narelle S Willis">Summary table of characteristics of included studies</TITLE>
<TABLE COLS="9" ROWS="21">
<TR>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Study</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Number of participants</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Age (years)</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Males (%)</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Diabetes</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Study design</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Blinding</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Study duration (weeks)</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>
Initial BP (SE)
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Dodson_x005f_P-1989" TYPE="STUDY">Dodson_P 1989</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>34</P>
</TD>
<TD ALIGN="CENTER">
<P>61</P>
</TD>
<TD ALIGN="CENTER">
<P>71/65</P>
</TD>
<TD>
<P>Type 2</P>
</TD>
<TD ALIGN="CENTER">
<P>P</P>
</TD>
<TD ALIGN="CENTER">
<P>SB</P>
</TD>
<TD ALIGN="CENTER">
<P>12</P>
</TD>
<TD ALIGN="CENTER">
<P>180(18)/91(11)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Dodson_x005f_X-1989" TYPE="STUDY">Dodson_X 1989</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>9</P>
</TD>
<TD ALIGN="CENTER">
<P>62</P>
</TD>
<TD ALIGN="CENTER">
<P>67</P>
</TD>
<TD>
<P>Type 2</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>DB</P>
</TD>
<TD ALIGN="CENTER">
<P>4</P>
</TD>
<TD ALIGN="CENTER">
<P>160(20)/88(11)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Miller-1995" TYPE="STUDY">Miller 1995</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>9</P>
</TD>
<TD ALIGN="CENTER">
<P>26</P>
</TD>
<TD ALIGN="CENTER">
<P>100</P>
</TD>
<TD>
<P>Type 1</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>SB</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Mulhauser-1996" TYPE="STUDY">Mulhauser 1996</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>14</P>
</TD>
<TD ALIGN="CENTER">
<P>31</P>
</TD>
<TD ALIGN="CENTER">
<P>75</P>
</TD>
<TD>
<P>Type 1</P>
</TD>
<TD ALIGN="CENTER">
<P>P</P>
</TD>
<TD ALIGN="CENTER">
<P>DB</P>
</TD>
<TD ALIGN="CENTER">
<P>4</P>
</TD>
<TD ALIGN="CENTER">
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-De_x0027_oliveira-1997" TYPE="STUDY">De'oliveira 1997</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>19</P>
</TD>
<TD ALIGN="CENTER">
<P>55</P>
</TD>
<TD ALIGN="CENTER">
<P>84</P>
</TD>
<TD>
<P>Type 2</P>
</TD>
<TD ALIGN="CENTER">
<P>P</P>
</TD>
<TD ALIGN="CENTER">
<P>NS</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>MAP 102(3)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Lopes-De-Faria-1997" TYPE="STUDY">Lopes De Faria 1997</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>10</P>
</TD>
<TD ALIGN="CENTER">
<P>30</P>
</TD>
<TD ALIGN="CENTER">
<P>70</P>
</TD>
<TD>
<P>Type 1</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>NS</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>MAP 91(9)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Miller-1997" TYPE="STUDY">Miller 1997</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>12</P>
</TD>
<TD ALIGN="CENTER">
<P>23</P>
</TD>
<TD ALIGN="CENTER">
<P>100</P>
</TD>
<TD>
<P>Type 1</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>SB</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>MAP 82(4)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Petrie-1998" TYPE="STUDY">Petrie 1998</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>9</P>
</TD>
<TD ALIGN="CENTER">
<P>57</P>
</TD>
<TD ALIGN="CENTER">
<P>89</P>
</TD>
<TD>
<P>Type 2</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>DB</P>
</TD>
<TD ALIGN="CENTER">
<P>5 days</P>
</TD>
<TD ALIGN="CENTER">
<P>148(25)/82(7)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Trevisan_x005f_Normo-1998" TYPE="STUDY">Trevisan_Normo 1998</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>9</P>
</TD>
<TD ALIGN="CENTER">
<P>42</P>
</TD>
<TD ALIGN="CENTER">
<P>67</P>
</TD>
<TD>
<P>Type 1</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>NS</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>120/72</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Trevisan_x005f_Micro-1998" TYPE="STUDY">Trevisan_Micro 1998</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>7</P>
</TD>
<TD ALIGN="CENTER">
<P>38</P>
</TD>
<TD ALIGN="CENTER">
<P>86</P>
</TD>
<TD>
<P>Type 1</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>NS</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>125/78</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Yoshioka_x005f_Normo-1998" TYPE="STUDY">Yoshioka_Normo 1998</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>8</P>
</TD>
<TD ALIGN="CENTER">
<P>60</P>
</TD>
<TD ALIGN="CENTER">
<P>58</P>
</TD>
<TD>
<P>Type 2</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>NS</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>134(5)/78(1)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Yoshioka_x005f_Micro-1998" TYPE="STUDY">Yoshioka_Micro 1998</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>7</P>
</TD>
<TD ALIGN="CENTER">
<P>58</P>
</TD>
<TD ALIGN="CENTER">
<P>58</P>
</TD>
<TD>
<P>Type 2</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>NS</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>133(6)/75(4)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Yoshioka_x005f_Adva_x005f_alb-1998" TYPE="STUDY">Yoshioka_Adva_alb 1998</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>4</P>
</TD>
<TD ALIGN="CENTER">
<P>51</P>
</TD>
<TD ALIGN="CENTER">
<P>58</P>
</TD>
<TD>
<P>Type 2</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>NS</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>131(4)/75(4)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Imanishi_x005f_Normo-2001" TYPE="STUDY">Imanishi_Normo 2001</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>8</P>
</TD>
<TD ALIGN="CENTER">
<P>59</P>
</TD>
<TD ALIGN="CENTER">
<P>63</P>
</TD>
<TD>
<P>Type 2</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>SB</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>132(11)/73(7)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Imanishi_x005f_Micro-2001" TYPE="STUDY">Imanishi_Micro 2001</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>8</P>
</TD>
<TD ALIGN="CENTER">
<P>61</P>
</TD>
<TD ALIGN="CENTER">
<P>50</P>
</TD>
<TD>
<P>Type 2</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>SB</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>136(9)/82(6)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Houlihan_x005f_Placebo-2002" TYPE="STUDY">Houlihan_Placebo 2002</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>10</P>
</TD>
<TD ALIGN="CENTER">
<P>63</P>
</TD>
<TD ALIGN="CENTER">
<P>90</P>
</TD>
<TD>
<P>Type 2</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>SB</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>MAP 111(3)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Houlihan_x005f_Losartan-2002" TYPE="STUDY">Houlihan_Losartan 2002</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>10</P>
</TD>
<TD ALIGN="CENTER">
<P>61</P>
</TD>
<TD ALIGN="CENTER">
<P>100</P>
</TD>
<TD>
<P>Type 2</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>SB</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD ALIGN="CENTER">
<P>MAP 114(3)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Luik-2002" TYPE="STUDY">Luik 2002</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>24</P>
</TD>
<TD ALIGN="CENTER">
<P>29</P>
</TD>
<TD ALIGN="CENTER">
<P>63</P>
</TD>
<TD>
<P>Type 1</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>NS</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Vedovato_x005f_Normo-2004" TYPE="STUDY">Vedovato_Normo 2004</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>21</P>
</TD>
<TD ALIGN="CENTER">
<P>60</P>
</TD>
<TD ALIGN="CENTER">
<P>75</P>
</TD>
<TD>
<P>Type 2</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>NS</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>125(2)/79(2)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Yoshioka_x005f_Micro-1998" TYPE="STUDY">Yoshioka_Micro 1998</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>20</P>
</TD>
<TD ALIGN="CENTER">
<P>57</P>
</TD>
<TD ALIGN="CENTER">
<P>75</P>
</TD>
<TD>
<P>Type 2</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>NS</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>130(2)/80(2)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>DB - double-blind; NS - not stated; P - parallel; X - crossover; SB - single blind; SE - standard error</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2010-09-20 16:15:16 +1000" MODIFIED_BY="Narelle S Willis" NO="2">
<TITLE MODIFIED="2010-09-20 16:00:11 +1000" MODIFIED_BY="Narelle S Willis">Outcomes reported in the included studies</TITLE>
<TABLE COLS="10" ROWS="15">
<TR>
<TH VALIGN="BOTTOM">
<P>Study</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Urinary sodium (24h)</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>SCr</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>CrCl or GFR</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>RPF</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Urinary albumin or protein (24h)</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>ACR</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>BP</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>HbA1c</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>BMI</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Dodson_x005f_P-1989" TYPE="STUDY">Dodson_P 1989</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Dodson_x005f_X-1989" TYPE="STUDY">Dodson_X 1989</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Miller-1995" TYPE="STUDY">Miller 1995</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Mulhauser-1996" TYPE="STUDY">Mulhauser 1996</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-De_x0027_oliveira-1997" TYPE="STUDY">De'oliveira 1997</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Lopes-De-Faria-1997" TYPE="STUDY">Lopes De Faria 1997</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Miller-1997" TYPE="STUDY">Miller 1997</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Petrie-1998" TYPE="STUDY">Petrie 1998</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Trevisan_x005f_Micro-1998" TYPE="STUDY">Trevisan_Micro 1998</LINK>; <LINK REF="STD-Trevisan_x005f_Normo-1998" TYPE="STUDY">Trevisan_Normo 1998</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Yoshioka_x005f_Adva_x005f_alb-1998" TYPE="STUDY">Yoshioka_Adva_alb 1998</LINK>; <LINK REF="STD-Yoshioka_x005f_Micro-1998" TYPE="STUDY">Yoshioka_Micro 1998</LINK>; <LINK REF="STD-Yoshioka_x005f_Normo-1998" TYPE="STUDY">Yoshioka_Normo 1998</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Imanishi_x005f_Micro-2001" TYPE="STUDY">Imanishi_Micro 2001</LINK>; <LINK REF="STD-Imanishi_x005f_Normo-2001" TYPE="STUDY">Imanishi_Normo 2001</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Houlihan_x005f_Losartan-2002" TYPE="STUDY">Houlihan_Losartan 2002</LINK>; <LINK REF="STD-Houlihan_x005f_Placebo-2002" TYPE="STUDY">Houlihan_Placebo 2002</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Luik-2002" TYPE="STUDY">Luik 2002</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Vedovato_x005f_Micro-2004" TYPE="STUDY">Vedovato_Micro 2004</LINK>; <LINK REF="STD-Vedovato_x005f_Normo-2004" TYPE="STUDY">Vedovato_Normo 2004</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>ACR - albumin-creatinine ratio; BMI - body mass index; CrCl - creatinine clearance; GFR - glomerular filtration rate; HbA1c - glycated haemoglobin; RPF - renal plasma flow; SCr - serum creatinine</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2010-10-26 17:05:06 +1100" MODIFIED_BY="Narelle S Willis" NO="3">
<TITLE MODIFIED="2010-09-20 16:35:29 +1000" MODIFIED_BY="Narelle S Willis">Measurements of urine albumin and protein excretion in included studies</TITLE>
<TABLE COLS="4" ROWS="7">
<TR>
<TH VALIGN="BOTTOM">
<P>Study</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Urine measurement</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Change from high/normal salt to low salt</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Significance</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Mulhauser-1996" TYPE="STUDY">Mulhauser 1996</LINK>
</P>
</TD>
<TD>
<P>Reported as proteinuria</P>
</TD>
<TD>
<P>-412.6 mg/d (-1035 to 210)</P>
</TD>
<TD ALIGN="CENTER">
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Houlihan_x005f_Placebo-2002" TYPE="STUDY">Houlihan_Placebo 2002</LINK>
</P>
</TD>
<TD ROWSPAN="2">
<P>Reported as % change in geometric mean of albumin excretion (tolerance factor)</P>
</TD>
<TD>
<P>+38.5% (CI -31.7 to 108.8)</P>
</TD>
<TD ALIGN="CENTER">
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Houlihan_x005f_Losartan-2002" TYPE="STUDY">Houlihan_Losartan 2002</LINK>
</P>
</TD>
<TD>
<P>-43.5% (CI -77.5 to -9.6)</P>
</TD>
<TD ALIGN="CENTER">
<P>P = 0.02</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Luik-2002" TYPE="STUDY">Luik 2002</LINK>
</P>
</TD>
<TD>
<P>Reported as mg/24h of albumin</P>
</TD>
<TD>
<P>+1.4 mg/24 h</P>
</TD>
<TD ALIGN="CENTER">
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Vedovato_x005f_Normo-2004" TYPE="STUDY">Vedovato_Normo 2004</LINK>
</P>
</TD>
<TD ROWSPAN="2">
<P>Reported as median of albumin (IQR)</P>
</TD>
<TD>
<P>9 (6 to 12) µg/min to 8 (5 to 12) µg/min</P>
</TD>
<TD ALIGN="CENTER">
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Vedovato_x005f_Micro-2004" TYPE="STUDY">Vedovato_Micro 2004</LINK>
</P>
</TD>
<TD>
<P>108 (84 to 178) µg/min to 80 (37 to 108) µg/min</P>
</TD>
<TD ALIGN="CENTER">
<P>P &lt; 0.001</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>IQR - intraquartile range; NS - not significant</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-10-21 15:33:30 +1100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2010-10-21 15:33:30 +1100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Net change with altering salt diet</NAME>
<IV_OUTCOME CHI2="46.56475317644252" CI_END="-5.382330768812537" CI_START="-8.706274108487623" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_SIZE="-7.04430243865008" ESTIMABLE="YES" I2="78.52452913879273" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-27 15:29:37 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="1.1329094459222588E-6" P_Q="0.6262949568312214" P_Z="9.786360499294581E-17" Q="0.23711869878627567" RANDOM="NO" SCALE="50.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="25" WEIGHT="100.0" Z="8.307349232560272">
<NAME>Systolic BP</NAME>
<GROUP_LABEL_1>Low salt</GROUP_LABEL_1>
<GROUP_LABEL_2>High salt</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low salt</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high salt</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="6.836105584360458" CI_END="-2.428815411000599" CI_START="-9.976281561851412" DF="4" EFFECT_SIZE="-6.202548486426005" ESTIMABLE="YES" I2="41.48715301953291" ID="CMP-001.01.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-27 15:29:29 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.14480709400045388" P_Z="0.001275579595338259" STUDIES="5" TAU2="0.0" TOTAL_1="45" TOTAL_2="25" WEIGHT="19.395674018895452" Z="3.2214179971878334">
<NAME>Long-term studies</NAME>
<IV_DATA CI_END="-0.07854543912278444" CI_START="-25.921454560877216" EFFECT_SIZE="-13.0" ESTIMABLE="YES" ESTIMATE="-13.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="482" SE="6.5927" STUDY_ID="STD-Dodson_x005f_P-1989" TOTAL_1="17" TOTAL_2="17" WEIGHT="1.6543386780258902"/>
<IV_DATA CI_END="-1.4556074954307139" CI_START="-17.944392504569286" EFFECT_SIZE="-9.7" ESTIMABLE="YES" ESTIMATE="-9.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="484" SE="4.2064" STUDY_ID="STD-Dodson_x005f_X-1989" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.0637774247631935"/>
<IV_DATA CI_END="-2.200197813157482" CI_START="-17.19980218684252" EFFECT_SIZE="-9.7" ESTIMABLE="YES" ESTIMATE="-9.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="481" SE="3.8265" STUDY_ID="STD-Houlihan_x005f_Losartan-2002" TOTAL_1="10" TOTAL_2="0" WEIGHT="4.9107476284357565"/>
<IV_DATA CI_END="9.499914509664057" CI_START="-5.8999145096640575" EFFECT_SIZE="1.8" ESTIMABLE="YES" ESTIMATE="1.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="483" SE="3.9286" STUDY_ID="STD-Houlihan_x005f_Placebo-2002" TOTAL_1="10" TOTAL_2="0" WEIGHT="4.658814583707494"/>
<IV_DATA CI_END="3.299901322120224" CI_START="-13.099901322120225" EFFECT_SIZE="-4.9" ESTIMABLE="YES" ESTIMATE="-4.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="480" SE="4.1837" STUDY_ID="STD-Mulhauser-1996" TOTAL_1="8" TOTAL_2="8" WEIGHT="4.107995703963117"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="39.491528893295786" CI_END="-5.395690116918235" CI_START="-9.098014240161266" DF="5" EFFECT_SIZE="-7.246852178539751" ESTIMABLE="YES" I2="87.33905690633108" ID="CMP-001.01.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-27 15:29:37 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.8908501564496305E-7" P_Z="1.6830091521375138E-14" STUDIES="6" TAU2="0.0" TOTAL_1="65" TOTAL_2="0" WEIGHT="80.60432598110455" Z="7.672785417167636">
<NAME>Short-term studies</NAME>
<IV_DATA CI_END="-5.587951449489548" CI_START="-16.412048550510452" EFFECT_SIZE="-11.0" ESTIMABLE="YES" ESTIMATE="-11.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="485" SE="2.7613" STUDY_ID="STD-Imanishi_x005f_Micro-2001" TOTAL_1="8" TOTAL_2="0" WEIGHT="9.430264307089764"/>
<IV_DATA CI_END="2.087961003515323" CI_START="-16.087961003515325" EFFECT_SIZE="-7.0" ESTIMABLE="YES" ESTIMATE="-7.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="488" SE="4.6368" STUDY_ID="STD-Imanishi_x005f_Normo-2001" TOTAL_1="8" TOTAL_2="0" WEIGHT="3.344370033147692"/>
<IV_DATA CI_END="0.035942375264086834" CI_START="-6.235942375264087" EFFECT_SIZE="-3.1" ESTIMABLE="YES" ESTIMATE="-3.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="487" SE="1.6" STUDY_ID="STD-Luik-2002" TOTAL_1="24" TOTAL_2="0" WEIGHT="28.087370663867706"/>
<IV_DATA CI_END="10.536427138265752" CI_START="-6.536427138265752" EFFECT_SIZE="2.0" ESTIMABLE="YES" ESTIMATE="2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="490" SE="4.3554" STUDY_ID="STD-Petrie-1998" TOTAL_1="9" TOTAL_2="0" WEIGHT="3.7904865272487274"/>
<IV_DATA CI_END="-0.08007203091989146" CI_START="-7.919927969080108" EFFECT_SIZE="-4.0" ESTIMABLE="YES" ESTIMATE="-4.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="486" SE="2.0" STUDY_ID="STD-Trevisan_x005f_Micro-1998" TOTAL_1="9" TOTAL_2="0" WEIGHT="17.975917224875335"/>
<IV_DATA CI_END="-13.080072030919892" CI_START="-20.91992796908011" EFFECT_SIZE="-17.0" ESTIMABLE="YES" ESTIMATE="-17.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="489" SE="2.0" STUDY_ID="STD-Trevisan_x005f_Normo-1998" TOTAL_1="7" TOTAL_2="0" WEIGHT="17.975917224875335"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="30.813841698886442" CI_END="-2.1149680816274787" CI_START="-3.951391620569727" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_SIZE="-3.0331798510986028" ESTIMABLE="YES" I2="67.54705207575145" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-27 17:10:42 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="6.29728240376326E-4" P_Q="0.3913559240974245" P_Z="9.515305841051901E-11" Q="0.734725032477705" RANDOM="NO" SCALE="20.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="25" WEIGHT="100.00000000000001" Z="6.474457706210856">
<NAME>Diastolic BP</NAME>
<GROUP_LABEL_1>Low salt</GROUP_LABEL_1>
<GROUP_LABEL_2>High salt</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low salt</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high salt</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="10.058845801591907" CI_END="-1.838433143510284" CI_START="-5.726881090159178" DF="4" EFFECT_SIZE="-3.7826571168347307" ESTIMABLE="YES" I2="60.23400617825394" ID="CMP-001.02.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-27 15:29:45 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.039448102263330065" P_Z="1.3713422124231214E-4" STUDIES="5" TAU2="0.0" TOTAL_1="45" TOTAL_2="25" WEIGHT="22.304532376989524" Z="3.8132806798915992">
<NAME>Long-term studies</NAME>
<IV_DATA CI_END="5.024006604973107" CI_START="-8.624006604973108" EFFECT_SIZE="-1.8" ESTIMABLE="YES" ESTIMATE="-1.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="495" SE="3.4817" STUDY_ID="STD-Dodson_x005f_P-1989" TOTAL_1="17" TOTAL_2="17" WEIGHT="1.8105346189840457"/>
<IV_DATA CI_END="0.6658220497199325" CI_START="-10.865822049719931" EFFECT_SIZE="-5.1" ESTIMABLE="YES" ESTIMATE="-5.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="492" SE="2.9418" STUDY_ID="STD-Dodson_x005f_X-1989" TOTAL_1="0" TOTAL_2="0" WEIGHT="2.5360817046294057"/>
<IV_DATA CI_END="-2.6000372884745357" CI_START="-8.399962711525465" EFFECT_SIZE="-5.5" ESTIMABLE="YES" ESTIMATE="-5.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="494" SE="1.4796" STUDY_ID="STD-Houlihan_x005f_Losartan-2002" TOTAL_1="10" TOTAL_2="0" WEIGHT="10.025380923463151"/>
<IV_DATA CI_END="8.299868124561678" CI_START="-1.6998681245616787" EFFECT_SIZE="3.3" ESTIMABLE="YES" ESTIMATE="3.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="491" SE="2.551" STUDY_ID="STD-Houlihan_x005f_Placebo-2002" TOTAL_1="10" TOTAL_2="0" WEIGHT="3.3726293188229044"/>
<IV_DATA CI_END="-1.0000350143175742" CI_START="-9.599964985682426" EFFECT_SIZE="-5.3" ESTIMABLE="YES" ESTIMATE="-5.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="493" SE="2.1939" STUDY_ID="STD-Mulhauser-1996" TOTAL_1="8" TOTAL_2="8" WEIGHT="4.559905811090015"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="20.02027086481683" CI_END="-1.7763170091605756" CI_START="-3.8597282757133162" DF="5" EFFECT_SIZE="-2.818022642436946" ESTIMABLE="YES" I2="75.02531292527672" ID="CMP-001.02.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-27 15:29:55 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0012388355227076486" P_Z="1.1448084065795185E-7" STUDIES="6" TAU2="0.0" TOTAL_1="65" TOTAL_2="0" WEIGHT="77.69546762301049" Z="5.302095630819601">
<NAME>Short-term studies</NAME>
<IV_DATA CI_END="-2.9794995034253224" CI_START="-9.020500496574677" EFFECT_SIZE="-6.0" ESTIMABLE="YES" ESTIMATE="-6.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="500" SE="1.5411" STUDY_ID="STD-Imanishi_x005f_Micro-2001" TOTAL_1="8" TOTAL_2="0" WEIGHT="9.241189743258351"/>
<IV_DATA CI_END="3.464824331869908" CI_START="-3.464824331869908" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="497" SE="1.7678" STUDY_ID="STD-Imanishi_x005f_Normo-2001" TOTAL_1="8" TOTAL_2="0" WEIGHT="7.02300971499077"/>
<IV_DATA CI_END="0.951956781448065" CI_START="-3.7519567814480648" EFFECT_SIZE="-1.4" ESTIMABLE="YES" ESTIMATE="-1.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="499" SE="1.2" STUDY_ID="STD-Luik-2002" TOTAL_1="24" TOTAL_2="0" WEIGHT="15.241476338750871"/>
<IV_DATA CI_END="11.061972607783934" CI_START="-1.0619726077839342" EFFECT_SIZE="5.0" ESTIMABLE="YES" ESTIMATE="5.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="496" SE="3.0929" STUDY_ID="STD-Petrie-1998" TOTAL_1="9" TOTAL_2="0" WEIGHT="2.2943399704079814"/>
<IV_DATA CI_END="-0.04003601545994573" CI_START="-3.959963984540054" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="501" SE="1.0" STUDY_ID="STD-Trevisan_x005f_Micro-1998" TOTAL_1="9" TOTAL_2="0" WEIGHT="21.947725927801255"/>
<IV_DATA CI_END="-3.040036015459946" CI_START="-6.959963984540054" EFFECT_SIZE="-5.0" ESTIMABLE="YES" ESTIMATE="-5.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="498" SE="1.0" STUDY_ID="STD-Trevisan_x005f_Normo-1998" TOTAL_1="7" TOTAL_2="0" WEIGHT="21.947725927801255"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="46.05820312778708" CI_END="-5.202806231637623" CI_START="-8.611499286355725" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_SIZE="-6.907152758996674" ESTIMABLE="YES" I2="80.45950690905207" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-27 15:28:33 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="5.874149388018779E-7" P_Q="0.35677768912494723" P_Z="1.97212480120811E-15" Q="0.8492040361513915" RANDOM="NO" SCALE="50.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="100" TOTAL_2="25" WEIGHT="100.0" Z="7.943085766911047">
<NAME>Systolic BP (excluding Houlihan_Losartan 2002)</NAME>
<GROUP_LABEL_1>Low salt</GROUP_LABEL_1>
<GROUP_LABEL_2>High salt</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low salt</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high salt</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="5.717470198339901" CI_END="-0.6500042786341789" CI_START="-9.383647888372671" DF="3" EFFECT_SIZE="-5.0168260835034255" ESTIMABLE="YES" I2="47.52924115160116" ID="CMP-001.03.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-22 17:32:20 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.12619501024971336" P_Z="0.024340863312717027" STUDIES="4" TAU2="0.0" TOTAL_1="35" TOTAL_2="25" WEIGHT="15.232979573610894" Z="2.251705904143773">
<NAME>Long-term studies</NAME>
<IV_DATA CI_END="-0.07854543912278444" CI_START="-25.921454560877216" EFFECT_SIZE="-13.0" ESTIMABLE="YES" ESTIMATE="-13.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="574" SE="6.5927" STUDY_ID="STD-Dodson_x005f_P-1989" TOTAL_1="17" TOTAL_2="17" WEIGHT="1.7397746188617715"/>
<IV_DATA CI_END="-1.4556074954307139" CI_START="-17.944392504569286" EFFECT_SIZE="-9.7" ESTIMABLE="YES" ESTIMATE="-9.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="573" SE="4.2064" STUDY_ID="STD-Dodson_x005f_X-1989" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.273645363078316"/>
<IV_DATA CI_END="9.499914509664057" CI_START="-5.8999145096640575" EFFECT_SIZE="1.8" ESTIMABLE="YES" ESTIMATE="1.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="579" SE="3.9286" STUDY_ID="STD-Houlihan_x005f_Placebo-2002" TOTAL_1="10" TOTAL_2="0" WEIGHT="4.899412359982629"/>
<IV_DATA CI_END="3.299901322120224" CI_START="-13.099901322120225" EFFECT_SIZE="-4.9" ESTIMABLE="YES" ESTIMATE="-4.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="572" SE="4.1837" STUDY_ID="STD-Mulhauser-1996" TOTAL_1="8" TOTAL_2="8" WEIGHT="4.320147231688177"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="39.491528893295786" CI_END="-5.395690116918235" CI_START="-9.098014240161266" DF="5" EFFECT_SIZE="-7.246852178539751" ESTIMABLE="YES" I2="87.33905690633108" ID="CMP-001.03.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-22 17:27:29 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.8908501564496305E-7" P_Z="1.6830091521375138E-14" STUDIES="6" TAU2="0.0" TOTAL_1="65" TOTAL_2="0" WEIGHT="84.76702042638911" Z="7.672785417167636">
<NAME>Short-term studies</NAME>
<IV_DATA CI_END="-5.587951449489548" CI_START="-16.412048550510452" EFFECT_SIZE="-11.0" ESTIMABLE="YES" ESTIMATE="-11.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-09-22 17:27:09 +1000" MODIFIED_BY="Narelle S Willis" ORDER="478" SE="2.7613" STUDY_ID="STD-Imanishi_x005f_Micro-2001" TOTAL_1="8" TOTAL_2="0" WEIGHT="9.917276739373982"/>
<IV_DATA CI_END="2.087961003515323" CI_START="-16.087961003515325" EFFECT_SIZE="-7.0" ESTIMABLE="YES" ESTIMATE="-7.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-09-22 17:27:13 +1000" MODIFIED_BY="Narelle S Willis" ORDER="479" SE="4.6368" STUDY_ID="STD-Imanishi_x005f_Normo-2001" TOTAL_1="8" TOTAL_2="0" WEIGHT="3.5170852117749973"/>
<IV_DATA CI_END="0.035942375264086834" CI_START="-6.235942375264087" EFFECT_SIZE="-3.1" ESTIMABLE="YES" ESTIMATE="-3.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-09-22 17:27:23 +1000" MODIFIED_BY="Narelle S Willis" ORDER="480" SE="1.6" STUDY_ID="STD-Luik-2002" TOTAL_1="24" TOTAL_2="0" WEIGHT="29.53790251091198"/>
<IV_DATA CI_END="10.536427138265752" CI_START="-6.536427138265752" EFFECT_SIZE="2.0" ESTIMABLE="YES" ESTIMATE="2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-09-22 17:27:25 +1000" MODIFIED_BY="Narelle S Willis" ORDER="481" SE="4.3554" STUDY_ID="STD-Petrie-1998" TOTAL_1="9" TOTAL_2="0" WEIGHT="3.98624075036081"/>
<IV_DATA CI_END="-0.08007203091989146" CI_START="-7.919927969080108" EFFECT_SIZE="-4.0" ESTIMABLE="YES" ESTIMATE="-4.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-09-22 17:27:27 +1000" MODIFIED_BY="Narelle S Willis" ORDER="482" SE="2.0" STUDY_ID="STD-Trevisan_x005f_Micro-1998" TOTAL_1="7" TOTAL_2="0" WEIGHT="18.90425760698367"/>
<IV_DATA CI_END="-13.080072030919892" CI_START="-20.91992796908011" EFFECT_SIZE="-17.0" ESTIMABLE="YES" ESTIMATE="-17.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-09-22 17:27:29 +1000" MODIFIED_BY="Narelle S Willis" ORDER="483" SE="2.0" STUDY_ID="STD-Trevisan_x005f_Normo-1998" TOTAL_1="9" TOTAL_2="0" WEIGHT="18.90425760698367"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="27.724497398078128" CI_END="-1.7902988467148897" CI_START="-3.7263322338724065" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_SIZE="-2.758315540293648" ESTIMABLE="YES" I2="67.53773433373807" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-27 15:28:43 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0010603759892390263" P_Q="0.7610578691562304" P_Z="2.3394221121701924E-8" Q="0.09247190488407853" RANDOM="NO" SCALE="20.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="100" TOTAL_2="25" WEIGHT="99.99999999999997" Z="5.584820130514453">
<NAME>Diastolic BP (excluding Houlihan_Losartan 2002)</NAME>
<GROUP_LABEL_1>Low salt</GROUP_LABEL_1>
<GROUP_LABEL_2>High salt</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low salt</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high salt</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="7.611754628377222" CI_END="0.2398231697068054" CI_START="-5.000869267244456" DF="3" EFFECT_SIZE="-2.380523048768825" ESTIMABLE="YES" I2="60.58727394054765" ID="CMP-001.04.01" LOG_CI_END="-0.6201088613133955" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-22 17:29:32 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.05475552203278433" P_Z="0.07498087918942696" STUDIES="4" TAU2="0.0" TOTAL_1="35" TOTAL_2="25" WEIGHT="13.647350307847502" Z="1.780581286189215">
<NAME>Long-term studies</NAME>
<IV_DATA CI_END="5.024006604973107" CI_START="-8.624006604973108" EFFECT_SIZE="-1.8" ESTIMABLE="YES" ESTIMATE="-1.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="586" SE="3.4817" STUDY_ID="STD-Dodson_x005f_P-1989" TOTAL_1="17" TOTAL_2="17" WEIGHT="2.012272613728895"/>
<IV_DATA CI_END="0.6658220497199325" CI_START="-10.865822049719931" EFFECT_SIZE="-5.1" ESTIMABLE="YES" ESTIMATE="-5.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="583" SE="2.9418" STUDY_ID="STD-Dodson_x005f_X-1989" TOTAL_1="0" TOTAL_2="0" WEIGHT="2.8186634527144694"/>
<IV_DATA CI_END="8.299868124561678" CI_START="-1.6998681245616787" EFFECT_SIZE="3.3" ESTIMABLE="YES" ESTIMATE="3.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="589" SE="2.551" STUDY_ID="STD-Houlihan_x005f_Placebo-2002" TOTAL_1="10" TOTAL_2="0" WEIGHT="3.7484230035516783"/>
<IV_DATA CI_END="-1.0000350143175742" CI_START="-9.599964985682426" EFFECT_SIZE="-5.3" ESTIMABLE="YES" ESTIMATE="-5.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="582" SE="2.1939" STUDY_ID="STD-Mulhauser-1996" TOTAL_1="8" TOTAL_2="8" WEIGHT="5.067991237852459"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="20.020270864816826" CI_END="-1.7763170091605756" CI_START="-3.8597282757133162" DF="5" EFFECT_SIZE="-2.818022642436946" ESTIMABLE="YES" I2="75.02531292527671" ID="CMP-001.04.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-22 17:29:32 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0012388355227072045" P_Z="1.1448084065795185E-7" STUDIES="6" TAU2="0.0" TOTAL_1="65" TOTAL_2="0" WEIGHT="86.35264969215247" Z="5.302095630819601">
<NAME>Short-term studies</NAME>
<IV_DATA CI_END="-2.9794995034253224" CI_START="-9.020500496574677" EFFECT_SIZE="-6.0" ESTIMABLE="YES" ESTIMATE="-6.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-09-22 17:29:22 +1000" MODIFIED_BY="Narelle S Willis" ORDER="484" SE="1.5411" STUDY_ID="STD-Imanishi_x005f_Micro-2001" TOTAL_1="8" TOTAL_2="0" WEIGHT="10.270885098604683"/>
<IV_DATA CI_END="3.464824331869908" CI_START="-3.464824331869908" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-09-22 17:29:25 +1000" MODIFIED_BY="Narelle S Willis" ORDER="485" SE="1.7678" STUDY_ID="STD-Imanishi_x005f_Normo-2001" TOTAL_1="8" TOTAL_2="0" WEIGHT="7.805545371652698"/>
<IV_DATA CI_END="0.951956781448065" CI_START="-3.7519567814480648" EFFECT_SIZE="-1.4" ESTIMABLE="YES" ESTIMATE="-1.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-09-22 17:29:27 +1000" MODIFIED_BY="Narelle S Willis" ORDER="486" SE="1.2" STUDY_ID="STD-Luik-2002" TOTAL_1="24" TOTAL_2="0" WEIGHT="16.939750893288824"/>
<IV_DATA CI_END="11.061972607783934" CI_START="-1.0619726077839342" EFFECT_SIZE="5.0" ESTIMABLE="YES" ESTIMATE="5.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-09-22 17:29:29 +1000" MODIFIED_BY="Narelle S Willis" ORDER="487" SE="3.0929" STUDY_ID="STD-Petrie-1998" TOTAL_1="9" TOTAL_2="0" WEIGHT="2.549985755934462"/>
<IV_DATA CI_END="-0.04003601545994573" CI_START="-3.959963984540054" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-09-22 17:29:31 +1000" MODIFIED_BY="Narelle S Willis" ORDER="488" SE="1.0" STUDY_ID="STD-Trevisan_x005f_Micro-1998" TOTAL_1="9" TOTAL_2="0" WEIGHT="24.393241286335908"/>
<IV_DATA CI_END="-3.040036015459946" CI_START="-6.959963984540054" EFFECT_SIZE="-5.0" ESTIMABLE="YES" ESTIMATE="-5.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-09-22 17:29:32 +1000" MODIFIED_BY="Narelle S Willis" ORDER="489" SE="1.0" STUDY_ID="STD-Trevisan_x005f_Normo-1998" TOTAL_1="7" TOTAL_2="0" WEIGHT="24.393241286335908"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="30.245397513482853" CI_END="-1.060896401088017" CI_START="-3.3216897040693794" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_SIZE="-2.191293052578698" ESTIMABLE="YES" I2="66.93711829860335" I2_Q="67.96886912315833" ID="CMP-001.05" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-27 15:30:22 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="7.809302696510922E-4" P_Q="0.07724398006256539" P_Z="1.4503314376840062E-4" Q="3.121962829988604" RANDOM="NO" SCALE="50.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="120" TOTAL_2="10" WEIGHT="100.0" Z="3.7994233767088357">
<NAME>MAP</NAME>
<GROUP_LABEL_1>Low salt</GROUP_LABEL_1>
<GROUP_LABEL_2>High salt</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low salt</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high salt</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="4.011846934468511" CI_END="-1.6865547707822905" CI_START="-8.272112051867627" DF="1" EFFECT_SIZE="-4.9793334113249585" ESTIMABLE="YES" I2="75.07382469135803" ID="CMP-001.05.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-27 15:30:16 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.045181712422775355" P_Z="0.0030381269085457026" STUDIES="2" TAU2="0.0" TOTAL_1="20" TOTAL_2="0" WEIGHT="11.785191744190882" Z="2.9638536988339728">
<NAME>Long-term studies</NAME>
<IV_DATA CI_END="-3.300105500350657" CI_START="-11.299894499649342" EFFECT_SIZE="-7.3" ESTIMABLE="YES" ESTIMATE="-7.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="502" SE="2.0408" STUDY_ID="STD-Houlihan_x005f_Losartan-2002" TOTAL_1="10" TOTAL_2="0" WEIGHT="7.986649977264116"/>
<IV_DATA CI_END="5.699925423050929" CI_START="-5.899925423050928" EFFECT_SIZE="-0.1" ESTIMABLE="YES" ESTIMATE="-0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="503" SE="2.9592" STUDY_ID="STD-Houlihan_x005f_Placebo-2002" TOTAL_1="10" TOTAL_2="0" WEIGHT="3.7985417669267663"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="23.111587749025738" CI_END="-0.6152816982920553" CI_START="-3.0223594057248167" DF="8" EFFECT_SIZE="-1.818820552008436" ESTIMABLE="YES" I2="65.38532926913584" ID="CMP-001.05.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-27 15:30:22 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.003223902879634366" P_Z="0.003056967053335126" STUDIES="9" TAU2="0.0" TOTAL_1="100" TOTAL_2="10" WEIGHT="88.21480825580912" Z="2.9619507216323417">
<NAME>Short-term studies</NAME>
<IV_DATA CI_END="3.293482100230584" CI_START="-21.293482100230584" EFFECT_SIZE="-9.0" ESTIMABLE="YES" ESTIMATE="-9.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="512" SE="6.2723" STUDY_ID="STD-De_x0027_oliveira-1997" TOTAL_1="9" TOTAL_2="10" WEIGHT="0.8454966638154142"/>
<IV_DATA CI_END="5.187685424455944" CI_START="-1.1876854244559443" EFFECT_SIZE="2.0" ESTIMABLE="YES" ESTIMATE="2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="504" SE="1.6264" STUDY_ID="STD-Lopes-De-Faria-1997" TOTAL_1="10" TOTAL_2="0" WEIGHT="12.575081586361662"/>
<IV_DATA CI_END="2.394853617621828" CI_START="-4.394853617621828" EFFECT_SIZE="-1.0" ESTIMABLE="YES" ESTIMATE="-1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="508" SE="1.7321" STUDY_ID="STD-Miller-1995" TOTAL_1="9" TOTAL_2="0" WEIGHT="11.087142240818288"/>
<IV_DATA CI_END="2.394853617621828" CI_START="-4.394853617621828" EFFECT_SIZE="-1.0" ESTIMABLE="YES" ESTIMATE="-1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="507" SE="1.7321" STUDY_ID="STD-Miller-1997" TOTAL_1="12" TOTAL_2="0" WEIGHT="11.087142240818288"/>
<IV_DATA CI_END="-4.758415565969204" CI_START="-11.241584434030795" EFFECT_SIZE="-8.0" ESTIMABLE="YES" ESTIMATE="-8.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="509" SE="1.6539" STUDY_ID="STD-Vedovato_x005f_Micro-2004" TOTAL_1="20" TOTAL_2="0" WEIGHT="12.160377251715902"/>
<IV_DATA CI_END="0.9599639845400543" CI_START="-2.959963984540054" EFFECT_SIZE="-1.0" ESTIMABLE="YES" ESTIMATE="-1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="506" SE="1.0" STUDY_ID="STD-Vedovato_x005f_Normo-2004" TOTAL_1="21" TOTAL_2="0" WEIGHT="33.26331608236412"/>
<IV_DATA CI_END="1.839855938160217" CI_START="-13.839855938160216" EFFECT_SIZE="-6.0" ESTIMABLE="YES" ESTIMATE="-6.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="511" SE="4.0" STUDY_ID="STD-Yoshioka_x005f_Adva_x005f_alb-1998" TOTAL_1="4" TOTAL_2="0" WEIGHT="2.0789572551477575"/>
<IV_DATA CI_END="4.06684614265762" CI_START="-10.06684614265762" EFFECT_SIZE="-3.0" ESTIMABLE="YES" ESTIMATE="-3.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="505" SE="3.6056" STUDY_ID="STD-Yoshioka_x005f_Micro-1998" TOTAL_1="7" TOTAL_2="0" WEIGHT="2.5586474673838446"/>
<IV_DATA CI_END="5.06684614265762" CI_START="-9.06684614265762" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="510" SE="3.6056" STUDY_ID="STD-Yoshioka_x005f_Normo-1998" TOTAL_1="8" TOTAL_2="0" WEIGHT="2.5586474673838446"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="5.676855895196504" CI_END="3.709125509637518" CI_START="-4.739693195227037" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="-0.5152838427947596" ESTIMABLE="YES" I2="82.38461538461537" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.5692715292630303" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-10-21 15:33:30 +1100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.017190169971456948" P_Q="1.0" P_Z="0.811049793464358" Q="0.0" RANDOM="NO" SCALE="25.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="0" WEIGHT="100.0" Z="0.23907194815569624">
<NAME>SCr</NAME>
<GROUP_LABEL_1>Low salt</GROUP_LABEL_1>
<GROUP_LABEL_2>High salt</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low salt</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high salt</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="6.70391356289613" CI_START="-2.7039135628961297" EFFECT_SIZE="2.0" ESTIMABLE="YES" ESTIMATE="2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="557" SE="2.4" STUDY_ID="STD-Luik-2002" TOTAL_1="24" TOTAL_2="0" WEIGHT="80.65166274773262"/>
<IV_DATA CI_END="-1.3961764757537338" CI_START="-20.603823524246266" EFFECT_SIZE="-11.0" ESTIMABLE="YES" ESTIMATE="-11.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-10-19 04:03:42 +1100" MODIFIED_BY="[Empty name]" ORDER="172" SE="4.9" STUDY_ID="STD-Mulhauser-1996" TOTAL_1="0" TOTAL_2="0" WEIGHT="19.34833725226738"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="5.071719689194008" CI_END="-2.185718027657466" CI_START="-10.46856326885542" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_SIZE="-6.327140648256442" ESTIMABLE="YES" I2="21.131287903735167" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-22 17:33:33 +1000" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.2800175381447695" P_Q="1.0" P_Z="0.002750087081205754" Q="0.0" RANDOM="NO" SCALE="50.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="51" TOTAL_2="8" WEIGHT="100.0" Z="2.994373897998481">
<NAME>CrCl</NAME>
<GROUP_LABEL_1>Low salt</GROUP_LABEL_1>
<GROUP_LABEL_2>High salt</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low salt</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high salt</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="1.9959063598041413" CI_START="-8.195906359804141" EFFECT_SIZE="-3.1" ESTIMABLE="YES" ESTIMATE="-3.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="546" SE="2.6" STUDY_ID="STD-Luik-2002" TOTAL_1="24" TOTAL_2="0" WEIGHT="66.04747583098411"/>
<IV_DATA CI_END="5.951506588198743" CI_START="-47.75150658819874" EFFECT_SIZE="-20.9" ESTIMABLE="YES" ESTIMATE="-20.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="545" SE="13.7" STUDY_ID="STD-Mulhauser-1996" TOTAL_1="8" TOTAL_2="8" WEIGHT="2.37882112322155"/>
<IV_DATA CI_END="-2.018269044446747" CI_START="-19.981730955553253" EFFECT_SIZE="-11.0" ESTIMABLE="YES" ESTIMATE="-11.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="547" SE="4.5826" STUDY_ID="STD-Yoshioka_x005f_Adva_x005f_alb-1998" TOTAL_1="4" TOTAL_2="0" WEIGHT="21.2607714556192"/>
<IV_DATA CI_END="3.639675860860489" CI_START="-31.63967586086049" EFFECT_SIZE="-14.0" ESTIMABLE="YES" ESTIMATE="-14.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="544" SE="9.0" STUDY_ID="STD-Yoshioka_x005f_Micro-1998" TOTAL_1="7" TOTAL_2="0" WEIGHT="5.512110328610527"/>
<IV_DATA CI_END="4.9013046777089215" CI_START="-32.90130467770892" EFFECT_SIZE="-14.0" ESTIMABLE="YES" ESTIMATE="-14.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="548" SE="9.6437" STUDY_ID="STD-Yoshioka_x005f_Normo-1998" TOTAL_1="8" TOTAL_2="0" WEIGHT="4.80082126156461"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="16.080096905395067" CI_END="0.6418456144091991" CI_START="-4.488869960789443" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_SIZE="-1.923512173190122" ESTIMABLE="YES" I2="44.03018804581711" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-0.19256942188952317" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-27 15:30:45 +1000" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="0.06522773937129633" P_Q="0.6958028971441399" P_Z="0.14167384098459535" Q="0.15287518992467852" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="106" TOTAL_2="8" WEIGHT="100.0" Z="1.4695862703833664">
<NAME>GFR</NAME>
<GROUP_LABEL_1>Low salt</GROUP_LABEL_1>
<GROUP_LABEL_2>High salt</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low salt</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high salt</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="1.0788662160460538" CI_END="1.1406035433243091" CI_START="-5.969614953863793" DF="2" EFFECT_SIZE="-2.414505705269742" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="0.05713471640199297" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-27 15:30:36 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.5830788115882972" P_Z="0.18314331055625" STUDIES="3" TAU2="0.0" TOTAL_1="28" TOTAL_2="8" WEIGHT="52.070288769855594" Z="1.3311389023183158">
<NAME>Long-term studies</NAME>
<IV_DATA CI_END="2.5999386105947604" CI_START="-7.999938610594761" EFFECT_SIZE="-2.7" ESTIMABLE="YES" ESTIMATE="-2.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="535" SE="2.7041" STUDY_ID="STD-Houlihan_x005f_Losartan-2002" TOTAL_1="10" TOTAL_2="0" WEIGHT="23.429024694432194"/>
<IV_DATA CI_END="1.8999672598393857" CI_START="-9.499967259839385" EFFECT_SIZE="-3.8" ESTIMABLE="YES" ESTIMATE="-3.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="534" SE="2.9082" STUDY_ID="STD-Houlihan_x005f_Placebo-2002" TOTAL_1="10" TOTAL_2="0" WEIGHT="20.255882366252234"/>
<IV_DATA CI_END="10.589037210121045" CI_START="-7.129037210121044" EFFECT_SIZE="1.73" ESTIMABLE="YES" ESTIMATE="1.73" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="536" SE="4.52" STUDY_ID="STD-Mulhauser-1996" TOTAL_1="8" TOTAL_2="8" WEIGHT="8.385381709171165"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="14.848355499424335" CI_END="2.315386653204362" CI_START="-5.095591511490638" DF="6" EFFECT_SIZE="-1.3901024291431383" ESTIMABLE="YES" I2="59.59148472547941" ID="CMP-001.08.02" LOG_CI_END="0.36462352551874283" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-27 15:30:45 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.021469556536580447" P_Z="0.462172494482575" STUDIES="7" TAU2="0.0" TOTAL_1="78" TOTAL_2="0" WEIGHT="47.9297112301444" Z="0.735274247311002">
<NAME>Short-term studies</NAME>
<IV_DATA CI_END="1.0222230847702392" CI_START="-23.02222308477024" EFFECT_SIZE="-11.0" ESTIMABLE="YES" ESTIMATE="-11.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="543" SE="6.1339" STUDY_ID="STD-Imanishi_x005f_Micro-2001" TOTAL_1="8" TOTAL_2="0" WEIGHT="4.553300610214559"/>
<IV_DATA CI_END="1.8411224125987378" CI_START="-21.841122412598736" EFFECT_SIZE="-10.0" ESTIMABLE="YES" ESTIMATE="-10.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="541" SE="6.0415" STUDY_ID="STD-Imanishi_x005f_Normo-2001" TOTAL_1="8" TOTAL_2="0" WEIGHT="4.693644003580069"/>
<IV_DATA CI_END="14.157905342675738" CI_START="-6.157905342675738" EFFECT_SIZE="4.0" ESTIMABLE="YES" ESTIMATE="4.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="538" SE="5.1827" STUDY_ID="STD-Lopes-De-Faria-1997" TOTAL_1="10" TOTAL_2="0" WEIGHT="6.378044800537533"/>
<IV_DATA CI_END="2.0718847505281737" CI_START="-10.471884750528174" EFFECT_SIZE="-4.2" ESTIMABLE="YES" ESTIMATE="-4.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="537" SE="3.2" STUDY_ID="STD-Luik-2002" TOTAL_1="24" TOTAL_2="0" WEIGHT="16.730146725688524"/>
<IV_DATA CI_END="14.423180782590833" CI_START="0.5768192174091658" EFFECT_SIZE="7.5" ESTIMABLE="YES" ESTIMATE="7.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="540" SE="3.5323" STUDY_ID="STD-Miller-1997" TOTAL_1="12" TOTAL_2="0" WEIGHT="13.73044281765642"/>
<IV_DATA CI_END="8.559603829940595" CI_START="-34.5596038299406" EFFECT_SIZE="-13.0" ESTIMABLE="YES" ESTIMATE="-13.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="539" SE="11.0" STUDY_ID="STD-Trevisan_x005f_Micro-1998" TOTAL_1="7" TOTAL_2="0" WEIGHT="1.4158405162896737"/>
<IV_DATA CI_END="17.199279690801085" CI_START="-61.199279690801085" EFFECT_SIZE="-22.0" ESTIMABLE="YES" ESTIMATE="-22.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="542" SE="20.0" STUDY_ID="STD-Trevisan_x005f_Normo-1998" TOTAL_1="9" TOTAL_2="0" WEIGHT="0.4282917561776263"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="34.25609081250139" CI_END="0.922345285542868" CI_START="-3.2542645384488647" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_SIZE="-1.1659596264529983" ESTIMABLE="YES" I2="79.56567771169784" I2_Q="91.44285743019189" ID="CMP-001.09" LOG_CI_END="-0.035106467738072626" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-27 15:31:00 +1000" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="1.54241736673999E-5" P_Q="6.296799638623174E-4" P_Z="0.273822012642133" Q="11.686143965022474" RANDOM="NO" SCALE="500.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="106" TOTAL_2="8" WEIGHT="100.0" Z="1.0943032610556707">
<NAME>ERPF</NAME>
<GROUP_LABEL_1>Low salt</GROUP_LABEL_1>
<GROUP_LABEL_2>High salt</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low salt</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high salt</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0020498179421638164" CI_END="1.3734673229017924" CI_START="-2.8329862794945004" DF="2" EFFECT_SIZE="-0.7297594782963539" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="0.13781833128315193" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-27 15:30:51 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.9989756162480257" P_Z="0.49647193105266507" STUDIES="3" TAU2="0.0" TOTAL_1="28" TOTAL_2="8" WEIGHT="98.58608157873209" Z="0.6800513829620239">
<NAME>Long-term studies</NAME>
<IV_DATA CI_END="1.7999340622808393" CI_START="-3.199934062280839" EFFECT_SIZE="-0.7" ESTIMABLE="YES" ESTIMATE="-0.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="551" SE="1.2755" STUDY_ID="STD-Houlihan_x005f_Losartan-2002" TOTAL_1="10" TOTAL_2="0" WEIGHT="69.77995934400472"/>
<IV_DATA CI_END="3.0999363364378" CI_START="-4.6999363364378" EFFECT_SIZE="-0.8" ESTIMABLE="YES" ESTIMATE="-0.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="549" SE="1.9898" STUDY_ID="STD-Houlihan_x005f_Placebo-2002" TOTAL_1="10" TOTAL_2="0" WEIGHT="28.672976905747085"/>
<IV_DATA CI_END="56.03094834856958" CI_START="-58.430948348569586" EFFECT_SIZE="-1.2" ESTIMABLE="YES" ESTIMATE="-1.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="550" SE="29.2" STUDY_ID="STD-Mulhauser-1996" TOTAL_1="8" TOTAL_2="8" WEIGHT="0.1331453289802861"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="22.567897029536752" CI_END="-14.0178922883457" CI_START="-49.14251995818536" DF="4" EFFECT_SIZE="-31.58020612326553" ESTIMABLE="YES" I2="82.2757078572061" ID="CMP-001.09.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-27 15:31:00 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.54448818205144E-4" P_Z="4.244933676735219E-4" STUDIES="5" TAU2="0.0" TOTAL_1="78" TOTAL_2="0" WEIGHT="1.413918421267902" Z="3.524368554608184">
<NAME>Short-term studies</NAME>
<IV_DATA CI_END="71.8941174021569" CI_START="-79.8941174021569" EFFECT_SIZE="-4.0" ESTIMABLE="YES" ESTIMATE="-4.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="554" SE="38.7222" STUDY_ID="STD-Lopes-De-Faria-1997" TOTAL_1="10" TOTAL_2="0" WEIGHT="0.07571319800051968"/>
<IV_DATA CI_END="-20.49635655305346" CI_START="-59.30364344694654" EFFECT_SIZE="-39.9" ESTIMABLE="YES" ESTIMATE="-39.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="556" SE="9.9" STUDY_ID="STD-Luik-2002" TOTAL_1="24" TOTAL_2="0" WEIGHT="1.1583005132308044"/>
<IV_DATA CI_END="279.2105028891599" CI_START="85.78949711084009" EFFECT_SIZE="182.5" ESTIMABLE="YES" ESTIMATE="182.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="553" SE="49.343" STUDY_ID="STD-Miller-1997" TOTAL_1="12" TOTAL_2="0" WEIGHT="0.046627328867383994"/>
<IV_DATA CI_END="64.43859539706212" CI_START="-88.43859539706212" EFFECT_SIZE="-12.0" ESTIMABLE="YES" ESTIMATE="-12.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="555" SE="39.0" STUDY_ID="STD-Trevisan_x005f_Micro-1998" TOTAL_1="16" TOTAL_2="0" WEIGHT="0.07463841768688438"/>
<IV_DATA CI_END="-11.761584680237618" CI_START="-184.2384153197624" EFFECT_SIZE="-98.0" ESTIMABLE="YES" ESTIMATE="-98.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="552" SE="44.0" STUDY_ID="STD-Trevisan_x005f_Normo-1998" TOTAL_1="16" TOTAL_2="0" WEIGHT="0.05863896348230947"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-09-27 15:23:41 +1000" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Proteinuria</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="0.20930858309919725" CI_START="-1.0333085830991973" EFFECT_SIZE="-0.412" ESTIMABLE="YES" ESTIMATE="-0.412" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-01-27 00:16:09 +1100" MODIFIED_BY="[Empty name]" ORDER="150" SE="0.317" STUDY_ID="STD-Mulhauser-1996" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="91.56047541530737" CI_END="0.006730435368020649" CI_START="-0.3097764406729478" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_SIZE="-0.15152300265246357" ESTIMABLE="YES" I2="94.53912839866702" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="-2.1719568418958684" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-27 15:31:16 +1000" MODIFIED_BY="Narelle S Willis" NO="11" P_CHI2="-2.220446049250313E-16" P_Q="0.4398872719155421" P_Z="0.060571874598468904" Q="0.5965768200030226" RANDOM="NO" SCALE="4.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="79" TOTAL_2="25" WEIGHT="100.0" Z="1.8766077485770316">
<NAME>HbA1c</NAME>
<GROUP_LABEL_1>Low salt</GROUP_LABEL_1>
<GROUP_LABEL_2>High salt</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low salt</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high salt</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.9160167351268691" CI_END="0.2470449332235427" CI_START="-0.35040198592361493" DF="3" EFFECT_SIZE="-0.05167852635003613" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="-0.6072240488606669" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-27 15:31:09 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.8215611189456569" P_Z="0.734557283285464" STUDIES="4" TAU2="0.0" TOTAL_1="45" TOTAL_2="25" WEIGHT="28.065168041444686" Z="0.33906962166534044">
<NAME>Long-term studies</NAME>
<IV_DATA CI_END="0.814660167252554" CI_START="-2.214660167252554" EFFECT_SIZE="-0.7" ESTIMABLE="YES" ESTIMATE="-0.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="514" SE="0.7728" STUDY_ID="STD-Dodson_x005f_P-1989" TOTAL_1="17" TOTAL_2="17" WEIGHT="1.0916310965617575"/>
<IV_DATA CI_END="0.6543483008610096" CI_START="-1.0543483008610097" EFFECT_SIZE="-0.2" ESTIMABLE="YES" ESTIMATE="-0.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="516" SE="0.4359" STUDY_ID="STD-Houlihan_x005f_Losartan-2002" TOTAL_1="10" TOTAL_2="0" WEIGHT="3.4311237927738056"/>
<IV_DATA CI_END="0.5879891953620162" CI_START="-0.5879891953620162" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="515" SE="0.3" STUDY_ID="STD-Houlihan_x005f_Placebo-2002" TOTAL_1="10" TOTAL_2="0" WEIGHT="7.243819431418193"/>
<IV_DATA CI_END="0.39199279690801087" CI_START="-0.39199279690801087" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="513" SE="0.2" STUDY_ID="STD-Mulhauser-1996" TOTAL_1="8" TOTAL_2="8" WEIGHT="16.29859372069093"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="90.04788186017747" CI_END="-0.003889112402651218" CI_START="-0.3770649641146228" DF="1" EFFECT_SIZE="-0.19047703825863702" ESTIMABLE="YES" I2="98.88947970863684" ID="CMP-001.11.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-27 15:31:16 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="4.440892098500626E-16" P_Z="0.045412206675371124" STUDIES="2" TAU2="0.0" TOTAL_1="34" TOTAL_2="0" WEIGHT="71.9348319585553" Z="2.000816146897589">
<NAME>Short-term studies</NAME>
<IV_DATA CI_END="-2.390451200808043" CI_START="-3.609548799191957" EFFECT_SIZE="-3.0" ESTIMABLE="YES" ESTIMATE="-3.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="517" SE="0.311" STUDY_ID="STD-Lopes-De-Faria-1997" TOTAL_1="10" TOTAL_2="0" WEIGHT="6.74045707579158"/>
<IV_DATA CI_END="0.29599639845400544" CI_START="-0.09599639845400543" EFFECT_SIZE="0.1" ESTIMABLE="YES" ESTIMATE="0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="518" SE="0.1" STUDY_ID="STD-Luik-2002" TOTAL_1="24" TOTAL_2="0" WEIGHT="65.19437488276373"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="47.16013883963077" CI_END="-0.8202337935351918" CI_START="-1.1980186594169422" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_SIZE="-1.009126226476067" ESTIMABLE="YES" I2="78.79565190847879" I2_Q="23.830119556763492" ID="CMP-001.12" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-27 17:19:40 +1000" MODIFIED_BY="Narelle S Willis" NO="12" P_CHI2="8.830054400998932E-7" P_Q="0.25187854225673045" P_Z="1.1766971623116538E-25" Q="1.3128548898605956" RANDOM="NO" SCALE="9.99" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="136" TOTAL_2="25" WEIGHT="100.00000000000001" Z="10.470779739318534">
<NAME>Weight</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.11382503716190445" CI_END="1.0858336805255424" CI_START="-1.5682828797789445" DF="2" EFFECT_SIZE="-0.2412245996267011" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.01" LOG_CI_END="0.03576330852939866" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-27 15:31:24 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.9446767121561473" P_Z="0.7216381070633142" STUDIES="3" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="2.026045193047929" Z="0.3562703571686306">
<NAME>Long-term studies</NAME>
<IV_DATA CI_END="7.970334515198296" CI_START="-9.170334515198295" EFFECT_SIZE="-0.6" ESTIMABLE="YES" ESTIMATE="-0.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="520" SE="4.3727" STUDY_ID="STD-Dodson_x005f_P-1989" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.04857732251417947"/>
<IV_DATA CI_END="2.4079148902851646" CI_START="-3.807914890285164" EFFECT_SIZE="-0.7" ESTIMABLE="YES" ESTIMATE="-0.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="521" SE="1.5857" STUDY_ID="STD-Dodson_x005f_X-1989" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.36939489251019597"/>
<IV_DATA CI_END="1.3645726282504413" CI_START="-1.6145726282504413" EFFECT_SIZE="-0.125" ESTIMABLE="YES" ESTIMATE="-0.125" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="519" SE="0.76" STUDY_ID="STD-Mulhauser-1996" TOTAL_1="8" TOTAL_2="8" WEIGHT="1.6080729780235536"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="45.73345891260827" CI_END="-0.8341704593072489" CI_START="-1.2158415240808544" DF="7" EFFECT_SIZE="-1.0250059916940517" ESTIMABLE="YES" I2="84.6939195800251" ID="CMP-001.12.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-27 15:31:30 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="9.850582582959788E-8" P_Z="6.469168037059904E-26" STUDIES="8" TAU2="0.0" TOTAL_1="111" TOTAL_2="0" WEIGHT="97.97395480695208" Z="10.527257699504988">
<NAME>Short-term studies</NAME>
<IV_DATA CI_END="-0.31161881184107565" CI_START="-1.4883811881589244" EFFECT_SIZE="-0.9" ESTIMABLE="YES" ESTIMATE="-0.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="523" SE="0.3002" STUDY_ID="STD-Lopes-De-Faria-1997" TOTAL_1="10" TOTAL_2="0" WEIGHT="10.306508431492091"/>
<IV_DATA CI_END="-0.11201080463798374" CI_START="-1.2879891953620162" EFFECT_SIZE="-0.7" ESTIMABLE="YES" ESTIMATE="-0.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="528" SE="0.3" STUDY_ID="STD-Luik-2002" TOTAL_1="24" TOTAL_2="0" WEIGHT="10.320255023404496"/>
<IV_DATA CI_END="-0.10958836182345333" CI_START="-1.8904116381765466" EFFECT_SIZE="-1.0" ESTIMABLE="YES" ESTIMATE="-1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="524" SE="0.4543" STUDY_ID="STD-Miller-1997" TOTAL_1="12" TOTAL_2="0" WEIGHT="4.500362167029783"/>
<IV_DATA CI_END="0.12734263466281415" CI_START="-1.327342634662814" EFFECT_SIZE="-0.6" ESTIMABLE="YES" ESTIMATE="-0.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="529" SE="0.3711" STUDY_ID="STD-Petrie-1998" TOTAL_1="9" TOTAL_2="0" WEIGHT="6.744519738280215"/>
<IV_DATA CI_END="-1.675222689739766" CI_START="-4.144777310260235" EFFECT_SIZE="-2.91" ESTIMABLE="YES" ESTIMATE="-2.91" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="526" SE="0.63" STUDY_ID="STD-Trevisan_x005f_Micro-1998" TOTAL_1="7" TOTAL_2="0" WEIGHT="2.340193882858162"/>
<IV_DATA CI_END="-0.9604093640195859" CI_START="-1.979590635980414" EFFECT_SIZE="-1.47" ESTIMABLE="YES" ESTIMATE="-1.47" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="522" SE="0.26" STUDY_ID="STD-Trevisan_x005f_Normo-1998" TOTAL_1="9" TOTAL_2="0" WEIGHT="13.739984498615451"/>
<IV_DATA CI_END="-1.690409364019586" CI_START="-2.7095906359804145" EFFECT_SIZE="-2.2" ESTIMABLE="YES" ESTIMATE="-2.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="527" SE="0.26" STUDY_ID="STD-Vedovato_x005f_Micro-2004" TOTAL_1="20" TOTAL_2="0" WEIGHT="13.739984498615451"/>
<IV_DATA CI_END="-0.1864057624735913" CI_START="-0.8135942375264087" EFFECT_SIZE="-0.5" ESTIMABLE="YES" ESTIMATE="-0.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="525" SE="0.16" STUDY_ID="STD-Vedovato_x005f_Normo-2004" TOTAL_1="20" TOTAL_2="0" WEIGHT="36.28214656665643"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="15.420882171499068" CI_END="-0.2751575761045997" CI_START="-0.5282970815141542" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_SIZE="-0.40172732880937695" ESTIMABLE="YES" I2="80.5458600446049" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-22 17:37:54 +1000" MODIFIED_BY="Narelle S Willis" NO="13" P_CHI2="0.0014901219831429113" P_Q="1.0" P_Z="4.944774372837023E-10" Q="0.0" RANDOM="NO" SCALE="2.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="48" TOTAL_2="8" WEIGHT="100.0" Z="6.22084723439726">
<NAME>BMI</NAME>
<GROUP_LABEL_1>Low salt</GROUP_LABEL_1>
<GROUP_LABEL_2>High salt</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low salt</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high salt</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="-0.004003601545994578" CI_START="-0.39599639845400547" EFFECT_SIZE="-0.2" ESTIMABLE="YES" ESTIMATE="-0.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="531" SE="0.1" STUDY_ID="STD-Luik-2002" TOTAL_1="24" TOTAL_2="0" WEIGHT="41.70265268352868"/>
<IV_DATA CI_END="0.41959063598041413" CI_START="-0.5995906359804141" EFFECT_SIZE="-0.09" ESTIMABLE="YES" ESTIMATE="-0.09" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="530" SE="0.26" STUDY_ID="STD-Mulhauser-1996" TOTAL_1="8" TOTAL_2="8" WEIGHT="6.169031462060456"/>
<IV_DATA CI_END="-0.6080072030919892" CI_START="-1.3919927969080108" EFFECT_SIZE="-1.0" ESTIMABLE="YES" ESTIMATE="-1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="532" SE="0.2" STUDY_ID="STD-Trevisan_x005f_Micro-1998" TOTAL_1="9" TOTAL_2="0" WEIGHT="10.42566317088217"/>
<IV_DATA CI_END="-0.3040036015459946" CI_START="-0.6959963984540054" EFFECT_SIZE="-0.5" ESTIMABLE="YES" ESTIMATE="-0.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="533" SE="0.1" STUDY_ID="STD-Trevisan_x005f_Normo-1998" TOTAL_1="7" TOTAL_2="0" WEIGHT="41.70265268352868"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-10-19 04:11:24 +1100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Net change in BP in type 1 and type 2 diabetes</NAME>
<IV_OUTCOME CHI2="46.56475317644252" CI_END="-5.382330768812534" CI_START="-8.706274108487621" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_SIZE="-7.044302438650077" ESTIMABLE="YES" I2="78.52452913879273" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-10-19 04:11:24 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.1329094459222588E-6" P_Q="0.9064090513757842" P_Z="9.786360499294721E-17" Q="0.013822505352216297" RANDOM="NO" SCALE="50.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="25" WEIGHT="99.99999999999999" Z="8.30734923256027">
<NAME>Systolic BP</NAME>
<GROUP_LABEL_1>Low salt</GROUP_LABEL_1>
<GROUP_LABEL_2>High salt</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low salt</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high salt</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="33.4313714050791" CI_END="-5.0992019328198595" CI_START="-9.125719528803653" DF="3" EFFECT_SIZE="-7.1124607308117564" ESTIMABLE="YES" I2="91.02639265482175" ID="CMP-002.01.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-07-14 14:32:31 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="2.6118193485746843E-7" P_Z="4.385071819668926E-12" STUDIES="4" TAU2="0.0" TOTAL_1="48" TOTAL_2="8" WEIGHT="68.14720081758148" Z="6.924180283106646">
<NAME>Type 1 diabetes</NAME>
<IV_DATA CI_END="0.035942375264086834" CI_START="-6.235942375264087" EFFECT_SIZE="-3.1" ESTIMABLE="YES" ESTIMATE="-3.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="593" SE="1.6" STUDY_ID="STD-Luik-2002" TOTAL_1="24" TOTAL_2="0" WEIGHT="28.087370663867702"/>
<IV_DATA CI_END="3.299901322120224" CI_START="-13.099901322120225" EFFECT_SIZE="-4.9" ESTIMABLE="YES" ESTIMATE="-4.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="590" SE="4.1837" STUDY_ID="STD-Mulhauser-1996" TOTAL_1="8" TOTAL_2="8" WEIGHT="4.107995703963116"/>
<IV_DATA CI_END="-0.08007203091989146" CI_START="-7.919927969080108" EFFECT_SIZE="-4.0" ESTIMABLE="YES" ESTIMATE="-4.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="592" SE="2.0" STUDY_ID="STD-Trevisan_x005f_Micro-1998" TOTAL_1="9" TOTAL_2="0" WEIGHT="17.97591722487533"/>
<IV_DATA CI_END="-13.080072030919892" CI_START="-20.91992796908011" EFFECT_SIZE="-17.0" ESTIMABLE="YES" ESTIMATE="-17.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="591" SE="2.0" STUDY_ID="STD-Trevisan_x005f_Normo-1998" TOTAL_1="7" TOTAL_2="0" WEIGHT="17.97591722487533"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="13.119559266011208" CI_END="-3.953722373216893" CI_START="-9.843241144922022" DF="6" EFFECT_SIZE="-6.898481759069457" ESTIMABLE="YES" I2="54.266756387585545" ID="CMP-002.01.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-07-14 14:32:50 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.04117617184490585" P_Z="4.4013389973185145E-6" STUDIES="7" TAU2="0.0" TOTAL_1="62" TOTAL_2="17" WEIGHT="31.852799182418508" Z="4.591470481676768">
<NAME>Type 2 diabetes</NAME>
<IV_DATA CI_END="-0.07854543912278444" CI_START="-25.921454560877216" EFFECT_SIZE="-13.0" ESTIMABLE="YES" ESTIMATE="-13.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="597" SE="6.5927" STUDY_ID="STD-Dodson_x005f_P-1989" TOTAL_1="17" TOTAL_2="17" WEIGHT="1.6543386780258897"/>
<IV_DATA CI_END="-1.4556074954307139" CI_START="-17.944392504569286" EFFECT_SIZE="-9.7" ESTIMABLE="YES" ESTIMATE="-9.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="600" SE="4.2064" STUDY_ID="STD-Dodson_x005f_X-1989" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.063777424763193"/>
<IV_DATA CI_END="-2.200197813157482" CI_START="-17.19980218684252" EFFECT_SIZE="-9.7" ESTIMABLE="YES" ESTIMATE="-9.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="596" SE="3.8265" STUDY_ID="STD-Houlihan_x005f_Losartan-2002" TOTAL_1="10" TOTAL_2="0" WEIGHT="4.910747628435756"/>
<IV_DATA CI_END="9.499914509664057" CI_START="-5.8999145096640575" EFFECT_SIZE="1.8" ESTIMABLE="YES" ESTIMATE="1.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="594" SE="3.9286" STUDY_ID="STD-Houlihan_x005f_Placebo-2002" TOTAL_1="10" TOTAL_2="0" WEIGHT="4.6588145837074935"/>
<IV_DATA CI_END="-5.587951449489548" CI_START="-16.412048550510452" EFFECT_SIZE="-11.0" ESTIMABLE="YES" ESTIMATE="-11.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="598" SE="2.7613" STUDY_ID="STD-Imanishi_x005f_Micro-2001" TOTAL_1="8" TOTAL_2="0" WEIGHT="9.430264307089763"/>
<IV_DATA CI_END="2.087961003515323" CI_START="-16.087961003515325" EFFECT_SIZE="-7.0" ESTIMABLE="YES" ESTIMATE="-7.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="595" SE="4.6368" STUDY_ID="STD-Imanishi_x005f_Normo-2001" TOTAL_1="8" TOTAL_2="0" WEIGHT="3.3443700331476918"/>
<IV_DATA CI_END="10.536427138265752" CI_START="-6.536427138265752" EFFECT_SIZE="2.0" ESTIMABLE="YES" ESTIMATE="2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="599" SE="4.3554" STUDY_ID="STD-Petrie-1998" TOTAL_1="9" TOTAL_2="0" WEIGHT="3.7904865272487265"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="30.813841698886442" CI_END="-2.1149680816274787" CI_START="-3.951391620569727" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_SIZE="-3.0331798510986028" ESTIMABLE="YES" I2="67.54705207575145" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-19 19:16:37 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="6.29728240376326E-4" P_Q="0.7921815609869635" P_Z="9.515305841051901E-11" Q="0.0694210818994847" RANDOM="NO" SCALE="20.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="25" WEIGHT="100.0" Z="6.474457706210856">
<NAME>Diastolic BP</NAME>
<GROUP_LABEL_1>Low salt</GROUP_LABEL_1>
<GROUP_LABEL_2>High salt</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low salt</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high salt</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="7.830495454062207" CI_END="-1.9758736476634113" CI_START="-4.276859389291582" DF="3" EFFECT_SIZE="-3.1263665184774965" ESTIMABLE="YES" I2="61.68824798380162" ID="CMP-002.02.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-07-14 14:33:36 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.04964796152393669" P_Z="1.003795659285252E-7" STUDIES="4" TAU2="0.0" TOTAL_1="48" TOTAL_2="8" WEIGHT="63.69683400544339" Z="5.326035418500182">
<NAME>Type 1 diabetes</NAME>
<IV_DATA CI_END="0.951956781448065" CI_START="-3.7519567814480648" EFFECT_SIZE="-1.4" ESTIMABLE="YES" ESTIMATE="-1.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="603" SE="1.2" STUDY_ID="STD-Luik-2002" TOTAL_1="24" TOTAL_2="0" WEIGHT="15.241476338750871"/>
<IV_DATA CI_END="-1.0000350143175742" CI_START="-9.599964985682426" EFFECT_SIZE="-5.3" ESTIMABLE="YES" ESTIMATE="-5.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="601" SE="2.1939" STUDY_ID="STD-Mulhauser-1996" TOTAL_1="8" TOTAL_2="8" WEIGHT="4.559905811090015"/>
<IV_DATA CI_END="-0.04003601545994573" CI_START="-3.959963984540054" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="602" SE="1.0" STUDY_ID="STD-Trevisan_x005f_Micro-1998" TOTAL_1="9" TOTAL_2="0" WEIGHT="21.947725927801255"/>
<IV_DATA CI_END="-3.040036015459946" CI_START="-6.959963984540054" EFFECT_SIZE="-5.0" ESTIMABLE="YES" ESTIMATE="-5.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="604" SE="1.0" STUDY_ID="STD-Trevisan_x005f_Normo-1998" TOTAL_1="7" TOTAL_2="0" WEIGHT="21.947725927801255"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="22.91392516292475" CI_END="-1.3457267234271584" CI_START="-4.39362592465009" DF="6" EFFECT_SIZE="-2.869676324038624" ESTIMABLE="YES" I2="73.81504933206233" ID="CMP-002.02.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-07-14 14:33:49 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="8.258274655662534E-4" P_Z="2.2362539462769549E-4" STUDIES="7" TAU2="0.0" TOTAL_1="62" TOTAL_2="17" WEIGHT="36.303165994556615" Z="3.6907140762045234">
<NAME>Type 2 diabetes</NAME>
<IV_DATA CI_END="5.024006604973107" CI_START="-8.624006604973108" EFFECT_SIZE="-1.8" ESTIMABLE="YES" ESTIMATE="-1.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="608" SE="3.4817" STUDY_ID="STD-Dodson_x005f_P-1989" TOTAL_1="17" TOTAL_2="17" WEIGHT="1.8105346189840457"/>
<IV_DATA CI_END="0.6658220497199325" CI_START="-10.865822049719931" EFFECT_SIZE="-5.1" ESTIMABLE="YES" ESTIMATE="-5.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="607" SE="2.9418" STUDY_ID="STD-Dodson_x005f_X-1989" TOTAL_1="0" TOTAL_2="0" WEIGHT="2.5360817046294057"/>
<IV_DATA CI_END="-2.6000372884745357" CI_START="-8.399962711525465" EFFECT_SIZE="-5.5" ESTIMABLE="YES" ESTIMATE="-5.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="610" SE="1.4796" STUDY_ID="STD-Houlihan_x005f_Losartan-2002" TOTAL_1="10" TOTAL_2="0" WEIGHT="10.025380923463151"/>
<IV_DATA CI_END="8.299868124561678" CI_START="-1.6998681245616787" EFFECT_SIZE="3.3" ESTIMABLE="YES" ESTIMATE="3.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="606" SE="2.551" STUDY_ID="STD-Houlihan_x005f_Placebo-2002" TOTAL_1="10" TOTAL_2="0" WEIGHT="3.3726293188229044"/>
<IV_DATA CI_END="-2.9794995034253224" CI_START="-9.020500496574677" EFFECT_SIZE="-6.0" ESTIMABLE="YES" ESTIMATE="-6.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="611" SE="1.5411" STUDY_ID="STD-Imanishi_x005f_Micro-2001" TOTAL_1="8" TOTAL_2="0" WEIGHT="9.241189743258351"/>
<IV_DATA CI_END="3.464824331869908" CI_START="-3.464824331869908" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="609" SE="1.7678" STUDY_ID="STD-Imanishi_x005f_Normo-2001" TOTAL_1="8" TOTAL_2="0" WEIGHT="7.02300971499077"/>
<IV_DATA CI_END="11.061972607783934" CI_START="-1.0619726077839342" EFFECT_SIZE="5.0" ESTIMABLE="YES" ESTIMATE="5.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="605" SE="3.0929" STUDY_ID="STD-Petrie-1998" TOTAL_1="9" TOTAL_2="0" WEIGHT="2.2943399704079814"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="30.245397513482857" CI_END="-1.060896401088017" CI_START="-3.3216897040693794" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_SIZE="-2.191293052578698" ESTIMABLE="YES" I2="66.93711829860335" I2_Q="87.95231802541886" ID="CMP-002.03" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-19 19:16:46 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="7.809302696507592E-4" P_Q="0.003963780844519871" P_Z="1.4503314376840062E-4" Q="8.300351902630364" RANDOM="NO" SCALE="50.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="120" TOTAL_2="10" WEIGHT="100.0" Z="3.7994233767088357">
<NAME>MAP</NAME>
<GROUP_LABEL_1>Low salt</GROUP_LABEL_1>
<GROUP_LABEL_2>High salt</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low salt</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high salt</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="2.171153389522711" CI_END="2.003235702125605" CI_START="-1.8319589838531911" DF="2" EFFECT_SIZE="0.08563835913620677" ESTIMABLE="YES" I2="7.883063000000009" ID="CMP-002.03.01" LOG_CI_END="0.3017320516950584" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.067331662546655" MODIFIED="2010-07-14 14:34:46 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.33770721035379414" P_Z="0.9302499070636379" STUDIES="3" TAU2="0.0" TOTAL_1="31" TOTAL_2="0" WEIGHT="34.74936606799824" Z="0.08753041936343565">
<NAME>Type 1 diabetes</NAME>
<IV_DATA CI_END="5.187685424455944" CI_START="-1.1876854244559443" EFFECT_SIZE="2.0" ESTIMABLE="YES" ESTIMATE="2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="614" SE="1.6264" STUDY_ID="STD-Lopes-De-Faria-1997" TOTAL_1="10" TOTAL_2="0" WEIGHT="12.575081586361662"/>
<IV_DATA CI_END="2.394853617621828" CI_START="-4.394853617621828" EFFECT_SIZE="-1.0" ESTIMABLE="YES" ESTIMATE="-1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="613" SE="1.7321" STUDY_ID="STD-Miller-1995" TOTAL_1="9" TOTAL_2="0" WEIGHT="11.087142240818288"/>
<IV_DATA CI_END="2.394853617621828" CI_START="-4.394853617621828" EFFECT_SIZE="-1.0" ESTIMABLE="YES" ESTIMATE="-1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="612" SE="1.7321" STUDY_ID="STD-Miller-1997" TOTAL_1="12" TOTAL_2="0" WEIGHT="11.087142240818288"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="19.77389222132978" CI_END="-2.0044886696388517" CI_START="-4.803266920304205" DF="7" EFFECT_SIZE="-3.403877794971528" ESTIMABLE="YES" I2="64.59978682169" ID="CMP-002.03.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-07-14 14:34:53 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.00607935615290689" P_Z="1.8659860780300215E-6" STUDIES="8" TAU2="0.0" TOTAL_1="89" TOTAL_2="10" WEIGHT="65.25063393200176" Z="4.767421559270586">
<NAME>Type 2 diabetes</NAME>
<IV_DATA CI_END="3.293482100230584" CI_START="-21.293482100230584" EFFECT_SIZE="-9.0" ESTIMABLE="YES" ESTIMATE="-9.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="622" SE="6.2723" STUDY_ID="STD-De_x0027_oliveira-1997" TOTAL_1="9" TOTAL_2="10" WEIGHT="0.8454966638154142"/>
<IV_DATA CI_END="-3.300105500350657" CI_START="-11.299894499649342" EFFECT_SIZE="-7.3" ESTIMABLE="YES" ESTIMATE="-7.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="615" SE="2.0408" STUDY_ID="STD-Houlihan_x005f_Losartan-2002" TOTAL_1="10" TOTAL_2="0" WEIGHT="7.986649977264116"/>
<IV_DATA CI_END="5.699925423050929" CI_START="-5.899925423050928" EFFECT_SIZE="-0.1" ESTIMABLE="YES" ESTIMATE="-0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="621" SE="2.9592" STUDY_ID="STD-Houlihan_x005f_Placebo-2002" TOTAL_1="10" TOTAL_2="0" WEIGHT="3.7985417669267663"/>
<IV_DATA CI_END="-4.758415565969204" CI_START="-11.241584434030795" EFFECT_SIZE="-8.0" ESTIMABLE="YES" ESTIMATE="-8.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="618" SE="1.6539" STUDY_ID="STD-Vedovato_x005f_Micro-2004" TOTAL_1="20" TOTAL_2="0" WEIGHT="12.160377251715902"/>
<IV_DATA CI_END="0.9599639845400543" CI_START="-2.959963984540054" EFFECT_SIZE="-1.0" ESTIMABLE="YES" ESTIMATE="-1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="619" SE="1.0" STUDY_ID="STD-Vedovato_x005f_Normo-2004" TOTAL_1="21" TOTAL_2="0" WEIGHT="33.26331608236412"/>
<IV_DATA CI_END="1.839855938160217" CI_START="-13.839855938160216" EFFECT_SIZE="-6.0" ESTIMABLE="YES" ESTIMATE="-6.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="617" SE="4.0" STUDY_ID="STD-Yoshioka_x005f_Adva_x005f_alb-1998" TOTAL_1="4" TOTAL_2="0" WEIGHT="2.0789572551477575"/>
<IV_DATA CI_END="4.06684614265762" CI_START="-10.06684614265762" EFFECT_SIZE="-3.0" ESTIMABLE="YES" ESTIMATE="-3.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="620" SE="3.6056" STUDY_ID="STD-Yoshioka_x005f_Micro-1998" TOTAL_1="7" TOTAL_2="0" WEIGHT="2.5586474673838446"/>
<IV_DATA CI_END="5.06684614265762" CI_START="-9.06684614265762" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="616" SE="3.6056" STUDY_ID="STD-Yoshioka_x005f_Normo-1998" TOTAL_1="8" TOTAL_2="0" WEIGHT="2.5586474673838446"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="91.56047541530737" CI_END="0.006730435368020649" CI_START="-0.3097764406729478" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_SIZE="-0.15152300265246357" ESTIMABLE="YES" I2="94.53912839866702" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-2.1719568418958684" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-07-14 14:36:26 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="-2.220446049250313E-16" P_Q="0.8982917489079565" P_Z="0.060571874598468904" Q="0.016337848218327622" RANDOM="NO" SCALE="4.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="79" TOTAL_2="25" WEIGHT="100.0" Z="1.8766077485770316">
<NAME>HbA1c</NAME>
<GROUP_LABEL_1>Low salt</GROUP_LABEL_1>
<GROUP_LABEL_2>High salt</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low salt</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high salt</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="90.78737025047506" CI_END="0.013183562977633151" CI_START="-0.32376730453854263" DF="2" EFFECT_SIZE="-0.15529187078045475" ESTIMABLE="YES" I2="97.79705041077612" ID="CMP-002.04.01" LOG_CI_END="-1.8799672018505502" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-07-14 14:36:13 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="2.220446049250313E-16" P_Z="0.0708258223938468" STUDIES="3" TAU2="0.0" TOTAL_1="42" TOTAL_2="8" WEIGHT="88.23342567924624" Z="1.8065926113511357">
<NAME>Type 1 diabetes</NAME>
<IV_DATA CI_END="-2.390451200808043" CI_START="-3.609548799191957" EFFECT_SIZE="-3.0" ESTIMABLE="YES" ESTIMATE="-3.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="148" SE="0.311" STUDY_ID="STD-Lopes-De-Faria-1997" TOTAL_1="10" TOTAL_2="0" WEIGHT="6.74045707579158"/>
<IV_DATA CI_END="0.29599639845400544" CI_START="-0.09599639845400543" EFFECT_SIZE="0.1" ESTIMABLE="YES" ESTIMATE="0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="149" SE="0.1" STUDY_ID="STD-Luik-2002" TOTAL_1="24" TOTAL_2="0" WEIGHT="65.19437488276373"/>
<IV_DATA CI_END="0.39199279690801087" CI_START="-0.39199279690801087" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="147" SE="0.2" STUDY_ID="STD-Mulhauser-1996" TOTAL_1="8" TOTAL_2="8" WEIGHT="16.29859372069093"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.7567673166139797" CI_END="0.3380858799736391" CI_START="-0.5846090372854236" DF="2" EFFECT_SIZE="-0.12326157865589227" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="-0.4709729669969835" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-07-14 14:36:26 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.6849678150935697" P_Z="0.6005164842198648" STUDIES="3" TAU2="0.0" TOTAL_1="37" TOTAL_2="17" WEIGHT="11.766574320753756" Z="0.523657929233547">
<NAME>Type 2 diabetes</NAME>
<IV_DATA CI_END="0.814660167252554" CI_START="-2.214660167252554" EFFECT_SIZE="-0.7" ESTIMABLE="YES" ESTIMATE="-0.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="144" SE="0.7728" STUDY_ID="STD-Dodson_x005f_P-1989" TOTAL_1="17" TOTAL_2="17" WEIGHT="1.0916310965617575"/>
<IV_DATA CI_END="0.6543483008610096" CI_START="-1.0543483008610097" EFFECT_SIZE="-0.2" ESTIMABLE="YES" ESTIMATE="-0.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="145" SE="0.4359" STUDY_ID="STD-Houlihan_x005f_Losartan-2002" TOTAL_1="10" TOTAL_2="0" WEIGHT="3.4311237927738056"/>
<IV_DATA CI_END="0.5879891953620162" CI_START="-0.5879891953620162" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="146" SE="0.3" STUDY_ID="STD-Houlihan_x005f_Placebo-2002" TOTAL_1="10" TOTAL_2="0" WEIGHT="7.243819431418193"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2010-09-27 17:12:02 +1000" MODIFIED_BY="Narelle S Willis" NO="3">
<NAME>Net change in BP in hypertensive and normotensive participants</NAME>
<IV_OUTCOME CHI2="46.564753176442515" CI_END="-5.382330768812534" CI_START="-8.706274108487621" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_SIZE="-7.044302438650077" ESTIMABLE="YES" I2="78.52452913879273" I2_Q="50.00009945924888" ID="CMP-003.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-27 15:32:05 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="1.1329094458112365E-6" P_Q="0.15729915264489314" P_Z="9.786360499294721E-17" Q="2.000003978377869" RANDOM="NO" SCALE="50.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="25" WEIGHT="100.0" Z="8.30734923256027">
<NAME>Systolic BP</NAME>
<GROUP_LABEL_1>Low salt</GROUP_LABEL_1>
<GROUP_LABEL_2>High salt</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low salt</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high salt</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="9.803105654482973" CI_END="-1.4100807746177053" CI_START="-8.31310174629002" DF="5" EFFECT_SIZE="-4.861591260453863" ESTIMABLE="YES" I2="48.99575526135951" ID="CMP-003.01.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-27 15:31:59 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0810104303684076" P_Z="0.005767973969280272" STUDIES="6" TAU2="0.0" TOTAL_1="54" TOTAL_2="25" WEIGHT="23.186160546144173" Z="2.7606880573436494">
<NAME>Hypertensive</NAME>
<IV_DATA CI_END="-0.07854543912278444" CI_START="-25.921454560877216" EFFECT_SIZE="-13.0" ESTIMABLE="YES" ESTIMATE="-13.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="150" SE="6.5927" STUDY_ID="STD-Dodson_x005f_P-1989" TOTAL_1="17" TOTAL_2="17" WEIGHT="1.6543386780258897"/>
<IV_DATA CI_END="-1.4556074954307139" CI_START="-17.944392504569286" EFFECT_SIZE="-9.7" ESTIMABLE="YES" ESTIMATE="-9.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="151" SE="4.2064" STUDY_ID="STD-Dodson_x005f_X-1989" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.063777424763193"/>
<IV_DATA CI_END="-2.200197813157482" CI_START="-17.19980218684252" EFFECT_SIZE="-9.7" ESTIMABLE="YES" ESTIMATE="-9.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="152" SE="3.8265" STUDY_ID="STD-Houlihan_x005f_Losartan-2002" TOTAL_1="10" TOTAL_2="0" WEIGHT="4.910747628435756"/>
<IV_DATA CI_END="9.499914509664057" CI_START="-5.8999145096640575" EFFECT_SIZE="1.8" ESTIMABLE="YES" ESTIMATE="1.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="153" SE="3.9286" STUDY_ID="STD-Houlihan_x005f_Placebo-2002" TOTAL_1="10" TOTAL_2="0" WEIGHT="4.6588145837074935"/>
<IV_DATA CI_END="3.299901322120224" CI_START="-13.099901322120225" EFFECT_SIZE="-4.9" ESTIMABLE="YES" ESTIMATE="-4.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="154" SE="4.1837" STUDY_ID="STD-Mulhauser-1996" TOTAL_1="8" TOTAL_2="8" WEIGHT="4.107995703963116"/>
<IV_DATA CI_END="10.536427138265752" CI_START="-6.536427138265752" EFFECT_SIZE="2.0" ESTIMABLE="YES" ESTIMATE="2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="155" SE="4.3554" STUDY_ID="STD-Petrie-1998" TOTAL_1="9" TOTAL_2="0" WEIGHT="3.7904865272487265"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="34.76164354358168" CI_END="-5.806864875228546" CI_START="-9.599437233803478" DF="4" EFFECT_SIZE="-7.703151054516011" ESTIMABLE="YES" I2="88.49306421606595" ID="CMP-003.01.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-27 15:32:05 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="5.199651480491951E-7" P_Z="1.6952017608504456E-15" STUDIES="5" TAU2="0.0" TOTAL_1="56" TOTAL_2="0" WEIGHT="76.81383945385582" Z="7.961824960405605">
<NAME>Normotensive</NAME>
<IV_DATA CI_END="-5.587951449489548" CI_START="-16.412048550510452" EFFECT_SIZE="-11.0" ESTIMABLE="YES" ESTIMATE="-11.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="156" SE="2.7613" STUDY_ID="STD-Imanishi_x005f_Micro-2001" TOTAL_1="8" TOTAL_2="0" WEIGHT="9.430264307089763"/>
<IV_DATA CI_END="2.087961003515323" CI_START="-16.087961003515325" EFFECT_SIZE="-7.0" ESTIMABLE="YES" ESTIMATE="-7.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="157" SE="4.6368" STUDY_ID="STD-Imanishi_x005f_Normo-2001" TOTAL_1="8" TOTAL_2="0" WEIGHT="3.3443700331476918"/>
<IV_DATA CI_END="0.035942375264086834" CI_START="-6.235942375264087" EFFECT_SIZE="-3.1" ESTIMABLE="YES" ESTIMATE="-3.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="158" SE="1.6" STUDY_ID="STD-Luik-2002" TOTAL_1="24" TOTAL_2="0" WEIGHT="28.087370663867702"/>
<IV_DATA CI_END="-0.08007203091989146" CI_START="-7.919927969080108" EFFECT_SIZE="-4.0" ESTIMABLE="YES" ESTIMATE="-4.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="159" SE="2.0" STUDY_ID="STD-Trevisan_x005f_Micro-1998" TOTAL_1="9" TOTAL_2="0" WEIGHT="17.97591722487533"/>
<IV_DATA CI_END="-13.080072030919892" CI_START="-20.91992796908011" EFFECT_SIZE="-17.0" ESTIMABLE="YES" ESTIMATE="-17.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="160" SE="2.0" STUDY_ID="STD-Trevisan_x005f_Normo-1998" TOTAL_1="7" TOTAL_2="0" WEIGHT="17.97591722487533"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="30.813841698886442" CI_END="-2.1149680816274787" CI_START="-3.951391620569727" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_SIZE="-3.0331798510986028" ESTIMABLE="YES" I2="67.54705207575145" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-27 17:12:02 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="6.29728240376326E-4" P_Q="0.9322960207460202" P_Z="9.515305841051901E-11" Q="0.0072175968670293855" RANDOM="NO" SCALE="20.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="25" WEIGHT="100.0" Z="6.474457706210856">
<NAME>Diastolic BP</NAME>
<GROUP_LABEL_1>Low salt</GROUP_LABEL_1>
<GROUP_LABEL_2>High salt</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low salt</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high salt</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="17.37020334058148" CI_END="-1.1121615235086877" CI_START="-4.814833604718209" DF="5" EFFECT_SIZE="-2.9634975641134482" ESTIMABLE="YES" I2="71.21507502264724" ID="CMP-003.02.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-07-14 14:38:31 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0038486708795180125" P_Z="0.0017046383532444615" STUDIES="6" TAU2="0.0" TOTAL_1="54" TOTAL_2="25" WEIGHT="24.598872347397506" Z="3.1373820670812274">
<NAME>Hypertensive</NAME>
<IV_DATA CI_END="5.024006604973107" CI_START="-8.624006604973108" EFFECT_SIZE="-1.8" ESTIMABLE="YES" ESTIMATE="-1.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="161" SE="3.4817" STUDY_ID="STD-Dodson_x005f_P-1989" TOTAL_1="17" TOTAL_2="17" WEIGHT="1.8105346189840457"/>
<IV_DATA CI_END="0.6658220497199325" CI_START="-10.865822049719931" EFFECT_SIZE="-5.1" ESTIMABLE="YES" ESTIMATE="-5.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="162" SE="2.9418" STUDY_ID="STD-Dodson_x005f_X-1989" TOTAL_1="0" TOTAL_2="0" WEIGHT="2.5360817046294057"/>
<IV_DATA CI_END="-2.6000372884745357" CI_START="-8.399962711525465" EFFECT_SIZE="-5.5" ESTIMABLE="YES" ESTIMATE="-5.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="163" SE="1.4796" STUDY_ID="STD-Houlihan_x005f_Losartan-2002" TOTAL_1="10" TOTAL_2="0" WEIGHT="10.025380923463151"/>
<IV_DATA CI_END="8.299868124561678" CI_START="-1.6998681245616787" EFFECT_SIZE="3.3" ESTIMABLE="YES" ESTIMATE="3.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="164" SE="2.551" STUDY_ID="STD-Houlihan_x005f_Placebo-2002" TOTAL_1="10" TOTAL_2="0" WEIGHT="3.3726293188229044"/>
<IV_DATA CI_END="-1.0000350143175742" CI_START="-9.599964985682426" EFFECT_SIZE="-5.3" ESTIMABLE="YES" ESTIMATE="-5.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="165" SE="2.1939" STUDY_ID="STD-Mulhauser-1996" TOTAL_1="8" TOTAL_2="8" WEIGHT="4.559905811090015"/>
<IV_DATA CI_END="11.061972607783934" CI_START="-1.0619726077839342" EFFECT_SIZE="5.0" ESTIMABLE="YES" ESTIMATE="5.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="166" SE="3.0929" STUDY_ID="STD-Petrie-1998" TOTAL_1="9" TOTAL_2="0" WEIGHT="2.2943399704079814"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="13.436420761437935" CI_END="-1.9984773905289441" CI_START="-4.113348625920748" DF="4" EFFECT_SIZE="-3.055913008224846" ESTIMABLE="YES" I2="70.2301671626728" ID="CMP-003.02.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-07-14 14:38:44 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.009329009010277556" P_Z="1.4775064828526572E-8" STUDIES="5" TAU2="0.0" TOTAL_1="56" TOTAL_2="0" WEIGHT="75.4011276526025" Z="5.664155184273935">
<NAME>Normotensive</NAME>
<IV_DATA CI_END="-2.9794995034253224" CI_START="-9.020500496574677" EFFECT_SIZE="-6.0" ESTIMABLE="YES" ESTIMATE="-6.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="167" SE="1.5411" STUDY_ID="STD-Imanishi_x005f_Micro-2001" TOTAL_1="8" TOTAL_2="0" WEIGHT="9.241189743258351"/>
<IV_DATA CI_END="3.464824331869908" CI_START="-3.464824331869908" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="168" SE="1.7678" STUDY_ID="STD-Imanishi_x005f_Normo-2001" TOTAL_1="8" TOTAL_2="0" WEIGHT="7.02300971499077"/>
<IV_DATA CI_END="0.951956781448065" CI_START="-3.7519567814480648" EFFECT_SIZE="-1.4" ESTIMABLE="YES" ESTIMATE="-1.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="169" SE="1.2" STUDY_ID="STD-Luik-2002" TOTAL_1="24" TOTAL_2="0" WEIGHT="15.241476338750871"/>
<IV_DATA CI_END="-0.04003601545994573" CI_START="-3.959963984540054" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="170" SE="1.0" STUDY_ID="STD-Trevisan_x005f_Micro-1998" TOTAL_1="9" TOTAL_2="0" WEIGHT="21.947725927801255"/>
<IV_DATA CI_END="-3.040036015459946" CI_START="-6.959963984540054" EFFECT_SIZE="-5.0" ESTIMABLE="YES" ESTIMATE="-5.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="171" SE="1.0" STUDY_ID="STD-Trevisan_x005f_Normo-1998" TOTAL_1="7" TOTAL_2="0" WEIGHT="21.947725927801255"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="30.245397513482857" CI_END="-1.060896401088017" CI_START="-3.3216897040693794" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_SIZE="-2.191293052578698" ESTIMABLE="YES" I2="66.93711829860335" I2_Q="75.38190247677883" ID="CMP-003.03" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-09-27 17:11:29 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="7.809302696507592E-4" P_Q="0.04385726057660255" P_Z="1.4503314376840062E-4" Q="4.06205231357437" RANDOM="NO" SCALE="50.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="120" TOTAL_2="10" WEIGHT="100.0" Z="3.7994233767088357">
<NAME>MAP</NAME>
<GROUP_LABEL_1>Low salt</GROUP_LABEL_1>
<GROUP_LABEL_2>High salt</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low salt</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high salt</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="4.395246934856262" CI_END="-2.0678155530586118" CI_START="-8.429137082244875" DF="2" EFFECT_SIZE="-5.248476317651743" ESTIMABLE="YES" I2="54.496299533500355" ID="CMP-003.03.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2009-03-10 09:59:30 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.11106689014617932" P_Z="0.0012199319800599718" STUDIES="3" TAU2="0.0" TOTAL_1="29" TOTAL_2="10" WEIGHT="12.630688408006296" Z="3.2341784671980593">
<NAME>Hypertensive</NAME>
<IV_DATA CI_END="3.293482100230584" CI_START="-21.293482100230584" EFFECT_SIZE="-9.0" ESTIMABLE="YES" ESTIMATE="-9.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="174" SE="6.2723" STUDY_ID="STD-De_x0027_oliveira-1997" TOTAL_1="9" TOTAL_2="10" WEIGHT="0.8454966638154142"/>
<IV_DATA CI_END="-3.300105500350657" CI_START="-11.299894499649342" EFFECT_SIZE="-7.3" ESTIMABLE="YES" ESTIMATE="-7.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="172" SE="2.0408" STUDY_ID="STD-Houlihan_x005f_Losartan-2002" TOTAL_1="10" TOTAL_2="0" WEIGHT="7.986649977264116"/>
<IV_DATA CI_END="5.699925423050929" CI_START="-5.899925423050928" EFFECT_SIZE="-0.1" ESTIMABLE="YES" ESTIMATE="-0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="173" SE="2.9592" STUDY_ID="STD-Houlihan_x005f_Placebo-2002" TOTAL_1="10" TOTAL_2="0" WEIGHT="3.7985417669267663"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="21.788098265052227" CI_END="-0.5399779998420777" CI_START="-2.9586746388909937" DF="7" EFFECT_SIZE="-1.7493263193665358" ESTIMABLE="YES" I2="67.87236813949984" ID="CMP-003.03.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2009-03-10 10:00:20 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.002763088735810215" P_Z="0.004581215420985455" STUDIES="8" TAU2="0.0" TOTAL_1="91" TOTAL_2="0" WEIGHT="87.36931159199371" Z="2.8350943461141362">
<NAME>Normotensive</NAME>
<IV_DATA CI_END="5.187685424455944" CI_START="-1.1876854244559443" EFFECT_SIZE="2.0" ESTIMABLE="YES" ESTIMATE="2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="182" SE="1.6264" STUDY_ID="STD-Lopes-De-Faria-1997" TOTAL_1="10" TOTAL_2="0" WEIGHT="12.575081586361662"/>
<IV_DATA CI_END="2.394853617621828" CI_START="-4.394853617621828" EFFECT_SIZE="-1.0" ESTIMABLE="YES" ESTIMATE="-1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="181" SE="1.7321" STUDY_ID="STD-Miller-1995" TOTAL_1="9" TOTAL_2="0" WEIGHT="11.087142240818288"/>
<IV_DATA CI_END="2.394853617621828" CI_START="-4.394853617621828" EFFECT_SIZE="-1.0" ESTIMABLE="YES" ESTIMATE="-1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="180" SE="1.7321" STUDY_ID="STD-Miller-1997" TOTAL_1="12" TOTAL_2="0" WEIGHT="11.087142240818288"/>
<IV_DATA CI_END="-4.758415565969204" CI_START="-11.241584434030795" EFFECT_SIZE="-8.0" ESTIMABLE="YES" ESTIMATE="-8.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="179" SE="1.6539" STUDY_ID="STD-Vedovato_x005f_Micro-2004" TOTAL_1="20" TOTAL_2="0" WEIGHT="12.160377251715902"/>
<IV_DATA CI_END="0.9599639845400543" CI_START="-2.959963984540054" EFFECT_SIZE="-1.0" ESTIMABLE="YES" ESTIMATE="-1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="178" SE="1.0" STUDY_ID="STD-Vedovato_x005f_Normo-2004" TOTAL_1="21" TOTAL_2="0" WEIGHT="33.26331608236412"/>
<IV_DATA CI_END="1.839855938160217" CI_START="-13.839855938160216" EFFECT_SIZE="-6.0" ESTIMABLE="YES" ESTIMATE="-6.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="177" SE="4.0" STUDY_ID="STD-Yoshioka_x005f_Adva_x005f_alb-1998" TOTAL_1="4" TOTAL_2="0" WEIGHT="2.0789572551477575"/>
<IV_DATA CI_END="4.06684614265762" CI_START="-10.06684614265762" EFFECT_SIZE="-3.0" ESTIMABLE="YES" ESTIMATE="-3.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="176" SE="3.6056" STUDY_ID="STD-Yoshioka_x005f_Micro-1998" TOTAL_1="7" TOTAL_2="0" WEIGHT="2.5586474673838446"/>
<IV_DATA CI_END="5.06684614265762" CI_START="-9.06684614265762" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="175" SE="3.6056" STUDY_ID="STD-Yoshioka_x005f_Normo-1998" TOTAL_1="8" TOTAL_2="0" WEIGHT="2.5586474673838446"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-09-27 17:47:16 +1000" MODIFIED_BY="Narelle S Willis">
<FIGURE FILENAME="156 flow chart.PNG" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2010-09-20 16:30:45 +1000" MODIFIED_BY="Narelle S Willis" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flow chart of study selection process</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2010-10-26 17:24:30 +1100" MODIFIED_BY="Narelle S Willis">
<APPENDIX ID="APP-01" MODIFIED="2010-10-26 17:24:30 +1100" MODIFIED_BY="Narelle S Willis" NO="1">
<TITLE MODIFIED="2009-01-29 02:06:25 +1100" MODIFIED_BY="[Empty name]">Electronic search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2010-10-26 17:24:30 +1100" MODIFIED_BY="Narelle S Willis">
<TABLE COLS="2" ROWS="4">
<TR>
<TH VALIGN="TOP">
<P>Database</P>
</TH>
<TH VALIGN="TOP">
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CENTRAL</P>
</TD>
<TD VALIGN="TOP">
<OL>
<LI>MeSH descriptor Sodium, Dietary explode all tree</LI>
<LI>MeSH descriptor Diet, Sodium-Restricted, this term only</LI>
<LI>(dietary salt*) or (dietary sodium) in Clinical Trials</LI>
<LI>(diet* and (salt* or sodium)) in Clinical Trials</LI>
<LI>(salt* or sodium) and (restrict* or intak* or chang*) in Clinical Trials</LI>
<LI>(#1 OR #2 OR #3 OR #4 OR #5)</LI>
<LI>MeSH descriptor Diabetic Nephropathies, this term only</LI>
<LI>MeSH descriptor Diabetes Mellitus, this term only</LI>
<LI>MeSH descriptor Diabetes Mellitus, Type 1 explode all trees</LI>
<LI>MeSH descriptor Diabetes Mellitus, Type 2 explode all trees</LI>
<LI>MeSH descriptor Glucose Intolerance explode all trees</LI>
<LI>MeSH descriptor Insulin Resistance explode all trees</LI>
<LI>(diabetic nephropath* or diabetic kidney* or diabetic renal*) in Clinical Trials</LI>
<LI>(IDDM or NIDDM) in Clinical Trials</LI>
<LI>(insulin dependent diabetes mellitus or non insulin dependent diabetes mellitus.) in Clinical Trials</LI>
<LI>(impaired glucose toleranc*) or (glucose intoleranc*) in Clinical Trials</LI>
<LI>(insulin resistanc*) in Clinical Trials</LI>
<LI>(#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17</LI>
<LI>(#6 AND #18)</LI>
</OL>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>MEDLINE</P>
</TD>
<TD VALIGN="TOP">
<OL>
<LI>exp Sodium, Dietary/</LI>
<LI>Diet, Sodium-Restricted/</LI>
<LI>(dietary salt or dietary sodium).tw.</LI>
<LI>(diet$ and (salt$ or sodium)).tw.</LI>
<LI>((salt$ or sodium$) and (restrict$ or intake$ or chang$)).tw.</LI>
<LI>or/1-5</LI>
<LI>diabetes mellitus/ or exp diabetes mellitus, type 1/ or exp diabetes mellitus, type 2/</LI>
<LI>(IDDM or NIDDM).tw.</LI>
<LI>Diabetic Nephropathies/</LI>
<LI>diabetic nephropath$.tw.</LI>
<LI>((diabetic or diabetes) and (kidney$ or renal$ or nephro$ or nephritis or glomerulo$)).tw.</LI>
<LI>(insulin dependent diabetes or non insulin dependent diabetes).tw.</LI>
<LI>Glucose Intolerance/</LI>
<LI>(impaired glucose toleranc$ or glucose intoleranc$).tw.</LI>
<LI>exp Insulin Resistance/</LI>
<LI>insulin resistanc$.tw.</LI>
<LI>or/7-16</LI>
<LI>and/6,17</LI>
</OL>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>EMBASE</P>
</TD>
<TD VALIGN="TOP">
<OL>
<LI>Salt Intake/</LI>
<LI>Sodium Intake/</LI>
<LI>Sodium Restriction/</LI>
<LI>(dietary salt or dietary sodium).tw.</LI>
<LI>(diet$ and (salt$ or sodium)).tw.</LI>
<LI>((salt$ or sodium) and (restrict$ or intak$ or change$)).tw.</LI>
<LI>or/1-6</LI>
<LI>Diabetic Nephropathy/</LI>
<LI>diabetic nephropath$.tw.</LI>
<LI>((diabetic or diabetes) and (kidney$ or renal$ or nephro$ or nephritis or glomerulo$)).tw.</LI>
<LI>(IDDM or NIDDM).tw.</LI>
<LI>diabetes mellitus/ or impaired glucose tolerance/ or insulin dependent diabetes mellitus/ or non insulin dependent diabetes mellitus/</LI>
<LI>(insulin dependent diabetes mellitus or non insulin dependent diabetes mellitus).tw.</LI>
<LI>Glucose Intolerance/</LI>
<LI>(impaired glucose toleranc$ or glucose intoleranc$).tw.</LI>
<LI>Insulin Resistance/</LI>
<LI>insulin resistanc$.tw.</LI>
<LI>or/8-17</LI>
<LI>and/7,18</LI>
</OL>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>